WO 00/50639

Continued

8 of 12

Al; phenalamide A1 SU 201 SU 65591 SUN 4599 Discontinued Discontinued	[1(S*),2E,4E,6Z,8E,1 0E,12R*,13R*,14E,1 6S*11,13-hvdrovy, N	Calicer
Discontinued Preclinical Discontinued	0E,12R*,13R*,14E,1	
Discontinuec Preclinical Discontinuec	60*11-12-hydroxy, N	
Discontinuec Preclinical Discontinued	-11-4YOUNGUE-11-1	
Discontinued Preclinical Discontinued	(2-hydroxy-1-	
Discontinued Preclinical Discontinued	methylethyl)-	
Discontinuec Preclinical Discontinued	2,10,12,14,16-	-
Discontinuec Preclinical Discontinuec	pentamethyl-18-	
Discontinued Preclinical Discontinued	phenyl-2,4,6,8,10,14-	
Discontinued Preclinical Discontinued	octadecahexaenamide	
Preclinical Discontinued		cancer
Discontinued		Cancer
-	2-alpha-L-	cancer
-		
	hydroxy-5,11-	
_	dimethyl-6H-	
	pyrido[4,3-	
	b]carbazolium	
	bromide	
superfibronectin Preclinical		cancer
suramin; CI 1003; Marketed	8,8'-	parasitic infection:
	[carbonylbis[imino-	cancer
	3,1-	
	phenylenecarbonylimi	
	no(4-methyl-3,1-	
	phenylene)carbonyli	
•	mino]]bis-1,3,5-	
	naphthalenetrisulfonic	
	acid	

swainsonine; (-)-	Phase II	[1S-	cancer: vira	viral
swainsonine;		(1alpha,2alpha,8beta,	infection	
swainsonine		Sabeta)]-octahydro-		
hydrochloride; GD 0039		1,2,8-indolizinetriol		
T4GEN	Phase I		HIV infection;	ection;
TAC 903	Drootinies!		cancer	
COC OUT	riecinneal	curome-8-acetic acid	cancer	
tamoxifen	Preclinical		Cancer	
methiodide; PA				
50300				
TBC 1635	Preclinical		retinono	that: 00000
+BCEII	Description	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Tetinopa	company, cancer
O TO CO	Freclinical	4-tert-butyl-[3-(2-	cancer	
		chloroethyl)ureido]		
		benzene		-
TER 286	Preclinical	(2R)-L-gamma-	cancer	
		glutamy1-3-[[2-		
		[[bis[bis(2-	_	
		chloroethyl)amino]ph		
		osphinyl]oxy]ethyl]su		
		lfonyl]-L-alanyl-2-		
		phenyl-glycine	_	

.

thalicarpine; (+)- thalicarpine; TBL; thalicarpin; NSC 68075 thrombopoietin mimetic, Axys TJ 14026 transforming growth factor beta receptor	-		
		[(1,2,3,4-tetrahydro-	
		methyl-1-	-
		isoquinoliny1)methy1]	
		phenoxy]-5,6,6a,7-	
		tetrahydro-1,2,10-	
		unmethoxy-6-methyl-	
		dibenzo[de,g]quinolin	
	inued		cancer.
			thrombocytonenia
_	panui		cancer
factor beta receptor	cal		cancer
inhibitors, Affymax			
triacetyluridine Phase I			cancer
triciribine; NSC Preclinical		1,5-dihydro-5-	HIV infection:
154020; TCN		methyl-1-beta-D-	cancer
		ribofuranosyl-	
	<u> </u>	1,4,5,6,8-	
	-	pentaazaacenaphthyle	
TRIFFNG		n-3-amine	
Treclinical			diarrhea;
			gastrointestinal
			disorder; sickle cell
			anemia; cancer
1 1 62 Discontinued		5-fluoro-2'-	cancer
	<u> </u>	deoxyuridine 5'-	
	٢	tetradecylphosphate	

SD-144110

tucaresol; BWA	Phase II	4-[(2-formyl-3-	biolelo goll and
589C; BW 589C80;		hydroxyphenoxy)met	viral infection: HIV
BW 589C; 589C		hyl]benzoic acid	infection; cancer;
tumor suppressor genes, oncology,	Preclinical		cancer
Onyx	:		
tumor suppressor genes, Onyx	Preclinical		cancer
U 77863	Discontinued	trans-3-(2'-	cancer
•		methylphenyl)-2-	
		propene-1- carboxamide	
UBC 10 inhibitors,	Preclinical		cancer
cancer, ProScript			
UK 21	Preclinical ·	N-(1-0xo-2-	cancer
		propylpentyl)glycine	
		triester with 5-	
V 489	Phase I		cancer
VA 5	Preclinical	6-17 S-	Carloca 1
		dimethoxyphenyl)-	neart failure; cancer
		2,3-	
	_	dihydroimidazo[2,1-b]thiazole	
variolin B	Discontinued		cancer; viral
	,		infection
V Dacac	Preclinical		cancer; contraception
ייייייייייייייייייייייייייייייייייייייי	Preclinical		cancer; contraception
velaresol; BW 12C79;Suspended	Suspended	5-(2-formyl-3-	cancer; sickle cell
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		hydroxyphenoxy)- pentanoic acid	anemia
VG 18563	Preclinical		anemia: cancer
			2

SD-144110

vitamin B12 growth	Preclinical			
blockers, Receptagen			cancel	
WIN 33377	Discontinued	N-[[1-[[2-	cancer	
		(diethylamino)ethyl]a		
		mino]-9-oxo-9H-		
		thioxanthen-4-	_	
		yl]methyl]-		
		methanesulfonamide		_
	Preclinical		Cancer	
Y 25510	Discontinued	(+,-)-3-[4-[2-	recrea	
		(dimethylamino)-1-		
		methylethoxy phenyl]		_
		-1H-pyrazolo[3,4-		
		b]pyridine-1-acetic		
		acid		
YM.534	Phase I	6-[4-[[5-(1H-	cancer	
		imidazol-1-		
		yl)pentyl]oxy]phenox		
		y]-2,2-		
		dimethylhexanoic		
		acid ethyl ester		
		monohydrochloride		_
	Preclinical		cancer	Τ
YW 213	cal		cancer	Γ
ZD 2767P	Phase I	N-[[4-[bis(2-	cancer	Τ
		iodoethyl)amino]phen		
		oxy]carbonyl]-L-		
		glutamic acid		
	Preclinical		cancer	Γ
zilascorb; ZOXXOZ	Suspended	5,6-0-((RS)-	cancer	T
		benzylidene-alpha-L)-		

011771 00

	2.7			
zinostatin stimalamer; Marketed drug delivery system,	;Marketed	zinostatin stimalamer		cancer
neocarzinostatin;				
neocarzinostatin	·			
delivery system; YM 881; SMANCS				
ZK 119010	Preclinical	2-(4-hydroxyphenyl)-		cancer
		3-methyl-1-[6-(1-		TO THE
	-	pyrrolidinyl)hexyl]-		
ZYN 176	Suspended	וח-כ-וחחווו-דדד		***************************************
ZYN-LINKER	Preclinical			רמווכו
conjugated				cancer
thiocolchicine				
analogues			-	
epristeride; SKF	Discontinued	17beta-[[(1,1-	5 alpha reductase	benign prostate
105657; ONO 9302		dimethylethyl)amino] inhibitor	inhibitor	hypertrophy; cancer;
		carbonyl]androsta-		alopecia; acne
		3,5-diene-3-		
finasteride MK 906.	Marketed		5 -1-1- 1	
MK 0906 VM 152			aipiia reductase	cancer; benign
PROSCAR:		3-0x0-4-22020drost 1	ากภายาเจา	prostate
FINASPROS:		9-040-4-azaanulost-1- ene-17-carhoxamide		nypertrophy;
CHIBRO-				alopecia, acne
PROSCAR;				
FINASTID;				
PROSTIDE; EUTIZ;				
PRODEL;	•			
PROPECIA				
I 23 ·	Discontinued	*	5 alpha reductase	cancer; acne;
			HILITOROL	nirsunsm

SD-144110

Preclinical N-hydroxy-N-[1-[4- 5 lipoxygenase (phenylmethoxy)phen inhibitor y]ethyl]acetamide col; CHX Marketed (R*,S*)-4,4'-(2,3- inhibitor butanediy)]bis-1,2- benzenedio] 1A Discontinued (1alpha,2alpha,4beta) 5HT agonist 4-[[2-(1- piperaziny)])-4- quinazoliny]loxy]-1 2-cyclopentanedio] Preclinical (N-3-[4-[4- 5HT] A antagonist; dietrahydro-1,3- fHT] A antagonist; dietrahydro-1,3- glutamate release pyrrolo[1,2- inhibitor c]minbitor c]minbitor c]minbitor c]minbitor c]manesulfonamide ol; OM 3223Preclinical 5-(7,8-dihydro-8- adenosine deaminase hydroxymidazo[4,5- inhibitor d][1,3]aizaepin- (hydroxymethy)]-3- (hydroxymethy)]-3- (colonente-i,2-dio]					
(phenylmethoxy)phen inhibitor yl]ethyl]acetamide (R*,S*)-4,4-(2,3- dimethyl-1,4- butanediyl)bis-1,2- benzenediol 5 lipoxygenase inhibitor (1alpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl]-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- guinazolinyl]oxy]-1 glutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol	A 63162	Preclinical	N-hydroxy-N-[1-[4-	5 lipoxygenase	cancer
yl]ethyl]acetamide (R*,S*)-4,4'-(2,3- dimethyl-1,4- butanediyl)bis-1,2- benzenediol 5 lipoxygenase inhibitor (lalpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- guinazolinyl]oxy]-1 gutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol			Jen	inhibitor	
(R*,S*)-4,4'-(2,3- dimethyl-1,4- butanediyl)bis-1,2- benzenediol 5 lipoxygenase inhibitor (1alpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- Gimidazol-1,3- Gilutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor 3(4H)-yl)-3- cyclopentene-1,2-diol			yl]ethyl]acetamide		
dimethyl-1,4- butanediyl)bis-1,2- benzenediol led (1alpha,2alpha,4beta) 5HT agonist 4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- glutamate release pyrrolo[1,2- glutamate release pyrrolo[1,2- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- hydroxymethyl)-3- cyclopentene-1,2-diol	masoprocol; CHX	Marketed	2,3-	5 lipoxygenase	skin disease; cancer;
butanediyl)bis-1,2- benzenediol 5 lipoxygenase inhibitor (1alpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- Gioxo-1H- giutamate release pyrrolo[1,2- giutamate release pyrrolo[1,2- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- hydroxyimidazo[4,5- hydroxymethyl)-3- cyclopentene-1,2-diol	100; ACTINEX		•	inhibitor	psoriasis
benzenediol benzenediol [1alpha,2alpha,4beta] 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- Glimidazol-1,3- Glimidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol			butanediyl)bis-1,2-		
(lalpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- Gioxo-1H- giutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol			benzenediol		
(1alpha,2alpha,4beta) 5HT agonist -4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 ,2-cyclopentanediol N-3-[4-[4- Gioxo-1H- giutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol	SC 41661A	Discontinued		5 lipoxygenase	cancer
4-[[2-(1- piperazinyl)-4- quinazolinyl]oxy]-1 ,2-cyclopentanediol N-3-[4-[4- dioxo-1H- glutamate release pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol	KBR 8498	Preclinical	(Talnha 2alnha Aheta)	SHT agoniet	20000
piperazinyl)-4- quinazolinyl]oxy]-1 ,2-cyclopentanediol N-3-[4-[4- 5HT antagonist; dioxo-1H- glutamate release pyrrolo[1,2- inhibitor c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- adenosine deaminase hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-dio]			-4-[[2-(1-	our agomet	Calical
quinazolinyl]oxy]-1 2-cyclopentanediol N-3-[4-[4- N-3-[4-[4- N-3-[4-[4- Internydro-1,3- Indioxo-1H- Internydro-1,3- Internydro			piperazinyl)-4-		
2-cyclopentanediol N-3-[4-[4-] N-3-[4-[4-] SHT antagonist; (tetrahydro-1,3-] Glutamate release pyrrolo[1,2-] inhibitor c]imidazol-2(3H)- y]buty]]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8-] hydroxyimidazo[4,5-] inhibitor d][1,3]diazepin-] 3(4H)-yl)-3-] cyclopentene-1,2-diol			quinazolinyl]oxy]-1		
N-3-[4-[4-] 5HT antagonist; (tetrahydro-1,3-) 5HT1A antagonist; dioxo-1H-) glutamate release pyrrolo[1,2-) inhibitor c]imidazol-2(3H)-) piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8-) adenosine deaminase hydroxyimidazo[4,5-) inhibitor d][1,3]diazepin-3(4H)-yl)-3- cyclopentene-1,2-diol			,2-cyclopentanediol		
(tetrahydro-1,3- 5HT1A antagonist; dioxo-1H- glutamate release pyrrolo[1,2- inhibitor c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- cyclopentene-1,2-diol	EF 7412	Preclinical		5HT antagonist;	neurodegeneration;
dioxo-1H- dioxo-1H- pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol			-1,3-	5HT1A antagonist;	depression; cancer
pyrrolo[1,2- c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol				glutamate release	
c]imidazol-2(3H)- yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol			pyrrolo[1,2-	inhibitor	
yl)butyl]-1- piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol			c]imidazol-2(3H)-		
piperazinyl]phenyl]et hanesulfonamide 5-(7,8-dihydro-8- hydroxyimidazo[4,5- inhibitor d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cvclopentene-1,2-diol			yl)butyl]-1-		
hanesulfonamide 5-(7,8-dihydro-8- adenosine deaminase hydroxyimidazo[4,5- inhibitor d][1,3]diazepin-3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol			piperazinyl]phenyl]et		
5-(7,8-dihydro-8- adenosine deaminase hydroxyimidazo[4,5- inhibitor d][1,3]diazepin-3(4H)-yl)-3- (hydroxymethyl)-3- cyclopentene-1,2-diol			hanesulfonamide		
1,5- 3- diol	adecypenol; OM 3223	Preclinical		adenosine deaminase	cancer
d][1,3]diazepin- 3(4H)-yl)-3- (hydroxymethyl)-3- cvclopentene-1.2-diol			-5,	inhibitor	
3(4H)-yl)-3- (hydroxymethyl)-3- cvclopentene-1.2-diol		-	d][1,3]diazepin-		
(hydroxymethyl)-3- cvclopentene-1.2-diol		•	3(4H)-yl)-3-		
cyclopentene-1.2-diol			(hydroxymethyl)-3-		
			cyclopentene-1,2-diol		

pentostatin: 2'-	Marketed	(P)-3-(7 deavy bate leden-in-1	1	
deoxycoformycin;		D-erythro-	aucilosine deaminase inhibitor	cancer
covidarabine; CI 825;		pentofuranosyl)-		
81565; CL 67310465;		3,4,7,8- tetrahvdroimidazo[4.5		
YK 176; NIPENT; COFORIN		-d][1,3]diazepin-8-ol		
adenosine allosteric	Preclinical		adenosine regulatino	cardiovasonlar
modulators, Medco			agent	disease; cancer;
OCT 1003	Preclinical	3-nitrosobenzamide	ADDRT Ligand	stroke
OCT 1004	Preclinical	1	ADPRT ligand	cancer
forfenimex	Discontinued		П	
forphenicinol; BF 121		hydroxy-4-	arkanne pnospnatase inhibitor;	bacterial infection;
		(hydroxymethyl)benz immunostimulant		
Smbom Stire . Drr	1			
amoamustine; P.1.1	Phase III		alkylating agent	cancer
112, DEASTOR		chloroethyl)amino]-		
		IN-(4-Iluoro-L-		
		phenylalanyl)-L-		
****		phenylalanyl]-L-		
		methionine, ethyl		
bistriazenes NIH	Preclinical	CSICI		
å	Dhogo I			cancer
	r nase 1	[S-(K*,K*)]-6,6'- [carbonvlbis(imino-	alkylating agent	cancer
		1H-indole-5,2-		
		diylcarbonyl)]bis[8-		
		(chloromethyl)-		
		3,6,7,8-tetrahydro-1-		
		methylbenzo[1,2-		
		0.4,3-0 dipyrrol-4-01		

44	carzelesin; U 80244 Phase II	N-[2-[[1-	alkylating agent	cancer
		(chloromethyl)-1,6-		
		dihydro-8-methyl-5-		
		[[(phenylamino)carbo		
		nyl]oxy]benzo[1,2-	-	
		b:4,3-b']dipyrrol-	-	
		3(2H)-yl]carbonyl]-		
		1H-indol-5-yl]-6-	•	
		(diethylamino)-2-	-	
		benzofurancarboxami		
7		de		
	Discontinued	Discontinued [4-[3-(2-chloroethyl)- alkylating agent	alkylating agent	cancer
		1-(benzyl)-2-	•	
		triazenyl]-1,4-		
		dioxobutyl-beta-		_
		alanyl-tryptophyl-		
		methionyl-aspartyl-		
		phenylalaninamide		
	DABIS maleate; NSC Preclinical		alkylating agent	cancer
		diazoniabicyclo[2.2.1	_	
]heptane ((Z)-2-		
_		butenedioate (1:2)		

drug delivery system, Marketed	, Marketed		alkvlating agent	Cancer
carmustine			0 0	
biodegradable				
implant; drug delivery		- -		
system, sustained		:		
release BCNU;			<u></u>	
BIODEL BCNU				
implant; carmustine				
delivery system;	-			
prolifeprosan 20,				
carmustine implant;		· •		
GLIADEL;				
GLIADEL WAFER				
electrophilic	Preclinical		alkvlating agent	Concor
alkylating agents			magn grunn farm	calical
BioNumerik				
EO 9; NSC 382459	Phase II	(E)-5-(1-aziridinyl)-3-alkylating agent	alkylating agent	cancer
		(hydroxymethyl)-2-)	
		(3-hydroxy-1-		
		propenyl)-1-methyl-		
		1H-indole-4,7-dione		
estramustine analoguePhase II	Phase II		alkylating agent	cancer
famide; D	Phase I	1-[N,N'-bis(2-	alkylating agent	cancer
19575		Ä	•	
		odiamidate]-beta-D-		
		glucopyranose		
glutathione S-	Discontinued		alkylating agent	cancer
transferase-activated				
toxins, Telik	÷			
isopropyl pyrrolizine derivative; IPP	Discontinued		alkylating agent	cancer
KF 22678	Preclinical		alkylating agent	Concer
			in Juning about	cancel

77.1

mafosfamide; mefosfamide; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued	cis-(+,-)-2-[[2-[bis(2- alkylating agent chloroethyl)amino]tet rahydro-2H-1,3,2- oxazaphosporin-4- yl]thio]ethansulfonic acid P-oxide	alkylating agent	cancer
melphalan + A-MSH; Discontinued F1K	Discontinued		alkylating agent	cancer
melphalan + L-amino Preclinical oxidase	Preclinical		alkylating agent	cancer
OCX 177; OCX 0177 Preclinical	Preclinical		alkylating agent	cancer
porfiromycin;	Phase III	[1aS-	alkylating agent	cancer
porfiromycine; N-		a.a)	
ENT 50825; NSC		ipna.,86.aipna.)J-6- amino-8-		
56410; U 14743;		[[(aminocarbonyl)oxy		
PROMYCIN]methyl]-	-	
		1,1a,2,8,8a,8b-		
		hexahydro-8a-		
		methoxy-1,5-	:	
		dimethyl-		
		azirino[2',3':3,4]pyrro		
		lo[1,2-a]indole-4,7-		
SBR 11170; SBR 170 Preclinical			alkylating agent	cancer
temozolomide;	Marketed	3,4-dihydro-3-		cancer
methazolastone; SCH				
52365; CCRG 81045;		d]-1,2,3,5-tetrazine-8-		
NSC 362856; M&B		carboxamide		•
39831; TEMODAL				
treosulfan;	Marketed	L-threitol 1,4-	alkylating agent	cancer
OVASTAT;		dimethanesulfonate		1
VIV. ITOCOCKY				

TANT 1 500 10				
FINO 139348	Phase I	(7S-cis)-9-acetyl-7-	alkylating agent; DNA cancer	cancer
		[[3-(1-aziridinyl)-	intercalator	
		2,3,6-trideoxy-4-0-		
		(methylsulfonyl)-		
-		alpha-L-lyxo-	-	
		hexopyranosyl]oxy]-	-	•
		7,8,9,10-tetrahydro-		
	7	6,9,11-trihydroxy-		
		5,12- nanhthacenedione		•
mitolactol:	Marketed	1 6-dibromo 1 6	ollen latine and	
bromoalcohol;		dideoxygalactitol	alkylating agent; pentide	cancer
dibromodulcitol;				
DBD; NSC 104800; MITOI A CTOI .				
METHOLACTOLE	·			
ELOBROMOL	•	مد جاندواجہ		
bisaziridinylspermine; Preclinical	Preclinical	N,N'-bis[3-(1-	alkylating agent;	cancer
DAS		aziridinylpropyl)]-	polyamine analogue	
diarizidinvlsnermine: Preclinical	Preclinical	N. N. P. C. C.	-11111	
DASPM	ricciilicai	1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1	alkylating agent;	cancer
141 TO 141		azındınyi)propyi]- 1.4-butendiamine	polyamine analogue	
O6-benzylguanine	Phase I		alkvltransferase	Cancer
			inhibitor;	
			chemosensitizer	
samarıum 153 Sm	Marketed	(OC-6-21)-[[[1,2-	Ď,	cancer; pain;
exidronam; Sm 153-		ethanediylbis[nitrilobiradiotherapeutic		rheumatoid arthritis
COLIME; samarium		s(methylene)]tetrakis[
133-EDIMP;		phosphonato]](8-)-	-,	
samanum EDTMP;		N,N',OP,OP',OP'',OP''	-	
OY 1 424; OUADBAMET]-samarate(5-)-	-	
Taken and the		1555III		

abiraterone; piraterone; CB 7630; CB 7598	Phase I	(3beta)-17-(3- pyridinyl)-androsta- 5,16-dien-3-ol	androgen synthesis inhibitor	cancer
cancer therapy, Institute of Cancer Research	Preclinical		androgen synthesis inhibitor	cancer
cancer therapy, Saarbrucken University	Preclinical		androgen synthesis inhibitor	cancer
GI 111924	Suspended		androgen synthesis	cancer
VN 851	Preclinical		synthesis	cancer
VN 871	Preclinical		androgen synthesis	cancer
YM 116	Phase I	2-(1H-imidazol-4- ylmethyl)-9H- carbazole	androgen synthesis inhibitor	cancer
YM 53789	Preclinical	2-(6,7-dihydro-5H- pyrrolo[1,2- c]imidazol-7-yl)-9H- carbazole	androgen synthesis inhibitor	cancer
YM 55208	Preclinical	2-[1-(1H-imidazol-1- androgen synthesis yl)ethyl]-9H-: inhibitor carbazole	androgen synthesis inhibitor	cancer
gene therapy, cancer, Genetix	Preclinical		angiogenesis inducer; biotechnology; gene therapy	cancer
2-methyl-2- phthalimidino- glutaric acid	Preclinical		nesis inhibitor	cancer

9alpha-	Preclinical	(6-alpha)-17-	Total des ninomonos principals	
fluoromedroxyprogest		-fluoro-		calicel
erone acetate; FMPA		6-methyl-pregn-4-		
		ene-3,20-dione	-	
ANG 453; ZD 6126	Preclinical		angiogenesis inhibitor	cancer
angiogenesis	Preclinical		angiogenesis inhibitor cancer	cancer
inhibitor, Boston Life	4)	-		
Sciences				
angiogenesis	Phase I		angiogenesis inhibitor cancer	cancer
inhibitor, Merck		-		
KGaA; EMD 121974				
angiogenesis	Preclinical	-	angiogenesis inhibitor cancer	cancer
AstraZeneca		•		
angiogenesis	Preclinical		angiogenesis inhihitor cancer	Cancer
inhibitors,			10110111111 011011-90191-	Toolino.
Nanodesign		:.	. •	
angiogenesis	Preclinical		angiogenesis inhibitor cancer	Cancer
inhibitors,				
Novartis/Schering				
AG			-	
angiogenesis	Preclinical		angiogenesis inhibitor cancer: retinonathy	cancer: retinopathy
inhibitors, Repligen				
CT 3577	Discontinued		angiogenesis inhibitor cancer	Sancer

FCE.26644; PNU	Preclinical	7,7'-	angiogenesis inhibitor cancer	cancer
151484		[carbonylbis[imino(1-		
-		methyl-1H-pyrrole-		
		4,2-		
		diyl)carbonylimino(1-		
		methyl-1H-pyrrole-		
		4,2-		
•		diyl)carbonylimino]]b		
	-	is-1,3-		
		naphthalenedisulfonic		
		acid tetrasodium salt	•	
FCE 27164; PNU	Preclinical	7,7'-	angiogenesis inhibitor cancer	cancer
165897		[carbonylbis[imino(1-		
		methyl-1H-pyrrole-	-	
-		4,2-		
	•	diyl)carbonylimino(1-		
		methyl-1H-pyrrole-		
		4,2-		
		diyl)carbonylimino]]b		
		is-1,3,5-		
		naphthalenetrisulfonic		
		acid hexasodium salt		
gene discovery, tumorPreclinical epithelium	rPreclinical		angiogenesis inhibitor cancer	cancer
greenstatin	Preclinical		angiogenesis inhibitor cancer	cancer
irsogladine;	Marketed		angiogenesis inhibitor gastrointestinal	gastrointestinal
irsogladine maleate;)	ulcer: cancer
isaglidole; MN 1695;	-	triazine		
GASLON;		: .	:	
GASLON-N			-	
RG 8803; RG	Preclinical		angiogenesis inhibitor cancer	ancer
8803B11; RG 1009				

squalamine	Phase I	(3heta Salfa 7alfa 24R	(3heta Salfa 7alfa 24Rangiogenesis inhihitan Limit infontion)	riant in Continue
· <u>-</u>)-3-[[3-[(4-		cancer: retinopathy
		aminobutyl)amino]pr		
		opyl]amino]cholestan		
		e-/-24-diol 24-	,	
00036 00		(nydrogen sultate)		
SK 23769	Discontinued		angiogenesis inhibitor	cancer
SU 301	Discontinued		angiogenesis inhibitor cancer	cancer
SU 302	Discontinued		angiogenesis inhibitor	cancer
suradista	Phase I			cancer
TAN 1120	Preclinical	8-acetyl-7,8,9,10-		cancer
			•	
		trihydroxy-1-		
		methoxy-10-		
		[[octahydro-5-		
	•	hydroxy-2-(2-	-	
		hydroxypropyl)-4,10-		
		dimethylpyrano[3,4-		
		d]-1,3,6-dioxazocin-		
		8-yl]oxy]-5,12-	٠.	
17 03		naphthacenedione		
12.93	Discontinued	3	angiogenesis inhibitor k	cancer
VE-cadherin-2	Preclinical		angiogenesis inhibitor cancer	ancer
antagonists, ImClone)	
Systems		. :.	-	
VEGF receptor	Preclinical		angiogenesis inhibitor cancer	ancer
modulators,				
Pharmacopeia				
INGN 401	Preclinical		angiogenesis inhibitor; cancer antiproliferative agent	ancer
soluble Tie-2	Preclinical		angiogenesis inhibitor; cancer	ancer
			biotechnology	

angiogenesis inhibitor, Bio-	Preclinical		angiogenesis inhibitor; cancer	cancer
Technology General;			coccomiotogy, populac	
plasminogen-related				
peptide Bio-				
l echnology General				
8999 OS	Phase I		angiogenesis inhibitor; cancer	cancer
			growth factor	
AE 941:	Phace III		inouniator	
NEOVASTAT;	2		Auglogenesis innibitor; cancer; psonasis;	cancer; psoriasis;
NEORETNA;				eve disesse:
PSOVASCAB.				cyc discase,
ARTHROVAS				retinopathy
FR 111142; WF	Discontinued	4,5-dihydroxy-2-	angiogenesis inhibitor; cancer; rheumatoid	cancer; rheumatoid
K015A		hexenoic acid 5-	NSAID	arthritis: retinopathy
		methoxy-4-[2-methyl-		(
		3-(3-methyl-2-		
	•	butenyl)oxiranyl]-1-		
, .		oxaspiro[2.5]oct-6-yl		
heparanase inhibitors, Preclinical InSight	Preclinical	***	angiogenesis inhibitor; cancer; inflammation	cancer; inflammation
troponin I; cartilage	Preclinical		angiogenesis inhibitor: cancer: rhenmatch	ancer rhenmatoid
derived inhibitor			NSAID: biotechnologyarthritis: eye disease	arthritis. eve disease
antiangiogenesis	Discontinued		angiogenesis inhibitor; cancer; restenosis	ancer; restenosis
agent, Ixsys			peptide	
XMP 300	Preclinical		angiogenesis inhibitor; inflammation; cancer	nflammation; cancer
			peptide	
ENDOSTATIN	Preclinical		angiogenesis inhibitor; cancer	ancer
			peptide; biotechnology	

thrombospondin 1	Preclinical		angiogenesis inhibitor; cancer; diagnosis;	cancer; diagnosis;
innibitor, inkine;			platelet antiaggregant; thrombosis	thrombosis
LSF-1 inhibitor,			radiodiagnostic;	
in The in the interest of the			contrast medium	
tecogalan sodium; DS Phase I	Phase I	sulfated	angiogenesis inhibitor; cancer	cancer
4152; SP PG		polysaccharide	polysaccharide sulfate	
		peptidoglycan	,	
SU 5416	Phase II	3-[(4,5-dimethyl-1H-	3-[(4,5-dimethyl-1H- angiogenesis inhibitor; cancer	cancer
	-	pyrrol-2-	tyrosine kinase	
		yl)methylene]-1,3-	inhibitor; signal	
		/dro-2H-indol-2-	transduction inhibitor	
		one		
rubiginone B1	Discontinued		angucyclinone;	cancer
aclamihicin.	L'andrada A	0 101 40 4171	antiblotic	
	Marketed	-2-		cancer
aciaruoicin		,	antibiotic; DNA	
nyarochloride;			intercalator	
aclacinomycin A;		trihydroxy-6,11-	•	
NSC 208734; MA		dioxo-4-[[2,3,6-		
144A1; JACLACIN;		trideoxy-4-0-[2,6-	-	
ACLAPLASTIN;		dideoxy-4-0-	-	
ACLACINOMYCIN;		[(2R,6S)-tetrahydro-		
ACLACINON		6-methyl-5-oxo-2H-		-
		pyran-2-yl]-alpha-L-		
		lyxo-hexopyranosyl]-		
		3-(dimethylamino)-		
		alpha-L-lyxo-hexo-		
		pyranosyl]oxy]-1-		
		naphthacenecarboxyla		
		te		

dance delinear	:			
ulug delivery system, Fnase II	Fnase II	:	anthracycline;	cancer
nposome			antibiotic: DNA	
anthracycline;			intercalator	
anthracycline		· ·		
liposome; AR 522;				
ANNAMYCIN				
IT 62B	Discontinued		anthracycline;	cancer; bacterial
		· • · · ·	antibiotic; DNA	infection
1 4360 00			mercarator	
SO U/SKI	Preclinical		anthracycline;	bacterial infection;
•		-	antibiotic; DNA	cancer
			intercalator	
bisantrene; bisantrene Phase III	Phase III	bis[(4,5-dihydro-1H-	anthracycline: DNA	Cancer
hydrochloride; CL			intercalator: antibiotic	
216942; NSC		yl)hydrazone]-9,10-		
337766; ADCA;		anthracenedicarboxal	•••	
CYABIN		dehyde		<i></i>
daunoform	Preclinical		anthracycline; DNA	cancer
			intercalator; antibiotic	
doxoform	Preclinical		anthracycline; DNA	cancer
			intercalator; antibiotic	
	Preclinical			cancer
micellar doxorubicin;		- F	intercalator; antibiotic	
doxorubicin micelles				
epidoxoform	Preclinical			cancer
			intercalator; antibiotic	

nemorubicin; FCE	Phase II		anthracycline; DNA	cancer
23762			intercalator; antibiotic	
		7,8,9,10-tetrahydro-		
,	.,, -	6,8,11-trihydroxy-8-		
		(hydroxyacetyl)-1-		
		methoxy-10-[[2,3,6-	***	
		trideoxy-3-(2-	-	
		methoxy-4-morpho		
		linyl)-alfa-L-lyxo-		
		hexopyranosyl]oxy]-	-	
		5,12-		
		naphthacenedione		
ZYN 191	Suspended		anthracyclinė; DNA	cancer
			intercalator; antibiotic	
D 26232; AN 207	Preclinical	(2S-cis)-6-[N6-[5-[2 - anthracycline; DNA	anthracycline; DNA	cancer
		[1,2,3,4,6,11-	intercalator; antibiotic;	
		5,12-	gonadorelin agonist;	
			peptide	
		methoxy-6,11-dioxo-		
		4-[[2,3,6-trideoxy-3-		
		(2,3-dihydro-1H-		
		pyrrol-1-yl)-alpha-L-		
		lyxo-		
		hexopyranosyl]oxy]-		
		2-naphthacenyl]-2-		
		oxoethoxy]-1,5-	.*	
		dioxopentyl]-D-		
		lysine]-luteinizing		
		hormone-releasing		
•		factor (swine)		
AN 1006	Discontinued		anthraquinone	cancer

anthraquinone prodrugs. De	Discontinued		anthraquinone;	cancer
Montfort University			radiosensitizer	
antiandrogen, prostatic carcinoma	Discontinued		antiandrogen	cancer
bicalutamide; Zeneca 176334; ICI 176334; CASODEX	Marketed	(+,-)-N-[4-cyano-3- (trifluoromethyl)phen yll-3-[(4-	antiandrogen	benign prostate hypertrophy; cancer
		fluorophenyl)sulfony I]-2-hydroxy-2- methylpronanamide		
ICI 192779	Suspended	Т	antiandrogen	cancer
LGD 1331	Preclinical	:	antiandrogen	cancer; benign
				prostate
				hypertrophy; acne; alonecia
nilutamide; RU	Marketed	thyl-3-[4-	antiandrogen	cancer
ANANDRON:		nitro-3-		
NILANDRON		yl]-2,4-		
osaterone; osaterone	Pre-	-	antiandrogen	honiga arogoto
	registration	-a-		hypertrophy; cancer;
ne; WIN	Phase II		antiandrogen	Osteoporosis henion prostate
		Ë		hypertrophy; cancer
		pregn-20-yno[3,2- c]pyrazol-17-ol		
	Discontinued		antibiotic	cancer
virenomycin M, V				

	Discontinued	2-(4,4-anhydro-1,6-	antibiotic	cancer
		dideoxy-alfa-L-sorbo-		
		2,3-oxiranosyl)-11-		
		hydroxy-5-methyl-10-		
		[2,3,6-trideoxy-3-		
		(dimethylamino)-3-C-		
		methyl-alfa-L-lyxo-		
		hexopyranosyl]-4H-	-	
		anthra[1,2-b]pyran-		
		4,7,12-trione		
antibiotic, Sagami	Preclinical	9"	antibiotic	cancer
ı		dideoxy-alpha-L-		
		lyxo-		
		hexopyranosyl)oxy]-	-	
		9-(fluoroacetyl)-		
		7,8,9,10-tetrahydro-		
		6,9,11-trihydroxy-		
	•	5,12-		
		naphthacenedione		
anticancer, Chugai	Discontinued	3'-deoxytalopiericidin antibiotic	antibiotic	cancer
		A1 (DTPA)		
	Discontinued	ġ.	antibiotic	cancer
		[2,4-dideoxy-4-		
		(methylamino)-alpha-		
		D-threo-pento		
		pyranosyl]-4-0-		
		methyl-beta-D-		
		glucopyranosyl]-		
		12,13-dihydro-6-5H-i		
		ndolo[2,3-		
		a]pyrrolo[3,4-		
		c]carbazole-5,7(6H)-		-
		dione		

azamitosenes	Preclinical		antibiotic	Concor
DE 12406 A		-1	animologic	calicer
PC 12400A	Discontinued		antibiotic	cancer
		mannopyranosyl)oxy]		
-		-1-hydroxy-10-	•	
		methoxy-8-methyl-		
		-H9		
		benzo[d]naphtho[1,2-		
		b]pyran-6-one		
betaclamycin B; BCMA	Preclinical		antibiotic	cancer
CC 1065	Discontinued		antibiotic	bacterial infection:
•	•	dihydro-4-hydroxy-5-		cancer
•		methoxy-7-[(4,5,8,8a-		
		tetrahydro-7-methyl-		
		4-		
		oxocyclopropa[c]pyrr		
		olo[3,2-e]indol-		
		Z(1H)-		
		yl)carbonyl]benzo[1,2		
		-b:4,3-b']dopyrrol-		
		3(2H)-yl]cabonyl-1;6-		
		dihydro-4-hydroxy-5-		
		methoxybenzo[1,2-		
		b:4,3-b']dipyrrole-		
		3(2H)-carboxamide		
collismycin A; SF	Discontinued		antibiotic	cancer
7/38A		(methylthio)-[2,2'-		
		bipyridine]-6-		
		carboxaldehyde		
		oxime		
		7	I	

collismycin B; SF 2738B	Discontinued	Discontinued (Z)-4-methoxy-5- (methylthio)-[2,2'- bipyridine]-6- carboxaldehyde oxime	antibiotic	cancer
collismycin C; SF 2738C	Discontinued		antibiotic	cancer
cypemycin	Discontinued	N,N-dimethyl-L- alanyl-(E)-2,3- didehydro-2- aminobutanoyl-L- prolyl-L-alanyl-(E)- 2,3-didehydro-2- aminobutanoyl-L- prolyl-(E)-2,3- didehydro-2- aminobutanoyl-L- prolyl-L-alanyl-L- glutaminyl-L- phenylalanyl-L- phenylalanyl-L- glutaminylglycyl-L- seryl-(E)-2,3- didehydro-2- aminobutanoyl-L-	antibiotic .	bacterial infection;
		isoleucyl-L-cysteinyl-L-leucyl-N-(2-		
		mercaptoethenyl)-L- leucinamide cyclic	:	
		(12-71)-sulude		

...

dioxamycin; BE	Preclinical	[2alfa, 3alfa, 4aalfa, 9[2 antibiotic	antibiotic	cancer, hacterial
16493		R*,3S*[1E(2S*,4S*,5		infection
		S*),3E,5E],6R*],12ba		TO T
		Ifa]-(+)-2,4-dimethyl-		
		5-[7-0xo-7-		
		[[tetrahydro-2-		
		methyl-6-		
		(1,2,3,4,4a,7,12,12b-		
		octahydro-		
		2,3,4a,8,12b-		
		pentahydroxy-3-		
		methyl-1,7,12-		
		trioxobenz[a]anthrace		
	•	n-9-yl)-2H-pyran-3-		
		yl]oxy]-1,3,5-		
-	•	heptatrienyl]-1,3-		
		dioxolane-2-		
		carboxylic acid		
eponemycin; BMY	Discontinued	*)]]-	antibiotic	cancer
2001, DO 30041		-1]-1		
		(hydroxymethyl)-2-		
		[[1-[[2-		
		(hydroxymethyl)oxira		
		hyl]carbonyl]-3-		
		methyl-3-	•	
*		butenyl]amino]-2-	·	
		oxoethyl]-6-		
		methylheptanamide		
epoxomicin	Discontinued		antibiotic	cancer
	200000000000000000000000000000000000000		alludionic	

esperatrucin;	Discontinued [1R-		antibiotic	cancer
esperamicin A1;		(1R*,4Z,8S*,12S*,13		
esperamycin;		E)]-4,5-dimethoxy-2-		
esperamcin; BMY		[(2-methoxy-1-oxo-2-		
28175; BBM		propenyl)amino]benz		
1675A1; BBM 1675		oic acid 3'(12)-ester		
		with methy] [8-[[4,6-		
		dideoxy2-0-[2,4-		
		dideoxy-3-0-methyl-		
		4-[(1-		
		methylethyl)amino]-		
		alfa-L-		
-		threopentopyranosyl]-	•	
		4-[[(2,6-dideoxy-4-S-		
		methyl-4-thio-beta-D-		
		nibo-		
		hexopyranosyl)oxy]a		
		mino]-beta-D-		
		glucopyranosyl]oxy]-		
	-	12-[(2,6-dideoxy-alfa-		
		L-lyxo-		
• -		hexopyranosyl)oxy]-		
		l-hydroxy-13-[2-		
	<u> </u>	(methyltrithio)ethylid		
	Ψ	ene]-11-		
	v	oxobicyclo[7.3.1]tride		
		ca-4,9-diene-2,6-		
		diyn-10-yl]carbamate		

									**																
cancer												cancer													
antibiotic												antibiotic													
	(hexahydro-2,4,6-	trioxo-5-	pyrimidinyl)octahydr	o-2-(2-	hydroxypropyl)-4,10-	dimethylpyrano[3,4-	d]-1,3,6-dioxazocin-	8-yl]oxy]-6,8,11-	trihydroxy-1-	methoxy-5,12-	naphthacenedione		(hexahydro-1,3-	dimethyl-2,4,6-trioxo-	5-	pyrimidinyl)octahydr	0-2-(2-	hydroxypropyl)-4,10-	dimethylpyrano[3,4-	d]-1,3,6-dioxazocin-	8-yl]oxy]-7,8,9,10-	tetrahydro-6,8,11-	trihydroxy-1-	methoxy-5,12-	haphthacenedione
Preclinical												Preclinical													
FCE 21424											•	FCE 24366		•											

FK 317 methoxy-5,12- naphthacenedione fluorodaunorubicin Preclinical 10-[(3-amino-2,3,6-antibiotic cancer trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]- 8-(fluoroacetyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione		Preclinical	8-acetyl-10-[[5- (hexahydro-4,6- dioxo-2-thioxo-5- pyrimidinyl)octahydr. o-2-(2- hydroxypropyl)-4,10- dimethylpyrano[3,4- d]-1,3,6-dioxazocin- 8-yl]oxy]-7,8,9,10- tetrahydro-6,8,11-	antibiotic	cancer
ical 10-[(3-amino-2,3,6- antibiotic trideoxy-alpha-L- lyxo- hexopyranosyl)oxy]- 8-(fluoroacetyl)- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione			methoxy-5,12- naphthacenedione		
10-[(3-amino-2,3,6- trideoxy-alpha-L- lyxo- hexopyranosyl)oxy]- 8-(fluoroacetyl)- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione	\neg	Phase I		antibiotic	cancer
lyxo-hexopyranosyl)oxy]- 8-(fluoroacetyl)- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione		Preclinical	-9		cancer
hexopyranosyl)oxy]- 8-(fluoroacetyl)- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione			lyxo-		
8-(Iluoroacetyl)- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione			hexopyranosyl)oxy]-		
6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione			8-(fluoroacetyl)-		
methoxy-5,12- naphthacenedione			/,8,9,10-tetrahydro-		
methoxy-5,12- naphthacenedione			o,o,11-unnyaroxy-1-		
naphthacenedione			methoxy-5,12-		
			naphthacenedione		

hatomamicin: VI	Dragitation	400		
os cos es	ן זכטוווונקן	[2K-	antibiotic	cancer
USSSIMA		[2alfa,3alfa,6alfa[1R*		
÷		(S*),2Z,4E(1alfaS*,7		
		alfaR*)111-6-[[4-(23-	7	
		dib.:d=00::010		
		umyarocyclopent b jo		
-	-	xıreno[c]pyridin-		
		7(1aH)-ylidene)-1-(1-		
		hydroxypropyl)-3-		
		methyl-2-		
×-		butenyl]oxy]tetrahydr		
		o-2-methyl-2H-pyran-		
		3-o1		
himastatin; BMY	Discontinued		antibiotic	bacterial infection;
40800				cancer
hydramycin	Discontinued	[4S-	antibiotic	cancer: bacterial
		(4alfa,4aalfa,5alfa,5aa		infection
		lfa,6alfa,12aalfa)]-4-		
		(dimethylamino)-		
		1,4,4a,5,5a,6,11,12a-		,
		octahydro-		
		3,5,10,12,12a-		
		pentahydroxy-6-		
		methyl-1,11-dioxo-2-		
		naphthacenecarboxam		
		ide		
K 818B	Discontinued		antibiotic	cancer
kedarcidin	Discontinued			
	naniiiiinaasi		מוזטוסוזורום:	pacterial infection;
		-		cancer
N.1 3432	Discontinued		antibiotic	cancer

0.144110

cancer: bacterial	infection	•								cancer	cancer											cancer	cancer; bacterial	infection			•
antibiotic										antibiotic	antibiotic											antibiotic	antibiotic		٠		
(S)-8-(bromomethyl)- antibiotic	3,6,7,8-tetrahydro-2- methyl-4-[[(4-methyl-		piperazinyl)carbonyl]	oxy]-6-[(5,6,7-	trimethoxy-1H-indol-	vl)carbonyl]benzo[1.2	-b:4,3-b']dipyrrole-1-	carboxylic acid,	methyl ester			[2'R*,6'R*(R*),9'E,11	R*,13'E,15'Z]]-4,11'-	dihydroxy-2',4,9'-	trimethylspiro[1,2-	dithiolane-3,6/-	[19]thia[3,20]diazabic	yclo[15.2.1]eicosa[1(20),9,13,15,17]pentae	ne]-4',5,12'-trione 2-	oxide		N1-[3-[[3-[bis[[3,4-	bis(phenylmethoxy)p	henyl]methyl]amino]	propyl]methylamino]	
Phase II	·			-						Discontinued	Discontinued		•									Preclinical	Discontinued				
KW 2189										lactimidomycin	leinamycin;	leinomycin; DC 107										leptolstatin	liblomycin; NK 313				

nisamycin; antibiotic Preclinical	reclinical	[1S-	antibiotic	bacterial infection:
106B		[1alfa,2beta,2(2E,4E,		cancer
		6E),4(2E,4E),6alfa]]-		
		7-[4-[(5-cyclohexyl-		
		1-0xo-2,4-		
		pentadienyl)amino]-		
		2-hydroxy-5-oxo-7-		
		oxabicyclo[4.1.0]hept		
		-3-en-2-yl]-2,4,6-		
		heptatrienoic acid		
nycin E; MCI	Discontinued	26-hydroxy-28-;	antibiotic	cancer
2225		oxooligomycin A		
oxaunomycin; D 788; Preclinical	eclinical	. •	antibiotic	cancer
R 20X2		(7alfa,8beta,10beta)]-		
•		10-[(3-amino-2,3,6-		
		trideoxy-alfa-L-lyxo-		
		hexopyranosyl)oxy]-	•	
		8-ethyl-7,8,9,10-		
		tetrahydro-1,6,7,8,11-		
		pentahydroxy-5,12-		
		naphthacenedione		-
phenazinomycin; (-)- Pre	Preclinical	[R-(E)]-5-[5-(2,2-	antibiotic	bacterial infection;
		methylenecyclohexyl)		cancer
		-3-methyl-2-pent		
		enyl]-1(5H)-		
		phenazinone		

(chloromethyl)- 1,2,3,6,7,8- hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7; trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2 b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- nantibiotic	pyrindamycin A	Discontinued		antibiotic	cancer
1,2,3,6,7,8- hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2- b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester B-chloro-2,3,6,7,8,9- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- flquinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- manthyl ester Discontinued 1,3,8,10,11-			(chloromethyl)-		
hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2 -b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- flquinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- nanhthacenedione			1,2,3,6,7,8-		
hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2 -b:4,3-b']dipyirrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyirrolo[3,2- flquinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- manhthacenedione			hexahydro-4-		
oxo-6-[(5,6,7; trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2 -b.4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- manhthacenedione			hydroxy-2-methyl-1-		
trimethoxy-1H-indol- 2- yl)carbonyl]benzo[1,2 -b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-2,3,6,7,8,9- antibiotic hexahydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione		-	oxo-6-[(5,6,7-		
2- yl)carbony]benzo[1,2 -b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbony]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			trimethoxy-1H-indol-		
yl)carbony l]benzo [1,2] -b:4,3-b'] dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo [3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			4		
-b:4,3-b']dipyrrole-2- carboxylic acid, methyl ester hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			yl)carbonyl]benzo[1,2		
carboxylic acid, methyl ester lycin B Discontinued 8-chloro-2,3,6,7,8,9- antibiotic hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione		· y-	-b:4,3-b']dipyrrole-2-		
methyl ester lycin B Discontinued 8-chloro-2,3,6,7,8,9- antibiotic hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			carboxylic acid,		
lycin B Discontinued 8-chloro-2,3,6,7,8,9- antibiotic hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			methyl ester		
hexahydro-4- hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione	pyrindamycin B	Discontinued	I	antibiotic	cancer
hydroxy-2-methyl-1- oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			hexahydro-4-		
oxo-6-[(5,6,7- trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- nanhthacenedione			hydroxy-2-methyl-1-		
trimethoxy-1H-indol- 2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- nanhthacenedione			oxo-6-[(5,6,7-		
2-yl)carbonyl]-1H- pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- hanhthacenedione			trimethoxy-1H-indol-		
pyrrolo[3,2- f]quinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- haphthacenedione	-		2-yl)carbonyl]-1H-		
fjquinoline-2- carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- nanhthacenedione			pyrrolo[3,2-		
Carboxylic acid, methyl ester Discontinued 1,3,8,10,11- pentahydroxy-5,12- manhthacenedione			f]quinoline-2-		
Discontinued 1,3,8,10,11- pentahydroxy-5,12- manhthacenedione			carboxylic acid,		
Discontinued 1,3,8,10,11- pentahydroxy-5,12- manhthacenedione			methyl ester		
	saintopin	Discontinued		antibiotic	bacterial infection;
haphthacenedione			pentahydroxy-5,12-		cancer
			naphthacenedione	•	

saptomycin D	Discontinued	Discontinued [2alfa 3heta(Z)]-10-	antihiotic	London Pooton
				infection
·		trideoxy-3-		IIIIectioii
	-	(dimethylamino)-3-C-		
		methyl-alfa-L-lyxo-		
		hexopyranosyl]-11-		
		hydroxy-5-methyl-2-		
		[2-methyl-3-(1-		
-	_	propenyl)oxiranyl]-		
		4H-anthra[1,2-		
		b]pyran-4,7,12-trione		
SPM VIII	Discontinued	$\overline{}$	antibiotic	cancer
		oxododecyl)amino]ac		
		etyl]amino]-N-1H-		
		purin-6-yl-L-glycero-		
		beta-L-manno-		
		heptopyranosylamine		
tetrazomine; Y	Preclinical		antibiotic	bacterial infection:
09194L-B		[2a,3,4,5,6,6a,7,11b-		cancer
		octahydro-5-		
		(hydroxymethyl)-11-		
		methoxy-12-methyl-		
		3,6-imino-1H-2-oxa-		
		11c-azanaphth[1,2,3-		
		cd]azulen-10-yl]-2-		
		piperidinecarboxamid		
		υ.		
UCA 1064B	Discontinued		antibiotic	cancer
vicenistatin	Discontinued		antibiotic	cancer

Y 05460MA	Preclinical	4-amino-4,5,6-	antibiotic	bacterial infection.
		trideoxy-N-[1-(3,4-		cancer
		dihydro-8-hydroxy-	•	
		1H-2-benzopyran-3-		
		yl)-3-methylbutyl]-5- methylbexonamide		
drug delivery system, Discontinued	Discontinued		antibiotic. alleviating	***************************************
mitomycin;			amout, any jamig	calicel
mitomycin			0	
Therapeutic Implant; MPI 5016				
HMAF	Phase II		antibiotic; alkylating	cancer
		methyl)-	agent; terpene	
			•	
		trimethylspiro[cyclop		
		ropane-1,5'-		
		[5H]inden]-7'(6'H)-		
		one		
AGM 1470; TNP 470 Phase I	_	[3R-[3alfa, 4alfa	antibiotic;	cancer
		(2R*,3R*),5beta,	angiogenesis inhibitor	
		6beta]]-5-methoxy-4-		
		[2-methyl-3-(3-		
		methyl-2-		
		outenyl)oxiranyl]-1-		
		oxaspiro[2.5]oct -6-yl		
	د ه	ביין השניין היום היום מיים מיים היום		
		chioroacetyl ester		

AD 143	Preclinical	hexanedioic acid (2S- antibiotic:	antihiotic:	***************************************
		cis)-mono[2-	anthracycline: DNA	Calicol
		[1,2,3,4,6,11-	intercalator	
		hexahydro-2,5,12-		
		trihydroxy-7-		
		methoxy-6,11-dioxo-		
•	-	4-[[2,3,6-trideoxy-3-		
		[(trifluoroacetyl)amin		
		o]-alfa-L-lyxo-		
		hexopyranosyl]oxy]-		
		2-naphthacenyl]-2-		
		oxoethyl] ester		
AD 198	Preclinical		antibiotic;	cancer
		cis)-2-[1,2,3,4,6,11-	anthracycline; DNA	
		hexahydro-2,5,12-	intercalator	•
		trihydroxy-7-	•	
		methoxy-6,11-dioxo-		
		4-[[2,3,6-trideoxy-3-		
		[(phenylmethyl)amin		
		o]-alpha-L-lyxo-		
		hexopyranosyl]oxy]-		
		2-naphthacenyl]-2-		
on the contract of the contrac		oxoethyl ester		
and acycline	Discontinued		antibiotic;	cancer
analogue, BioChem			anthracycline; DNA	
			intercalator	
B 880308	Suspended	7-0-(3-N-methyl-3-N-antibiotic;	antibiotic;	cancer
	*	(R)-glycidyl-alpha-L- anthracycline; DNA	anthracycline; DNA	
	• :	daunosaminyI)-beta-	intercalator	
		rhodomycinone		

n, Discontinued n, Preclinical n, Preclinical n, Preclinical n, Preclinical n, Preclinical n, Preclinical	drug delivery system, ATRIGEL sustained	Preclinical		antibiotic;	cancer
m, Discontinued antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator in, Discontinued antibiotic; anthracycline; DNA intercalator in, Phase I antibiotic; anthracycline; DNA intercalator in, Phase I antibiotic; anthracycline; DNA intercalator intercalator	release doxorubicin;			intercalator	
m, Discontinued antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator t, h, Phase I antibiotic; anthracycline; DNA intercalator in, Phase I antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator	doxorubicin				
m, Discontinued antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator	ATRIGEL				
m, Discontinued n, Discontinued n, Preclinical n, Preclinical n, Preclinical n, Discontinued n, Discontinued antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator t; the phase I antibiotic;	drug delivery system,	Discontinued		antibiotic;	cancer
m, Discontinued n, Discontinued n, Preclinical n, Preclinical n, Discontinued n, Discontinued n, Discontinued antibiotic;	doxorubicin;		-	anthracycline: DNA	
m, Discontinued n, Preclinical n, Preclinical n, Discontinued n, Discontinued n, Discontinued n, Discontinued antibiotic;	doxorubicin drug			intercalator	
m, Discontinued n, Preclinical n, Preclinical n, Discontinued n, Discontinued antibiotic;	delivery system; AD				
m, Discontinued antibiotic; anthracycline; DNA intercalator n, Preclinical n, Discontinued antibiotic; anthracycline; DNA intercalator t; antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; antibracycline; DNA intercalator intercalator intercalator	70; ADM OXD; GC		·		
m, Discontinued n, Preclinical n, Preclinical n, Discontinued n, Discontinued n, Phase I n, Phase I antibiotic;	1004				
n, Preclinical antibiotic; ant	drug delivery system,			antibiotic:	Cancer
n, Preclinical antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator t; n, Phase I antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator intercalator intercalator	loxorubicin;			anthracycline: DNA	
n, Preclinical antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator t; n, Phase I antibiotic; anthracycline; DNA intercalator intercalator intercalator antibiotic; anthracycline; DNA intercalator intercalator	doxorubicin drug			intercalator	
n, Preclinical antibiotic; anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator t; n, Phase I antibiotic; anthracycline; DNA intercalator 1 intercalator 1 intercalator	delivery system				
anthracycline; DNA intercalator n, Discontinued antibiotic; anthracycline; DNA intercalator t; n, Phase I antibiotic; anthracycline; DNA intercalator Intercalator intercalator antibiotic; anthracycline; DNA intercalator	frug delivery system,	Preclinical		antibiotic:	cancer
n, Discontinued antibiotic; anthracycline; DNA intercalator n, Phase I antibiotic; anthracycline; DNA intercalator anthracycline; DNA intercalator intercalator	loxorubicin;		-	anthracycline: DNA	
n, Discontinued anthracycline; DNA intercalator in, Phase I antibiotic; anthracycline; DNA intercalator intercalator	loxorubicin-tumor			intercalator	
n, Discontinued antibiotic; anthracycline; DNA intercalator antibiotic; antibiotic; anthracycline; DNA intercalator intercalator	noming peptide;				
n, Discontinued antibiotic; anthracycline; DNA intercalator t; n, Phase I antibiotic; anthracycline; DNA intercalator	fHP-doxorubicin				
anthracycline; DNA intercalator n, Phase I antibiotic; anthracycline; DNA intercalator	Irug delivery system,			antibiotic:	cancer
t; n, Phase I antibiotic; anthracycline; DNA intercalator	loxorubicin;			anthracycline: DNA	
n, Phase I antibiotic; anthracycline; DNA intercalator	loxorubicin			intercalator	
n, Phase I antibiotic; anthracycline; DNA intercalator	Therapeutic Implant;			-	
n, Phase I antibiotic; anthracycline; DNA intercalator	MPI 5015				
anthracycline; DNA intercalator	Ing delivery system,	Phase I		antibiotic;	Sancer
	IPMA polymer-	•		anthracycline: DNA	
	oound doxorubicin;			intercalator	
oolvmer-bound: PK 1	loxorubicin HPMA	₹.	•		
	polymer-bound; PK 1				

متعربين رصوريزاما مرسام	h (- 1 - 1 - 1			
lingent of system, marketed	IMAINCICA		antibiotic;	cancer
ашогоди			anthracycline; DNA	
daunorubicin;			intercalator	
daunorubicin				
liposome; VS 103;				
DannoXome				
drug delivery system,	Discontinued		antibiotic;	cancer
liposome			anthracycline: DNA	
doxorubicin;		•	intercalator	
doxorubicin				
liposome; DOXOME				
drug delivery system, Pre-	Pre-		antibiotic;	cancer
liposome	registration		anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin				
liposome; TLC D99;				
TLC DOX 99; DOX				
99; EVACET;				
LIPODOX				
drug delivery system, Clinicals	Clinicals		antibiotic;	cancer
liposome			anthracycline; DNA	
doxorubicin;			intercalator	
doxorubicin liposome				
drug delivery system, Phase III	Phase III		antibiotic;	cancer
liposome			anthracycline; DNA	
doxorubicin;			intercalator	
doxorubicin liposome				
drug delivery system, Preclinical	Preclinical		antibiotic:	cancer
micellar doxorubicin;			anthracycline; DNA	
doxorubicin micelles			intercalator	

drug delivery system, Phase I	Phase I		antibiotic	Cancer
nanosphere			anthracycline: DNA	
doxorubicin;	-	·	intercalator	
doxorubicin				
nanosphere				
drug delivery system,	Discontinued		antibiotic;	cancer
ONCHOLAB			anthracycline: DNA	
aclarubicin;		-	intercalator	
aclarubicin				
ONCHOLAB				
drug delivery system, Discontinued	Discontinued		antibiotic:	cancer
ONCHOLAB AD 32;			anthracycline: DNA	
AD 32 ONCHOLAB			intercalator	
	Marketed		antibiotic:	cancer
STEALTH liposome			anthracycline: DNA	
doxorubicin;		· .	intercalator	
doxorubicin				
STEALTH; DOXIL;				
DOX-SL; S-DOX;			÷	
CAELYX		-		
drug delivery system, Preclinical	Preclinical	3-	antibiotic;	cancer
tetrapeptide		-	anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin		 		
tetrapeptide; Super-				
Leu-Dox				

leoxy-anthracycline; DNA intercalator oxy]- dro- dro- iv-81- antibiotic; anthracycline; DNA intercalator oxy]- mintercalator oxy]- anthracycline; DNA intercalator oxy]- anthracycline; DNA intercalator oxo- anthracycline; DNA on intercalator oxo- sta- oxo- sta- oride	epirubicin;	Marketed	(8S-cis)-10-[(3-	antibiotic:	cancer
alfa-L-arabino- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- maphthacenedione Discontinued (7S-cis)-9-acetyl-7- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- maphthacenedione Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	pidorubicin; 4'-epi-		amino-2,3,6-trideoxy-	anthracycline; DNA	
hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione Discontinued (7S-cis)-9-acetyl-7- [13-[bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- apha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- aphha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	doxorubicin; IMI 28;		alfa-L-arabino-	intercalator	
7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione Discontinued (78-cis)-9-acetyl-7- anthracyline; DNA chloroethyl)amino]- 12,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy- 6,9,11-trihydroxy- 6,9,11-trihydroxy- 6,9,11-trihydroxy- 6,9,11-trihydroxy- 12,1,2,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alamine hydrochloride	MSC 256942; FI		hexopyranosyl)oxy]-	-	
(hydroxyacetyl)-1- methoxy-5,12- methoxy-5,12- maphthacenedione Discontinued (7S-cis)-9-acetyl-7- chloroethyl)amino]- anthracycline; DNA chloroethyl)amino]- chloroethyllamino]- alpha-L-lyxo- hexopyranosyl]oxy]- hexopyranosyl]oxy]- (6,9,11-trihydroxy- 5,12- maphthacenedione Phase II 2-[(25,4S)-4-[(2,6- dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-6,11-dioxo- 2-naphthaceny]-2- oxoethyl ester beta- alamine hydrochloride	(7701;		7,8,9,10-tetrahydro-		
(hydroxyacetyl)-1- methoxy-5,12- naphthacenedione Discontinued (7S-cis)-9-acetyl-7- [[3-[bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(25,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	PHARMORUBICIN;		6,8,11-trihydroxy-8-		
methoxy-5,12- naphthacenedione Discontinued (7S-cis)-9-acetyl-7- [[3-[bis(2-chloroethyl)amino]-chloroethyl)amino]-chloroethyl)amino]-chloroethyl)amino]-chloroethyl)amino]-chloroethyllomyl)-chloroethylsulfonyl)-chloroethyllomyl-	FARMORUBICIN;		(hydroxyacetyl)-1-		
naphthacenedione Discontinued (7S-cis)-9-acetyl-7- antibiotic; [[3-[bis(2- anthracycline; DNA chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxyl- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxyl- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	FARMORUBICINE		methoxy-5,12-		
Discontinued (7S-cis)-9-acetyl-7- antibiotic; [[3-[bis(2-chloroethyl)amino]-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxyl-7,8,9,10-tetrahydro-6,9,11-trihydroxy-2-fluoro-anthracycline; DNA alpha-L-talopyran intercalator osyl)oxyl-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester beta-alanine hydrochloride			naphthacenedione	-	
[[3-[bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- maphthacenedione Phase II 2-[(25,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	FCE 27726	Discontinued		antibiotic;	cancer
chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride				anthracycline; DNA	•
(methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxyl- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Aideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxyl- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride				intercalator	
(methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(25,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			2,3,6-trideoxy-4-O-		
alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]]-2- oxoethyl ester beta- alanine hydrochloride			(methylsulfonyl)-		
hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2,6-) antibiotic; dideoxy-2-fluoro- alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]]-2- oxoethyl ester beta- alanine hydrochloride			alpha-L-lyxo-		
7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]-2- oxoethyl ester beta- alanine hydrochloride			hexopyranosyl]oxy]-		
6,9,11-trihydroxy- 5,12- naphthacenedione Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			7,8,9,10-tetrahydro-		
5,12- naphthacenedione Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]]-2- oxoethyl ester beta- alanine hydrochloride			6,9,11-trihydroxy-		
Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			5,12-		
Phase II 2-[(2S,4S)-4-[(2,6- antibiotic; dideoxy-2-fluoro- anthracycline; DNA alpha-L-talopyran intercalator osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]]-2- oxoethyl ester beta- alanine hydrochloride	r		naphthacenedione		
-0 1.de	galarubicin; DA 125	Phase II			ancer
				anthracycline; DNA	
osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	-			intercalator	
1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			osyl)oxy]-		
hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaceny]]-2- oxoethyl ester beta- alanine hydrochloride			1,2,3,4,6,11-		
trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			hexahydro-2,5,12-		
methoxy-6, 1 1-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			trihydroxy-7-	٠	
2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride			methoxy-6,11-dioxo-		
oxoethyl ester beta- alanine hydrochloride			2-naphthacenyl]-2-		
alanine hydrochloride			oxoethyl ester beta-		
			alanine hydrochloride		-

GPX 100	Phase I		antibiotic;	cancer
			anthracycline; DNA intercalator	
I-DOX	Phase I	4'-iodo-4'-	antibiotic;	cancer
		deoxydoxorubicin	anthracycline; DNA	
			intercalator	
idarubicin; IMI 30;	Marketed	9-acetyl-7-[(3-amino- antibiotic;	antibiotic;	cancer
NSC 256439; IMI 22;		2,3,6-trideoxy-alfa-L-anthracycline; DNA	anthracycline; DNA	
ZAVEDOS;			intercalator	
ZAVEDOSE;		hexopyranosyl)oxy]-		
ZAVIDOS;		7,8,9,10-tetrahydro-		
IDAMYCIN;		6,9,11-trihydroxy-	-	
DAUNOBLASTINA;	,	5,12-		
CERUBIDINE		naphthacenedione		
icin;	Phase II		antibiotic:	ancer
FCE 21954;		[2alfa(8S*,10S*),4bet	anthracycline: DNA	
ТОБОБОХ		a,5beta,6beta]]-10- intercalator	intercalator	
		[(4-aminotetrahydro-		
		5-iodo-6-methyl-2H-		
		pyran-2-yl)oxy]-		
		7,8,9,10-tetrahydro-		-
		6,8,11-trihydroxy-8-		
		(hydroxyacetyl)-1-		
		methoxy-5,12-		
		naphthacenedione		

сапсет	cancer
antibiotic; anthracycline; DNA intercalator	antibiotic; anthracycline; DNA intercalator
[7R- antibiotic; (7alfa,8beta,10beta)]- anthracycline; DNA 8-ethyl-7,8,9,10- intercalator tetrahydro-1,6,7,8,11- pentahydroxy-10- [[2,3,6-trideoxy-3-(4- morpholinyl)-alfa-L- lyxo- hexopyranosyl]oxy]- 5,12- naphthacenedione hydrochloride	heptanedioic acid, mono[2-[4-[(2,6- dideoxy-2-fluoro- alfa-L- talopyranosyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- methoxy-6,12- cis)- oxoethyl] ester, (2S - cis)-
Phase II	Discontinued
KRN 8602; MX 2	ME 2303; FAD 104

D. 144110

iotic; cancer	anthracycline; DNA	ntercalator									otic; cancer	ine; DNA	ntercalator									
,5R,6R,11		(dimethylamino)- interc	3,4,5,6,11,12,13,14-	octahydro-	3,5,8,10,13-	pentahydroxy-11-	methoxy-6,13-	dimethyl-2,6-epoxy-	2H-naphthaceno[1,2-	b]oxocin-9,16-dione	[8S- antibiotic;	[8alfa,10alfa(S*)]]- anthra		trideoxy-4-0-	(tetrahydro-2H-pyran-	2-yl)-alfa-L-lyxo-	hexopyranosyl]oxy]-	7,8,9,10-tetrahydro-	6,8,11-trihydroxy-8-	(hydroxyacetyl)-1-	methoxy-5,12-	hanhthacenedione
menogaril; 7-OMEN; Phase III	NSC 269148; TUT 7;	U 52047;	TOMOSAR;	TAMOSAR							pirarubicin; Marketed	tirarubicin;	theprubicin; THP-	doxorubicin; THP-	ADM; thepirubicin;	THERARUBICIN;	PINORUBIN;	BERIRUBIN;	THEPRUBICINE			

ruboxvl	Dhace II	175 cia 1 111 1417	1.41.1.1.1.1	
			anthracycline; DNA	cancer
		apnaL-iyxo- hexopyranosyl)oxyll	intercalator	
		2,3,4,6,11-hexahydro-		-
		2,5,12-trihydroxy-7-		
		methoxy-6,11-dioxo- 2-		
		naphthacenyl]ethylide		
		ne]hydrazono-2,2,6,6-		
		tetramethyl-1-		
valrubicin; antibiotic	Marketed	Pentanoic acid (78	antibiotic.	
AD 32; AD 32; NSC		cis)-2-[1.2.3.4.6.11-	anthracycline. DNA	cancer
246131; VALSTAR		hexahydro-2,5,12-	intercalator	
		trihydroxy-7-		
		methoxy-6,11-dioxo-	<u>:</u>	
		4-[[2,3,6-trideoxy-3-		•
		o]-alfa-L-lyxo-		
		hexopyranosylloxy]-		
		2-naphthacenyl]-2-		
2YN 198	Suspended	oxoeinyi ester	antihiotic.	router
	•		anthracycline; DNA	caricol
ממצוות ז ועונ			intercalator	
ZYN-LINKER	Suspended		antibiotic;	cancer
conjugated doxombicin			anthracycline; DNA	
doxorubicin +	Marketed		mercalator	
estrone; estrone +			anthracycline: DNA	cancer
doxorubicin; DDS- DEA	ŝ	·	intercalator; estrogen	

SD-144110

amrubicin; SM 5887 Phase II	Phase II	(7S-cis)-9-acetyl-9-	antibiotic;	cancer
			anthracycline; DNA	
		beta-D-	topoisomerase	-
		erythropentopyranosy inhibitor	inhibitor	
<u>-</u>		l)oxy]-7,8,9,10-		
		tetrahydro-6,11-	-	
		dihydroxy-5,12-		
		naphthacenedione		
		hydrochloride		
MEN 10755; BMS	Phase I	(7S-cis)-7-[[4-O-(3-	antibiotic;	cancer
519561		amino-2,3,6-frideoxy-anthracycline; DNA	anthracycline; DNA	
		alpha-L-lyxo-	topoisomerase	
-		-6	inhibitor	
		dideoxy-alpha-L-		
		lyxo-		
	• • • • • • • • • • • • • • • • • • • •	hexopyranosyl]oxy]-		-
		7,8,9,10-tetrahydro-		
	<u>:</u>	6,9,11-trihydroxy-9-	-	
		(hydroxyacetyl)-5,12-		
		naphthacenedione		
		hydrochloride		
BU 4704	Discontinued	1-(4-methoxyphenyl)-antibiotic; antifungal 4-(4-	ntibiotic; antifungal	mycosis; cancer
		hydroxysulfonyloxyp		
		neny1)-2,3-		
		diisocyano-1,3-		
		butadiene		
NK 860279I	Discontinued	44-homooligomycin a B	antibiotic; antifungal	mycosis; cancer
NK 860279II	Discontinued	Discontinued 44-homooligomycin a	antibiotic; antifungal	mycosis; cancer
		4		

Carboxy-3-methyl- 1(B),3(B)- butadienyl]-9-(hydrox ysuccinyloxy)-3- methyl-1;7- dioxaspiro- [5.5]undec-2-yl]-5- dioxaspiro- [5.5]undec-2-yl]-5- hydroxy-4,8- dimethyl- 2(E),6(E),8(B)- decatrienoic acid Discontinued 5,6-dihydro-5- hydroxy-5-methyl-4- hydroxy-5-methyl-4- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; ocicatrizant in initiotic; beta lactam can be preclinical antibiotic; beta lactam can be preclinical antibiotic antibiotic; beta lactam can be preclinical antibiotic	reveromycin A	Preclinical	10 6 5.41 0 1.4		
butadienyl]-9-(hydrox ysuccinyloxy)-3- methyl-1;7- dioxaspiro- [5.5]undec-2-yl]-5- hydroxy-4,8- dimethyl- 2(E),6(E),8(E)- decatrienoic acid 5,6-dibydro-5- hydroxy-6-(6- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant preclinical antibiotic; antioxidant; cicatrizant cicatrizant preclinical antibiotic; beta lactam antibiotic; beta lactam antibiotic; beta lactam	•		carboxy-3-methyl-1(E),3(E)-	amoroue, anniungar	bacterial infection; cancer; mycosis
methyl-1,7- dioxaspiro- [5.5]undec-2-yl]-5- hydroxy-4,8- dimethyl- 2(E),6(E),8(E)- decatrienoic acid Discontinued 5,6-dihydro-5- hydroxy-5-methyl-4- hydroxy-5-methyl-4- hydroxy-5-methyl-4- hydroxy-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; beta lactam Preclinical antibiotic; beta lactam antibiotic; beta lactam			butadienyl]-9-(hydrox		
dioxaspiro- [5.5]undec-2-y1]-5- hydroxy-4,8- dimethyl- 2(E),6(E),8(E)- decatrienoic acid 5,6-dihydro-5- hydroxy-6-(6- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam Preclinical antibiotic; beta lactam antibiotic; beta lactam			methyl-1,7-		
Discontinued Discontinued S,6-dihydro-S- Autibiotic; antifungal			dioxaspiro-		
dimethyl- 2(E),6(E),8(E)- decatrienoic acid biscontinued 5,6-dihydro-5- hydroxy-6-(6- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; beta lactam Preclinical antibiotic; beta lactam antibiotic; beta lactam			[5.5]undec-2-yl]-5-		
Discontinued 5,6-dihydro-5- decatrienoic acid hydroxy-6-(6- hydroxys-1-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; beta lactam Preclinical antibiotic; beta lactam Preclinical antibiotic; beta lactam			nyaroxy-4,8-		
Discontinued 5,6-dihydro-5- hydroxy-6-(6- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam	-		2(E),6(E),8(E)-		
Discontinued 5,6-dihydro-5- hydroxy-6-(6- hydroxy-6-(6- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Antibiotic; antioxidant; cicatrizant cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam			decatrienoic acid		
hydroxy-6-(6- hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam	sultriecin	Discontinued		antibiotic; antifungal	cancer: mycosis
hydroxy-5-methyl-4- hydroxysulfonyloxyh eptadec-1,7,9,11- tetraenyl)-2H-pyron- 2-one antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; beta lactam antibiotic; beta lactam					
Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Autibiotic; antioxidant; cicatrizant Cicatrizant Cicatrizant Cicatrizant Cicatrizant Cicatrizant Autibiotic; antioxidant; cicatrizant Cicatrizant Autibiotic; beta lactam Areclinical Autibiotic; beta lactam			hydroxy-5-methyl-4-		-
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam	-	:	hydroxysulfonyloxyh		-
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam antibiotic; beta lactam			eptadec-1,7,9,11-		
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; beta lactam antibiotic; beta lactam			tetraenyl)-2H-pyron-		
Preclinical antibiotic; antioxidant; cicatrizant cicatrizant Preclinical antibiotic; antioxidant; cicatrizant antibiotic; beta lactam antibiotic; beta lactam	JSM ASB001	Preclinical		antibiotic; antioxidant:	cancer: hacterial
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant cicatrizant antibiotic; beta lactam antibiotic; beta lactam				cicatrizant	infection:
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant, cicatrizant Preclinical antibiotic; beta lactam antibiotic; beta lactam					gastrointestinal
Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; antioxidant; cicatrizant Preclinical antibiotic; beta lactam	101 11 101				disorder; skin ulcer
Preclinical antibiotic; antioxidant; cicatrizant cicatrizant	point BCY LUUI	Preclinical	,,,	antibiotic; antioxidant;	cancer; bacterial
Preclinical antioxidant; cicatrizant cicatrizant Preclinical antibiotic; beta lactam				cicatrizant	infection;
Preclinical antibiotic; antioxidant; cicatrizant					gastrointestinal
Preclinical antibiotic; antioxidant; cicatrizant cicatrizant reclinical antibiotic; beta lactam	TONA DIA COO!				disorder; skin ulcer
cicatrizant Preclinical antibiotic; beta lactam	IOUCATO MICO	Frecinical	co.	antibiotic; antioxidant;	cancer; bacterial
Preclinical antibiotic; beta lactam			<u>.</u>	cicatrizant	infection;
Preclinical antibiotic; beta lactam			:		gastrointestinal
Preclinical antibiotic; beta lactam	10040				disorder; skin ulcer
	derivatives, Pliva	Preclinical			cancer
	n				

011771

	·			
clavalanıne; SYN 1931; Ro 22-5417	Preclinical	[3S- [3alpha(R*),5alpha]]- alpha-amino-7-oxo-4- oxa-1- azabicyclo[3.2.0]hept ane-3-propanoic acid	antibiotic; beta lactam	cancer
SYN 1127	Preclinical	3-(hydroxymethyl)-4- oxa-1- azabicyclo[3.2.0]hept an-7-one	3-(hydroxymethyl)-4- antibiotic; beta lactam cancer oxa-1- azabicyclo[3.2.0]hept and an-7-one	cancer
SYN 1932	Preclinical .	[3R- [3alpha(alphaS*, beta R*), 5alpha]]-alpha- amino-7-oxo-beta- (phenylmethoxy-4- oxa-1- azabicyclo[3.2.0]hept ane-3-propanoic acid	antibiotic; beta lactam	cancer
MAb, doxorubicin conjugate	Preclinical	· :	antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
MAb, drug delivery system, liposome doxorubicin conjugate; MAb, STEALTH doxorubicin conjugate; SPI 49	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelle	Preclinical		antibiotic; DNA intercalator; anthracycline	cancer

IST 622; A 132; NSC Phase II	Phase II	3-ethoxypropanoic	antibiotic; DNA	cancer
000000		acid (S)-10-[[6-	topoisomerase	
		3-O-methyl-alfa-D-	ronono	
		galactopyranosyl)-		
		3,4-0-		-
		(phenylmethylene)-		
		beta-D-		-
		galactopyranosyl]oxy		
]-5,12-dihydro-1-		
		methyl-5,12-	-	
		dioxobenzo[h][1]benz		
		opyrano[5,4,3-		
		cde][1]benzopyran-6-		
		yl ester	-	
NSC 655649; BMY	Phase I	1,11-dichloro-6-[2-	antibiotic; DNA	cancer
/55/7			topoisomerase	
		4	inhibitor; DNA	
		O-met hyl-beta-D-	intercalator	
		glucopyranosyl)-5H-		
		indolo[2,3-		
	-	a]pyrrolo[3,4 ¹	· <u>.</u>	
		c]carbazol e-5,7(6H)-		
		dione	,	
WIN 58161	Preclinical	(S)-10-(2,6-dimethyl- antibiotic; DNA	antibiotic; DNA	cancer
		fluoro-	opoisomerase	
			inhibitor; quinolone	
		pyrido[1,2,3-de]-1,4-		
		benzothiazine-6-		
- 1		carboxylic acid	.*.	
MI 4337F11; MI 43	Preclinical		antibiotic;	cancer
			immunostimulant	

gludapcin; FK 565;	Discontinued	heptanovl-gamma-D- antibiotic:	antihiotic.	11117
FK 41565			imminostimilant	infection
		diaminopimelyl-(D)-	peptide	III COROII
		alanine		
teldamycin; BMY	Discontinued	(S)-N-methyl-L-	antibiotic; melanin	cancer
58585		histidyl-N3-[1-	synthesis inhibitor	
	:	carboxy-2-(1H-		
		[imidazol-4-yl]ethyl]-		
		L-threo-2,3-		
		diaminobutanoic acid	3. •	
cordycepin; NSC	Phase I		antibiotic; nucleoside;	cancer
03964			antimetabolite	
C 102/	Preclinical	Antibiotic C	antibiotic; peptide	cancer; bacterial
		>: -		infection
cecropin B	Discontinued		antibiotic; peptide	bacterial infection;
1.4:0				cancer
Iyue peptides, Proteus Discontinued International	Discontinued		antibiotic; peptide	bacterial infection;
Veniconentin: BII	Discontinue	*		cancer
3983T; BMY 28782	Discontinued	-	antibiotic; peptide	cancer
placetin A	Preclinical		antibiotic; platelet	thrombosis: bacterial
				infection: cancer
placetin B	Preclinical		telet	thrombosis; bacterial
			antiaggregant	infection; cancer
MS 073	Preclinical	1:1-	noline	cancer
		dinydro-5H-		
		dibenzo(a,d)cyclohept	-	
		ene-5-yt)piperazin -1- vl)2-		
		hydroxypropoxy)quin		
		oline		

A 74932	Discontinued	Discontinued 6-[2-[(2-amino-1-	antihiotic. guinolong	
		oxopentyl)amino]-1-	minorous, quinorous	Calicel
		pyrrolidinyl]-5-		
		fluoro-3-oxo-3H-		
		pyrido[3,2,1-		
	-	k]phenoxazine-2-		
		carboxylic acid.		
		monohydrochloride		
E 7010	Discontinued	N-[2-[(4-	antibiotic; sulfonamidecancer	cancer
		hydroxyphenyl)amino		
•]-3-pyridinyl]-4-	-	
		methoxybenzenesulfo		
		namide		
E 7070	Phase I		antibiotic: sulfonamidecancer	Cancer
ER 34410	Preclinical	ihydro-2-	antibiotic; sulfonamide cancer	cancer
		dibenzo[b,e][:1,4]diaz		
•		epin-6-yl)-4-	- .	
		methoxybenzenesulfo		
		namide		
ER 35744	Preclinical	N-(3-chloro-1H-	antibiotic; sulfonamidecancer	cancer
		penzene-		
		disulfonamide		
HMN 214	Preclinical	(E)-N-[(4-	antibiotic; sulfonamidecancer	cancer
		ollus		
		nyl]-N-[2-[2-(1-		
		oxido-4-		
		pyridinyl)ethenyl]phe		
		nyl]acetamide		
	Preclinical		antibiotic; terpene	cancer
PN 271; PN 27,1; AndroCar	Phase II			cancer; restenosis

PN 972	D			
DN1 070	ricumcai		antibiotic; terpene	cancer
FN 2/3	Preclinical	; e :	antibiotic; terpene	cancer
PN 274	Preclinical		antibiotic; terpene	cancer
PN 275	Preclinical	 	antibiotic; terpene	cancer
giracodazole;	Discontinued	[S-(R*,R*)]-2-amino-antibiotic: tRNA	antibiotic: tRNA	Cancer
girodazole; girolline;		alfa-(2-amino-1-	synthetase inhihitor	
(+)-girolline; RP		chloroethyl)-1H-		
49532; RP 49532A;		imidazole-4-methanol	-	
NSC 627434				
glycopine;	Marketed	N2-[N-[N-acetyl-4-O-antibiotic: vaccine	antibiotic: vaccine	msoriasis: cancer.
glucosaminylmuramy		[2-(acetylamino)-2-	adjuvant;	leukopenia: septic
dipeptide; GMDP;		deoxy-beta-D-	immunostimulant:	shock: infections
LICOPID; LIKOPID		ıra		disease: eve disease
		Ģ		
Ontionter A T A T A T A		aipna-giutamine	٠	
aluesu ogens, AVAX Preclinical Technologies	Freclinical		antiestrogen	cancer
antiestrogene	D. 0.1			
BioNumerik	rrecimical		antiestrogen	cancer
antiestrogens, Ligand Preclinical	Preclinical		antiestrogen	cancer;
- 1				endometriosis
alogues	Suspended		antiestrogen	cancer
droloxifene;	Pre-	(E)-alpha-[p-[2-	antiestrogen	cancer: osteonorosis
	registration	ethox		organization (carried
hydroxytamoxifen; K		y]phenyl]-alpha-		
21060E citrate		ethyl-3-stilbenol		
drug delivery system, GEOMATRIX	Discontinued		antiestrogen	cancer
controlled release				
tamoxifen; tamoxifen			rurus Leggn	
OLOWINIA INIA				
	•			

D-144 10.1

001711				
EM 139	Preclinical	(7alfa, 16alfa, 17beta) - antiestrogen	antiestrogen	cancer
•		N-butyl-16-chloro-		
		3,17-dihydroxy-N-		
		methylestra-	• •	
		1,3,5(10)-triene-7-		
		undecanamide	٠	
EM 170	Preclinical	(7alfa, 16alfa, 17alfa)-	antiestrogen	cancer
		N-butyl-16-chloro-)	
		3,17-dihydroxy-N-		
		methylestra-		
		1,3,5(10)-triene-7-	٠.	
		undecanamide		
EM 800	Phase III	2,2-	antiestrogen	Cancer
	·	dimethylpropanoic	0	
		acid (S)-4-[7-(2,2-		
		dimethyl-1-	*	
		oxopropoxy)-4-		
	· · · · ·	methyl-2-[4-[2-(1-		
		piperidinyl)ethoxy]ph		
		enyl]-2H-1-	• • •	
		benzopyran-3-		
en antagonists,	Discontinued		antiestrooen	300000
				Calicel
fulvestrant; ZD	Phase III	(7alpha, 17beta)-7-19- antiestrogen	antiestrogen	Concor.
		[(4,4,5,5,5-	11090110011	cancel,
Zeneca 182780; ICI	•	pentafluoropentyl)sul		67 1100010g10a1
182780; FASLODEX		phinyl]nonyl]-estra-		
~		1,3,5(10)-triene-3,17-		
-		peta-diol		

providene; 1A1 39				
	Phase III	(E)-4-[1-[4-[2-	antiestrogen	cancer
	•	(dimethylamino)ethox		
		y]phenyl]-2-[4-(1-		
		methylethyl)phenyl]-		
		1-butenyl]phenol		
		dihydrogen phosphate		
		(ester)		
MDL 103323	Suspended	(E)-4-[4-(2-chloro-	antiestrogen	cancer
-		1,2-)	
		diphenylethenyl)phen		
		oxy]-N,N-		
		diethylbutanamine		
	Discontinued	(E)-2-[[2-[p-(3,3,3-	antiestrogen	cancer
5650; GYKI 13504				
		diphenylpropenyl)phe	•	
		noxy]ethyl]amino]eth		
		anol		
K 1128B	Discontinued	ئ ے۔	antiestrogen	cancer
RU 53637	Discontinued		antiestrogen	cancer
		-	•	
		N-(methylethyl)-19-		
		norpregna-1,3,5(10)-		
•		trien-20-yne-11-		
		undecanamide	. •	
RU 58668; RU 59428 Discontinued	Discontinued		antiestrogen	cancer
SH 646 P	Phase I		antiestrogen	Cancer
	Marketed	2-(p-((Z)-4-chloro-	antiestrogen	cancer
tolemifene; FC				
1157a; NK 622;		butenyl)phenoxy)-		
FARESTON;		N,N-dimethyl	•	
INCIMILEIN		ethylamine		

ישואסבייו שיייד				
		(acetyloxy)phenyl]-1- ethyl-3-methyl-1H- indol-5-ol acetate	annosir ogon	
arzoxifene; LY 353381	Phase II	2-(4-methoxyphenyl)- 3-[4-[2-(1- piperidinyl)ethoxy]ph enoxy]benzo[b]thioph ene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preclinical	No. 3645 Table Transit	antiestrogen; estrogen agonist	cancer
estrogen receptor modulator, Genaissance; estrogen receptor modulator, Telik	Preclinical		antiestrogen; estrogen cancer; osteoporosis agonist	cancer; osteoporosis
estrogen receptor modulators, Nanodesign	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
idoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1:(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethy	antiestrogen; estrogen agonist	cancer
LY 326315	Preclinical	6-(4-hydroxyphenyl)- 5-[[4-[2-(1- piperidinyl)ethoxy]ph enyl]methyl]-2- naphthalenol hydrochloride	6-(4-hydroxyphenyl)- antiestrogen; estrogen 5-[[4-[2-(1- piperidinyl)ethoxy]ph enyl]methyl]-2- naphthalenol hydrochloride	cancer

0-144110

LY 139481; LY	; Marketed	[6-hydroxy-2-(4- antiestre	ogen; estrogen	osteoporosis;
156758; EVISTA		[b]thien-3-y1][4-[2-(1-		nyperiipidemia; myocardial
		piperidinyl)		infarction; cancer
	-	ethoxy]phenyl]metha	-	
	_	none		
aminopterin; aminopterine:	Phase II	N-[4-[[(2,4-diamino- antifolate	antifolate	cancer
pteramina; NSC 739;		oteridinyl)methyllami		
APGA		no]benzoyl]-L-		
		glutamic acid	•	
anticancer agent,	Discontinued	N-[4-[3-(2,4-diamino-antifolate		cancer
Eisai		6,7-dihydro-5H-		
		cyclopenta[d]pyrimidi		
		n-5-		
		yl)propyl]benzoyl]-L-		
edatrexate:	Discontinued			
aminonterin O other		-1 ,	antitolate	cancer
ammopterm, O-emyi- 10-deaza: 10 FD A M:		diamino-6-		
ED ANY 10 COR		prendinyi)methyi]pro		
EDAM 10; CGP 30694		pyl]benzoyl]-L-		
ł	Phase I		antifolate	ancer
249543; LY 264618		amino-1,4,5,6,7,8-		Tooling
		hexahydro-4-		
		oxopyrido[2,3-		
		d]pyrimidin-6-		
		yl)ethyl]benzoyl]-L-		
		glutamic acid		
	•			

	cancer								cancer							cancer						cancer	olite				cancer;			-, -	
	IN-[13-[2-(2-amino-antitolate	1,4,5,6,7,8-	hexahydro-4	oxopyrido[2,3-	d]pyrimidin-6-	yl)ethyl-2-	thienyl]carbonyl]-L-	glutamic acid	N-((2,4-diamino-antifolate	3,4,5,6,7,8-	hexahydropyrido[2,3-	d]pyrimidine-6-	yl)ethyl)-2-	thienylcarbonyl-L-	glutamic acid	(S)-2-[[[4-carboxy-4- antifolate	[[4-[[(2,4-diamino-6-	pteridinyl)methyl]ami	no]benzoyl]amino]but	yl]amino]carbonyl]be	nzoic acid	N-[4-[3-(2,4-diamino-antifolate;	iH-pyrrolo[2,3-	d]pyrimidin-5-	yl)propyl]benzoyl]-L-	glutamic acid	r. %		methyl]-5-methyl- reductase inhibitor	pyrido[2,3- '' '	, C
I V 954155 Dhan I	riiase i			2					Y 335580 Preclinical							PT 523 Preclinical						INP 351 Discontinued					piritrexim; BW 301U;Phase II	NSC 351521			

0-144110

Trega Biosciences/RiboGen e liarozole; liarozole				vital intection,
				mycoeie, cancer
				inycosis, cancer
	Pre-	5-[(3-chlorophenyl)-	antifungal; androgen	cancer; psoriasis
ate: R	registration	nn-iiiiidazoi- i- vimethvil- i H	synthesis inhibitor;	
75251; R 85246; LIAZAL		benzimidazole	iiiiuazole	
BBR 3438	Preclinical		antifungal;	cancer
BBR 3439	Discontinued		antifungal;	cancer
		*	anthrapyrazole	
DUP 942	Discontinued		antifungal;	cancer
		1	anthrapyrazole	
losoxantrone; F	Phase III	7-hydroxy-2-[2-[(2-	antifungal;	cancer
hydrochloride:		hydroxyethyl)amino eanthrapyrazole	anthrapyrazole	
biantrazole: Cl 941.	•			
DuP 941: NSC		thyllamino (thyllamino)		
357885; PD 113785;		anthra[19-		
BIANDA		cd]pyrazol-6(2H)-		
		one,		
	Discontinued	7-10-dihydroxy-2-[2- antifungal		cancer
teloxantrone		[(2-	zole	
hydrochloride;		hydroxyethyl)amino]e		
moxantrazole; DUP		thyl]-5-[[2-		
937; CI 937; PD		(methylamino)ethyl]a		
113309; NSC 355644		mino]anthra[1,9-		
		cd]pyrazol-6(2H)-		
	٠,	one, dihydrochloride,		
		monohydrate		

zole; BAY Marketed antifungal; imidazole ENT; ENT; FERMAL; CORDES; ITAX;	cancer therapy, Lorus Preclinical Therapeutics/Ion	Preclinical		antifungal; imidazole cancer	cancer
IYCON; ENT; JD; ERIN; IM AF; HERMAL; CORDES; ITAX; ITEN; IN IN AF; ITAX; ITEN; ITEN; IN AF; ITAX; ITEN; IN AF; ITAX; ITEN; IN AF; ITAX; IN Intifungal; IN AFCOMMINE AFCOMENTY IN ACTION IN AFCOMMINE AFCOMENTY IN ACTION IN INTERESSE IN INTIFURE AFCOMENTY IN ACTION IN INDIPITORS, IN AFOURTON; IN INDIPITORS, IN IN IN INTIPITORS, IN IN IN INTIPITORS, IN INTIP	clotrimazole; BAY 5097;	Marketed		antifungal; imidazole	mycosis; sickle cell
ERIN; HERMAL; CORDES; TTAX; TIEN; ITEN; IN Preclinical [2S- (2R*,4E,6S*,8R*)]- N-[2-bromo-N-(8- hydroxy-2,4,6- trimethyl-1-oxo-4- monenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone antifungal; nide cotide cotide cotide solide inhibitor; NSAID; imidazole inhibitors, imidazole inhibitors, imidazole inhibitors,	CUTAMYCON; ENSCHENT:				anemia; cancer; diarrhea
ERIN; fun AF; HERMAL; CORDES; ITAX; ITAX; ITEN; fun AF; HERMAL; CORDES; ITAX; ITEN; fun AF; ITEN; fun AF; ITEN; fun AF; f	FUNGIZID;				
HERMAL; CORDES; TTAX; TEN; ITIN; ITI	HAKUSERIN;			<u>.</u> -	
HERMAL; CORDES; ITAX; ITAX; ITEN; ININ Olide; Preclinical [2S- (2R*,4E,6S*,8R*)]- N-[2-bromo-N-(8- hydroxy-2,4,6- trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone alanine rho-lactone alanine rho-lactone sotide nide sotide Inhibitor; Inhibitors, ITAX; ITAX; Interpretable (formyltransferase inhibitor; NSAID; imidazole inhibitors,	LOTRIMIN AF;				
CORDES; ITAX; ITEN; ITEN	MYCO-HERMAL;				
TFAX; TEN; In Miles: Preclinical [2S- (2R*,4E,6S*,8R*)]- N-[2-bromo-N-(8- hydroxy-2,4,6- trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone alanine rho-lactone alanine rho-lactone formyltransferase unsferase unsferase inhibitors, NSAID; imidazole	MYKO CORDES;			٠.	
TEN; In this iter in the indication of the indivisor of the indivisor of the indicators, and	TRIGENTAX;		**************************************		
tolide; Preclinical [2S- (2R*,4E,6S*,8R*)]- (2R*,4E,6S*,4R*)]- (2R*,4R*)]- (2R*,4R*)	CANESTEN; LOTRIMIN			·	
le (2R*,4E,6S*,8R*)]- N-[2-bromo-N-(8- hydroxy-2,4,6- trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone alanine rho-lactone formyltransferase unsferase inhibitor; NSAID; inhibitors,	jasplakinolide;	Preclinical	[2S-	antifungal: peptide	mycosis: cancer
N-[2-bromo-N-(8-hydroxy-2,4,6-trimethyl-1-oxo-4-nonenyl)-L-alanyl]-N-methyl-1-3-(4-hydroxyphenyl)-beta-alanine rho-lactone alanine rho-lactone cotide nosferase inhibitor; NSAID; inhibitors, inhibitors,	jaspamide	•	(2R*,4E,6S*,8R*)]-)	
hydroxy-2,4,6- trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl]-beta- alanine rho-lactone alanine rho-lactone cotide nide nrsferase nrsferase inhibitor; NSAID; inhibitors,			N-[2-bromo-N-(8-		
trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone alanine rho-lactone ide cotide nide nisferase insferase inhibitor; NSAID; inhibitors,	-		hydroxy-2,4,6-		
nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone antifungal; nide sotide tryptophyl]-L-3-(4- hydroxyphenyl]-L-3-(4- hydroxyphenyl]-L-3-(4- hydroxyphenyl]-L-3-(4- hydroxyphenyl]-E-3-(4- hydroxyphenyl)-E-3-(4-			trimethyl-1-0xo-4-		
N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl]-beta- alanine rho-lactone antifungal; nide sotide notide notide sotide notide s, Agouron; inhibitors, NSAID; inhibitors,			nonenyl)-L-alanyl]-		
idazole Discontinued alanine rho-lactone alanine rho-lactone antifungal; nide cotide cotide inhibitors, NSAID; imidazole inhibitors, imidazole inhibitors, NSAID;			N-methyl-D-		
idazole Discontinued antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole lingarole inhibitors, and inhibitors, alanine rho-lactone antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole			tryptophyl]-L-3-(4-		
idazole Discontinued antifungal; nidazole Discontinued antifungal; nidazole piscontinued antifungal; nidazole anti			hydroxyphenyl)-beta-	· .	
nide ribonucleotide sotide insferase inhibitor; NSAID; inhibitors,	aminoimidazole	Discontinued			onon inflormation
ootide unsferase s, Agouron; inhibitors,	carboxamide			tide	caricot, minalimitation
insterase s, Agouron; inhibitors,	ribonucleotide			formvltransferase	
s, Agouron; inhibitors,	formyltransferase			inhibitor; NSAID;	
A politon	inhibitors, Agouron; AICART inhibitors			imidazole	
1 Political	Agouron				

D-144110

1011771

drug delivery system, Marketed	, Marketed		antimetabolite	cancer; psoriasis;
fluorouracil				viral infection
Therapeutic Implant;				,
MPI 5003; AccuSite				
drug delivery system,	Discontinued		antimetabolite	cancer
fluorouracil;				
fluorouracil			-	
Therapeutic Implant;		· ··		
MPI 5011;				
INTRADOSE-FU		-		
drug delivery system,	Preclinical		antimetabolite	Cancer
fluorouracil;				
fluorouracil			-	
Therapeutic Adhesive				
drug delivery system,	Discontinued		antimetabolite	Cancer
methotrexate;	•			
methotrexate delivery				
system; HYAL				
CV1281				
drug delivery system,	Discontinued		antimetabolite	Concer
sustained release				Calicol
methotrexate;				
methotrexate				
DepoFoam			-	
fazarabine;	Phase II	4-amino-1-beta-D-	antimetabolite	Cancer
arabinosyl-5-		arabinofuranosyl-		
azacytosine; ara-AC;		1,3,5-triazin-2(1H)-		
NSC 281272		one	. :·	
fludarabine +	Discontinued		ahtimetabolite	cancer
chlorambucil +				
fludarabine				

folic acid analogue,	Discontinued	Discontinued N-alpha-(5-deaza-	antimetabolite	roomoo
Glaxo Wellcome		•		calicol
		tetrahydropteroyl)-L- omithine		
levamisole +	Registered		antimetabolite	cancer
fluorouracil;	·			
fluorouracil + levamisole			*	
T 506	Discontinued	mono[2-	antimetabolite	cancer
		hyl ester of 2'-deoxy-		
		5-fluoro-5'-uridylic		-
		acid 3'-(9-		
		octadecenoate)		
30.04		ilydroxide inner sait		
1AS 102	Phase I		antimetabolite	cancer
tegafur; BMS	Marketed	5-fluoro-1-	antimetabolite	cancer
20060401; MJF		(tetrahydro-2-		
12264; NSC 148958;		furanyl)-		
DAIYALOSE;		2,4(1H,3H)pyrimidin		
FENTAL;		edione		
FTORAFUR;				
FTORALON;	-	10.41		
FURAFLOR;				
FUTRAFUL;				
LAMAR; NEBERK;		-		
TORAFURIN; UFT				
ZYN-LINKER	Suspended		antimetabolite	cancer
conjugated				
fluorouracil			·	

Г				
equinar 785;	Suspended	6-fluoro-2-(2'- antimetabolite; fluoro[1,1'-biphenyl]- immunosuppressant	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant
NSC 368390		4-yl)-3-methyl-4- quinolinecarboxylic	:	rejection
ZYN-LINKER	Suspended	acid	Or A DIG . chile debouring	
	populadan		antimetationile, INSIALD cancer; rneumatold	cancer; rneumatold
methotrexate		-		artnrus; psonasis
	Marketed	4-amino-1-[5-0-	antimetabolite;	cancer
phosteabine sodium;		[hydroxy(octadecylox nucleoside analogue	nucleoside anajogue	
YNK 01; C18PCA;		y)phosphinyl]-beta-		
STARASID		D-arabinofuranosyl]		
		2(1H)-pyrimidinone		
drug delivery system, Marketed	Marketed		antimetabolite;	cancer
Deportoam		-	nucleoside analogue	•
cytarabine; cytarabine	•			
DepoFoam; DTC				
101; DepoCyt; SAVEDAR		**************************************	_	
hio	Preclinical		antimetabolite.	cancer
Oklahoma			nucleoside analogue	
		,		
LY 207702 P	Preclinical		antimetabolite;	cancer
			ribonucleotide	
		2,6-diaminopurine (dFdAAP)	reductase inhibitor	
antineoplaston A10 P	Phase II		antineoplaston: peptidecancer	cancer
antineoplaston AS2-1 Phase II	hase II		antineoplaston; peptideHIV infection:	HIV infection:
			•	cancer

nitroxide antioxidant, Preclinical	Preclinical		antioxidant; free	respiratory distress
uivi	-		radical scavenger;	syndrome;
				millalimation;
				cancer; repertusion
antioxidants,	Preclinical		antioxidant: NSAID	skin disease.
University of California				inflammation; cancer
naphterpin; CL	Preclinical	(4aS-cis)-3,4a,5,12b-	antioxidant: NSAID	diahetes.
190Y2		tetrahydro-8,10-		cardiovascular
		dihydroxy-2,5,5,9-	···	disease; cancer;
		tetramethyl-4H-	-	inflammation
	٠	benzo[d]naphtho[2,3- b]pyran-7,12-dione		
OS 535	Preclinical		antiplasmin	Cancer
LG 1127	Preclinical		antiprogestogen	cancer:
			L . <u>.</u> .	endometriosis
LG 1147	Preclinical	- -	antiprogestogen	cancer;
				endometriosis
LG 1447	Preclinical		antiprogestogen	cancer;
	•	6-phenyl-		endometriosis
T				
milepristone; KU 486; RU 4866; RU	Marketed	(11beta,17beta)-11- [4-	antiprogestogen	abortion; cancer;
38486; R 38486;	-	(dimethylamino)nhen		contraccpuon
MIFEGYNE		yl]-17-hydroxy-17-(1-		
		propynyl)estra-4,9-		
		dien-3-one		

D-14411(

onapristone; ZK 98299; SH 549; ZK	Discontinued	(11beta,13alfa,17alfa) antiprogestogen -11-f4-) antiprogestogen	cancer; contraception
599	•	(dimethylamino)phen		
		yl]-17-hydroxy-17-(3-		
r		hydroxypropyl)estra-		
01717		4,9-dien-3-one		
OKG 31/10	Discontinued	(6beta,11beta,17beta) antiprogestogen -11-f4-	antiprogestogen	cancer
		(dimethylamino)phen		
		yl]-4',5'-dihydro- 6-	<u>.</u>	
		methyl-spiro[estra-		
	·····	4,9-diene-17,2'(3'H)-		
		furan]-3-one		
ORG 31806	Discontinued	(7beta, 11beta, 17beta) antiprogestogen	antiprogestogen	cancer
		-11-[4-		
		(dimethylamino)phen		
		yl]-4',5'-dihydro-7-	-	
		methyl-spiro[estra-		
		4,9-diene-17,2'(3'H)-		
		furan]-3-one.		
ORG 33245	Discontinued		antiprogestogen	cancer: abortion
ORG 33628	Discontinued	(11beta,17alpha)-11-	antiprogestogen	cancer
)	
		17,23-epoxy-19,24-		
		dinorchola-4,9,20-		
0000000000		trien-3-one		
UKG 33832	Discontinued		antiprogestogen	cancer; abortion
KU 46556	Discontinued	(11beta,17beta)-11-		cancer;
	-		 	endometriosis; labor
		(methylthio)phenyl sp		induction
		ro estra-4,9-diene-		
		17,2'(5'H)-furan]-3-		-
		OIIC		

70007 110	1			
NO 49293	Discontinued	Discontinued (11beta, 17beta)-11-	antiprogestogen	cancer;
•		- +)		endometriosis
		acetylphenyl)spiro[est	_	
	-	ra-4, y-diene-	-	
		17,2'(5'H)-furan]-3-		
100		one		
SH 207	Phase I		antiprogestogen	cancer
ZK 112993	Discontinued	(11beta,17beta)-11-	antiprogestogen	cancer
		(4-acetylphenyl)-17-		
		hydroxy-17-(1-		
		propynyl)estra-4,9-		
000000		dien-3-one		
ZK 136798	Discontinued	4	antiprogestogen	cancer
		\overline{Z}))	
)]-9,11-dihydro-17-		
		hydroxy-17-(3-		
		hydroxy-1 -		
i.		propenyl)-3-oxo-		
		4'Hnaphth[3',2',1':10,		
		9,11]estra-4,9(11)-	* ***	
-	-	dien-6' -		
		yl]benzonitrile		
21-substituted	Preclinical	: .	antiprogestogen:	endometriosis: Jahor
progesterone			ment	induction: hormone
derivatives, NIH				deficiency: cancer
topsentin; topsentine;	Preclinical	(6-hydroxy-1H-indol-	(6-hydroxy-1H-indol- antiproliferative agent cancer	cancer
topsentin B1;		3-yl)[4-(1H-indol-3-		
topsentine B1		yl)-1H-imidazol-2-		
		vl]methanone		

::

Č

carboxyamidotriazole	Phase I	5-amino_1_[[3 5_	antimolifosotiis garati	
; CAJ; NSC 609974;			antipronieranye agent, cancer imidazole	cancer
L 651582		chlorobenzyl)phenyl]		
-		methyl]-1H-1,2,3-		
		rnazore-4- carboxamide		
antisense	Preclinical		antisense;	cancer
oligonucleotide,			oligonucleotide;	
BCL-X			biotechnology	
antisense	Preclinical		antisense;	cancer
oligonucleotide, c-fos			oligonucleotide;	
			biotechnology	
antisense	Preclinical			cancer
oligonucleotide, c-jun		<u> </u>	oligonucleotide;	-
			biotechnology	
antisense	Preclinical			cancer
oligonucleotide,			otide:	
calcium binding			biotechnology	
protein in placenta;		7 25	3	
antisense				
oligonucleotide, CAPL		v		
Se	Phase I		anticence.	***************************************
eotide, DNA			otide.	בשונים
methyltransferase;			biotechnology	
	Preclinical		antisense; c	cancer
oligonucleotide,			otide;	
Epstein Barr virus;	_	<u>م</u>	biotechnology	
antisense			r.	
oligonucleotide, EBV				
			T	

antisense	Preclinical		antisense;	cancer
oligonucleotide, jun			oligonucleotide;	
kinase-1			biotechnology	
antisense	Preclinical	.co	antisense;	cancer
oligonucleotide,			oligonucleotide;	
transforming growth			biotechnology	
factor beta; antisense				
oligonucleotide, TGF-				
beta; antisense				
oligonucleotide,				
cancer				
antisense	Preclinical		antisense;	cancer
oligonucleotides,			oligonucleotide;	
basic fibroblast		· ·	biotechnology	
growth factor		:	3	
oligonucleotides,	Preclinical		antisense;	cancer
cancer, Children's			oligonucleotide;	
Hospital of Orange		بي	biotechnology	
County				
antisense	Preclinical		antisense;	cancer
oligonucleotide,			oligonucleotide;	
multiple drug		<u></u>	biotechnology; mRNA	
resistance		ţ	translation inhibitor	
anticancer agents, OSI/Pfizer	Preclinical	8	apoptosis inducer	cancer
apoptosis inhibitors,	Preclinical		apoptosis inducer	cancer; cardiac
Oxford				therapy; transplant
Asymmetry/LXR				rejection;
Biotechnology			·	gastrointestinal
				disoldel

			.21	
breast cancer therapy, Preclinical Temple University; breast cancer therapy, Alliance	Preclinical	-	apoptosis inducer	cancer
C 857	Preclinical	2-[(1-nitro-9- acridinyl)amino]ethan	apoptosis inducer	cancer
cancer therapy,	Preclinical	oi mononyarocnionae	apoptosis inducer	cancer
Axiom Biotechnologies/Zaiy a				
cancer therapy, BioChem	Preclinical		apoptosis inducer	cancer
Pharma/ImmunoGen				
cancer therapy, Hitachi; cancer	Phase I		apoptosis inducer	cancer
therapy, Nippon Chemiphar				
apy, t	Preclinical	-	apoptosis inducer	cancer
erapy, Rigel	Preclinical		apoptosis inducer	cancer
DDE 313	Preclinical	, o	apoptosis inducer	cancer
Fas modulators, Menarini	Preclinical			cancer
2.175	Preclinical		apoptosis inducer	cancer
	Preclinical			cancer
	Preclinical			cancer
Cadus		-	2.53	
ibitors,	Preclinical		apoptosis inducer;	cancer; psoriasis;
Prolifix			gent	viral infection;
1			1	restenosis

D-144110

apoptosis inducer, IDUN	Preclinical	·. ·.	apoptosis inducer; caspase inhibitor	cancer
CP 461	Phase I		apoptosis inducer; phosphodiesterase	cancer
			inhibitor	
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[[4-	apoptosis inducer;	cancer
		yl)phen -1H -		
		indene-3-acetic acid		
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor	cancer
apoptosis modulators, Preclinical	Preclinical		apoptosis inhibitor;	cancer; autoimmune
University of Colorado			apoptosis inducer	disease;
anastrozole; ZD 1033; Marketed	Marketed	alpha, alpha, alpha, alp aromatase inhibitor	aromatase inhibitor	cancer
ICI D1033;		ha'-tetramethyl-5-		
ARIMIDEX		(1H-1,2,4-triazol-1-		
		ylmethyl)-1,3- benzenediacetonitrile		
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor	cancer
aromatase inhibitor,	Discontinued	19-acetylenic-	aromatase inhibitor	cancer
Merrell Dow		Je	-	
aromatase inhibitors,	Preclinical		aromatase inhibitor	cancer
Washington Research	•			
Foundation			·	
atamestane; SH 489;	Discontinued	1-methylandrosta-1,4-aromatase inhibitor	aromatase inhibitor	cancer; benign
ZK 95639	$\neg \neg$	diene-3,17-dione		prostate hypertrophy
CGP 47645	Discontinued		aromatase inhibitor	cancer

CGS 18320B; CGS	Discontinued	١.	aromatase inhibitor	cancer
18320		ylmethylene)bis[be	•	
		nzonitnie compound		
		with butanedioic acid		
		(2.1)		
dexaminoglutethimid Phase III	Phase III	3-(4-aminophenyl)-3- aromatase inhibitor	aromatase inhibitor	cancer
e; D 3967		ethyl-2,6-		
i c		piperidinedione		
exemestane; FCE	Pre-	6-methyleneandrosta- aromatase inhibitor	aromatase inhibitor	cancer
24304; PNU 971;	registration	1,4-diene-3,17-dione		
ONC 0028;				
AROMASIN				
fadrozole; CGS	Marketed	4-(5,6,7,8-	aromatase inhibitor	Cancer
16949A; AFEMA		midazo[1,5]		
		-alpyridin-5-	-	
		yl)benzonitrile		
formestane; CGP	Marketed	4-hydroxyandrostene- aromatase inhibitor	aromatase inhibitor	Cancer
32349; AT 0931;		3.17-dione		
LENTARON;				
LENTARE				
letrozole; CGS	Marketed	4,4'-(1H-1,2,4-triazol-aromatase inhibitor	aromatase inhibitor	cancer
20267; FEMARA				
•		ylmethylene)bisbenzo		
		nitrile	• •••	
minamestane; FCE	Discontinued	loandrosta-	aromatase inhibitor	cancer
24928		1,4,6-triene-3,17-		
		dione	• .	
213; MPV	Phase I		aromatase inhibitor	cancer; benign
7213ad		fluorophenyl)-2-		prostate hypertrophy
		hydroxy-1-(1H-1,2,4-	<u>-</u>	
		triazol-1-		
		yl)propyl]benzonitrile		

NIV O O1				
10 501	Discontinued	Discontinued 14alpha-hydroxy-4-	aromatase inhibitor	cancer
-		androstene-3,6,17-		
		trione		
ORG 30958	Discontinued	19-	aromatase inhibitor	cancer
		(ethyldithio)androst-		
		4-ene-3,17-dione		
ORG 33201	Discontinued	(3alphaR)-trans-1-[(3 aromatase inhibitor	aromatase inhibitor	cancer:
_		alpha-ethyl-9-		endometriosis
		(ethythio)-	÷	
		2,3,3alpha,4,5,6-		
		hexahydro-1H-		
		phenalen-2-yl)-		
		methyl]-1H-imidazole		
		HCI		
pentrozole; SH 582;	Preclinical	17-[(1-	aromatase inhibitor	cancer
ZK 154065	•	oxohexyl)oxy]-19-		
1-	-	norpregn-4-ene-3,20-		
		dione		
rogletimide;	Discontinued	ethyl-3-(4-	aromatase inhibitor	cancer
pyridoglutethimide				
		piperidinedione	-	
RU 54115	Discontinued		aromatase inhibitor	cancer;
		(methylthio)ethyl]estr		endometriosis
		a-4,9(11)-diene-3,17-		
		dione		
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-		cancer
		formyl-5-		
		hydroxybenzoic acid	_	

vorozole; R 76713; R Phase III	_	aromatase inhibitor	cancer
	IH-1,2,4-triazol-1- ylmethyl]-1-methyl-		
Phase II	4-[f(4-	aromatase inhibitor	cancer.
	bromophenyl)methyl]		endometriosis
	-4H-1,2,4-triazol-4-		
	ylamino]benzonitrile		
Preclinical		aromatase inhibitor	cancer
	1]-5-		
	pyrimidinylamino]be nzonitrile		
Phase III	N-(phosphonoacetyl)-aspartate	aspartate	cancer; viral
	L-aspartic acid,	transcarbamylase	infection
		-	
NSC 328005		- 2 -	
Discontinued		azaanthraquinone	cancer
Discontinued		azaanthraquinone	cancer
Discontinued			cancer
Discontinued		azaanthraquinone	cancer
Discontinued	6,9-dihydro-4-	azaanthraquinone	cancer
	methyl-6-(2-		
	nitrophenyl)-		
	pyrtuol.5,2- g]quinoline-		
	2,5,10(1H)-trione		
Discontinued	-	azaanthraquinone	cancer
Discontinued		azaanthraquinone	cancer
Discontinued		azaanthraquinone	cancer

-144110

ImuVert	Discontinued		biological response modifier	cancer
ONO 4005	Discontinued		biological response modifier	cancer
ONO 4007	Phase II	(S)-2-deoxy-2-[[1- oxo-3-[1-oxo-9-		cancer
		phenylnonyl)oxy]tetra decyl]amino-D- glucose, 3-		
		benzenenonanoate 4- (hydrogensulfate), monosodium salt	···	
VIRULIZIN	Registered		biological response modifier	cancer
RS 83277	Discontinued		biological response modifier; peptide	cancer
adiposin; lipotropin	Preclinical		biotechnology	obesity; cancer
alpha mutein; mutein, Preclinical alpha; HT 003	Preclinical		biotechnology	cancer
anticancer oligonucleotides, MicroProbe	Preclinical		biotechnology	cancer
ATF HI 8	Preclinical		biotechnology	cancer
B 2036PEG; PEG-B 2036; TROVERT	Phase II		biotechnology	retinopathy;
			· ·	diabetes; kidney
cancer	Discontinued	:-	biotechnology	cancer
MedImmune	,	× × ×		
•				

cancer therapy,	Preclinical		biotechnology	cancer
University			ę.	
Technologies				
International		٠		
cell lysis factor, Texas University	Preclinical		biotechnology	cancer
colon cancer therapy, Preclinical Axis Genetics	Preclinical		biotechnology	cancer
cytolytic factor; CF	Preclinical		biotechnology	cancer
DCC tumor	Preclinical		biotechnology	cancer
drug delivery system, Preclinical HIT breast cancer	Preclinical	-	biotechnology	cancer
drug delivery system, Preclinical	Preclinical		hiotechnology	cancer
ONYX 015; ONYX			(9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1001110
015, viraMASC				
coating; ONYX 015				
drug delivery system, ONYX 838; ONYX	Preclinical		biotechnology	cancer
838, viraMASC				
coating		-		
G 207	Phase I		biotechnology	cancer
gene discovery,	Preclinical		biotechnology	cancer
hereditary glioma, Myriad		**************************************		
gene discovery, leukemia, Myriad	Preclinical		biotechnology	cancer
gene discovery, lung cancer, Myriad	Preclinical		biotechnology	cancer
gene therapy, anti- erbB-2 single chain	Preclinical		biotechnology	cancer

10000	i			
gene merapy, antisense insulin-like	Phase I		biotechnology	cancer
growth factor-1; gene therapy, antisense			-	
IGF-1			-	
gene therapy, breast	Preclinical		biotechnology	cancer
cancer; gene therapy,			3	
gene therapy.	Preclinical		hi otoslar 1	
interleukin-2			biotechnology	cancer
HER-2/neu oncogene	Discontinued		biotechnology	cancer
protein			3	
HGF/NK1	Preclinical		biotechnology	Cancer
hPRL G129R	Preclinical		biotechnology	Cancer
HSV 1716	Phase I		biotechnology	Cancer
human chorionic	Phase III		biotechnology	infertility: concer
gonadotropin; hCG;		:,	69000000000	metunty, cancer
OVIDREL				
IL-2 analogue; INGN Preclinical	Preclinical		biotechnology	cancer
let	Phase II		biotechnology	heparin
factor 4; PF4;	• • • •			neutralization;
endostatin B; Debi ich 4 mi			-	psoriasis; HIV
MELLIS I A I IIN	·			infection; cancer;
micmotohod deLle				diabetes
inishiatched double	rre-		biotechnology	allergy; viral
stratided KLVA;	registration			infection; blood
poly(1)poly(C(sup12)				clotting disorder;
O), AMPLIGEN			,	cancer; chronic
				fatigue syndrome
fleu differentiation factor; NDF	Discontinued		biotechnology	cancer
	Preclinical		biotechnology	cancer

ONYX 015	Phase II		hiotechnolomy	
osteoprotegerin; OPG Phase I	3 Phase I		biotechnology	osteonorosis: cancer
p53 gene	Preclinical		biotechnology	cancer
prostate cancer	Preclinical	-	biotechnology	cancer
therapy, Axis		<u></u>	6	
Genetics				
protein replacement	Preclinical		biotechnology	cancer
therapy,			6	
retinoblastoma		• ···		
protein; protein			-	
replacement therapy,		-	···.	
Rb protein		· _ ·		
Salmonella	Preclinical		biotechnology	cancer
typhimurium,			6	
mutagenized;				
mutagenized S				
typhimurium			-	
single chain antigen	Preclinical		biotechnology	diagnosis; cancer
omaing protein, sea				
transcription factor, GM-CSF	Preclinical		biotechnology	cancer
urogenital sinus-	Preclinical		biotechnology	cancer. henion
derived growth			8	prostate hypertrophy
inhibitory factor;				fired in beinghis
UGIF; ps20		:		
vaccine, beta-human	Preclinical		biotechnology	cancer
chorionic	.:		6	
gonadotrophin,				
Vaxcel; vaccine,				
cancer				
vaccine, cancer,	Preclinical		biotechnology	cancer
Ludwig)	
Institute/SIGA				

011001.03

vaccine, non-	Preclinical		1	
Hodokin's B cell			ororecnnology	cancer
lymphoma				
verotoxin	Preclinical		biotechnology	Cancer
angiogenesis	Preclinical		hiotophologi	Called
inhibitor, Genzyme			angiogenesis inhibitor	cancer
angiopoietin 2	Preclinical		biotechnology;	cancer
ANGIOSTATIN	Preclinical		biotechnology;	retinopathy; cancer
.000			angiogenesis inhibitor	
BST 2001; ANGIOCOL	Preclinical		biotechnology;	cancer
gene therapy, endostatin	Preclinical		biotechnology;	cancer
			anglogenesis innibitor	
Del-1 angiogenic	Preclinical		biotechnology;	cancer; ischemia;
theranies			angiogenesis inhibitor; restenosis	restenosis
1 1.			angiogenesis inducer	
drug delivery system, Preclinical	Preclinical		biotechnology;	cancer
ICS, antisense			angiogenesis inhibitor;	
oligonucleotide,			antisense;	
VEGFR; antisense			oligonucleotide	
oiigonucleotide,			•	
VEGFR, ICS				
BST 2002	Preclinical		biotechnology;	cancer
			angiogenesis inhibitor;	
antisense	Dhase I			
	T Algood T		logy;	cancer
ongonucieonde, -	-		antisense;	
3001 LK 3001; INX			oligonucleotide	
antisense	Preclinical		biotechnology:	cancer
oligonucleotide, c-kit				
		: 	Oligonucleotide	

antisense	Preclinical		biotechnology;	cancer
oligonucleotide, c-			antisense;	
myo			oligonucleotide	
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
cancer, Enzo		•	oligonucleotide	
antisense	Preclinical	u.	biotechnology;	cancer
oligonucleotide,			antisense;	
cancer, INSERM			oligonucleotide	
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
chimeric 2-5A,	·		oligonucleotide	
chronic myelogenous)	
leukemia				
antisense	Discontinued		biotechnology:	cancer
oligonucleotide,	•		antisense:	
chronic myelogenous			oligonucleotide	
leukemia; RGA 1512			<u>.</u> .	
antisense	Preclinical		biotechnology:	cancer
oligonucleotide,			antisense:	
epidermal growth			oligonucleotide	
factor receptor;		٠		
antisense				
oligonucleotide,	-			
DOFK.	1000			
oligonicleotide	r ilase i		biotechnology;	cancer
ingometricolog,			antisense;	
insulin-like growth			oligonucleotide	
factor-1 receptor;			1	
antisense	-			
oligonucleotide, IGF- IR; INX 4437				

0-144110

antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
mdm2			oligonucleotide	
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
multi-drug resistance			oligonucleotide	
protein-1; antisense				
oligonucleotide,				
MDR-1			-	
antisense	Discontinued	1	biotechnology;	cancer
oligonucleotide,			antisense;	
myelogenous		0	oligonucleotide	
leukemia; GT 1102			•	
antisense	Discontinued		biotechnology;	cancer
oligonucleotide,			antisense;	
myelogenous			oligonucleotide	
leukemia; GT 1106		,		
antisense	Preclinical	-	biotechnology;	cancer
oligonucleotide,			antisense;	
p120; ISIS 3466			oligonucleotide	
antisense	Preclinical.		biotechnology;	cancer
oligonucleotide,			antisense;	
phospholipase A2;	-	-	oligonucleotide	
antisense				
oligonucleotide,				
PLA2				
antisense	Phase II		biotechnology;	cancer
oligonucleotide,		•	antisense;	
protein kinase A;			oligonucleotide	
עליין איזיקר			1.	

antisense	Phase II		biotechnology;	cancer
oligonucleotide,			antisense;	
protein kinase C-			oligonucleotide	
alpha; antisense				
oligonucleotide,				
cancer; ISIS 3521;				•
CGP 64128A; ISI				•
641A				
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense:	
protein kinase type I;		٥.	oligonucleotide	
antisense				
oligonucleotide;			a	
PKA-I				
antisense	Discontinued		biotechnology:	cancer
oligonucleotide,	-		antisense:	
tumor necrosis factor;			oligonucleotide	
AR 797				
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
vascular endothelial			oligonucleotide	
growth factor; AR)	
639				
antisense	Preclinical		biotechnology:	retinopathy: cancer.
oligonucleotide,			antisense:	skin disease
vascular endothelial			oligonucleotide	
growth factor;				
antisense				
oligonucleotide,				
VEGF; GEM 220				
antisense	Discontinued		biotechnology;	cancer
oligonucleotides,			antisense;	
cancer, Matritech			oligonucleotide	

antisense	Preclinical		hiotechnology.	Concer. winol
oligonucleotides,			antisense:	infection
human			oligonucleotide	TO T
papillomavirus 16/18;				
antisense		-	. :	
oligonucleotides,				
HPV 16/18				
antisense	Preclinical		biotechnology:	Cancer
oligonucleotides,			antisense:	
multi-drug resistance			oligonucleotide	
protein; antisense)	
oligonucleotides,				
MRP				
drug delivery system, Preclinical	Preclinical		biotechnology:	cancer
antisense			antisense:	
oligonucleotide,			oligonucleotide	
erbB-2			3	
drug delivery system, Preclinical	Preclinical		biotechnology;	cancer
antisense				
oligonucleotide, p27			oligonucleotide	
drug delivery system,	Preclinical		biotechnology;	cancer
TCS antisense			antisense:	
oligonucleotide, c-			oligonucleotide	
myb; antisense				
oligonucleotide, TCS				•
c-myb; INX 3000,				
ICS				
drug delivery system, I	Preclinical		logy;	cancer
3280 TCS: INX			antisense;	
6295			oirgonucieotide	

dury delivery gratem Destinis	D-201:-:-1			
TCS, antisense	, ricciniicai		biotechnology;	cancer
oligonucleotide, IGF-			oligonucleotide	
1R; antisense				
oligonucleotide, IGF-				
1R, TCS; INX 4437,			• • • •	
TCS				
antisense	Phase II		biotechnology;	cancer
oligonucleotide, bel-			antisense;	
2; G 3139			oligonucleotide;	
			cnemosensitizer	
antisense	Preclinical		biotechnology;	cancer
Moonhome, dans			antisense;	
reopilarin; urug	•		oligonucleotide;	
delivery system,		•	radiosensitizer	
antisense	•			-
oligonucleotide, raf-1,				
Neopharm				
antisense	Preclinical		biotechnology:	cancer
oligonucleotide, p65		-	antisense:	
NF-kappaB		:	oligonucleotide:	-
			transcription factor	
			regulator	
tumor necrosis factor Preclinical	Preclinical		biotechnology:	Cancer
apoptosis inducing			apoptosis inducer	
ligand; TRAIL				
secreted apoptosis	Preclinical		biotechnology;	cancer: myocardial
related proteins;			er;	infarction: stroke
\neg	-		apoptosis inhibitor	
vth	Preclinical	٠.	biotechnology;	cancer
lactor antagonist,			aptamer;	
antagonist			oligonucleotide	

1000				
FUGF antagonist,	Preclinical		biotechnology;	cancer
NeXstar			aptamer; oligoniicleotide	
TGF-beta antagonist,	Preclinical		hinterhnology.	Concer
NeXstar			antamer:	TO TO TO
			oligonucleotide	
NX 1838	Phase I		biotechnology;	cancer; diabetes;
			aptamer;	retinopathy
			oligonucleotide;	
			angiogenesis inhibitor	
MIG	Preclinical		biotechnology;	cancer
			chemokine;	
			angiogenesis' inhibitor	
somatomedin binding Suspended	Suspended		biotechnology;	skin ulcer; cancer
protein; insulin-like			cicatrizant	
growth factor binding	•			
protein; IGF BP-1				
interleukin-1 beta; IL-Discontinued	Discontinued			cancer; infectious
l beta			okine;	disease
	Phase II	transforming growth	biotechnology;	cancer; skin ulcer;
transforming growth		beta3 (human),	cicatrizant; growth	mucositis
factor beta-3; TGF		dimer	factor	
beta-3; CGP 46614				
tumor growth factor-	Discontinued		biotechnology;	eye disease: cancer:
alpha; TGF-alpha			wth	skin ulcer
	Suspended		biotechnology;	arthritis; cancer; skin
anticollagenase;			cicatrizant; NSAID	ulcer; arthritis
FIBAC;				
anticollagenase fibroblast			. '	
- Coronaria				

tissue inhibitor of	Discontinued		biotechnology:	cancer
metalloproteinase 2;			collagenase inhibitor;	
[1]MP-2			matrix	
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor; gene	
BC 1; AS 122;	Phase I		biotechnology;	cancer; diagnosis
AngioMab			contrast medium;	
			monoclonal antibody;	
			radiotherapeutic;	
			radiodiagnostic;	
			angiogenesis inhibitor	
senescence derived	Discontinued		clin	cancer; psoriasis; eve
inhibitor 1; Sdi 1		. 4 1 1		disease: cancer
		erin Te Te F	inhibitor	
multiple tumor	Preclinical.		biotechnology; cyclin cancer	cancer
suppressor 1-based			dependent kinase	
therapy			inhibitor; gene	
AR 324	Discontinued		biotechnology;	cancer
			cytokine	
	Phase II		biotechnology;	cancer
ALVAC-hIL-2			cytokine	
•	Preclinical		biotechnology;	cancer
interleukin secreting			cytokine	
implant; interleukin			1	
secreting implant				
	Preclinical		biotechnology;	cancer
Ajinomoto; Gal3				
modified IL-2				

interleukin-	Suspended		1	
3/interleukin-6	nonindan.		ototechnology;	cancer;
mutein chimeric			c) towning	unomocytopenia
molecule; IL-3/IL-6	-			
m chimeric molecule				
interleukin-6; IL-6	Suspended		biotechnology;	cancer
interleukin-6; IL-6;	Discontinued		cytokine biotechnology:	cancer:
SDZ ILS 969; ILS			dytokine	thrombocytopenia;
, , , ,				leukopenia
interleukin-6; IL-6; SIGOSIX	Phase II		biotechnology;	cancer;
	-		cytokine	thrombocytopenia
Ë,	Phase I	-	biotechnology;	cancer;
27809			cytokine	thrombocytopenia
nagrestipen;	Discontinued	Chuman clone	hiotechnology.	1111/
nagrestip; BB 10010;		ophage		infection
MIP-1alpha				
		reduced), 26-L-		
		alanine-lymphokine		
SC 68420: MPO 1	Discontinued	MIF laipna		
			ototecimology;	cancer
sonermin; tumor	Discontinued	3-157-tumor necrosis biotechnology:	biotechnology:	cancer
necrosis factor; TNF;		factor (human)	cytokine	
PT 050; TIENEF; TINEF				
sonermin; tumor	Pre-	3-157-tumor necrosis hiotechnology.		
necrosis factor; TNF; registration PAC 4D	registration	factor (human)		cancel, psoliasis
		-		

tasonermin; tumor	Registered		biotechnology;	cancer
necrosis factor alpha;			cytokine	
TNF-alpha; FK 516;		:	-	
BEROMUN		•	: '	
tumor necrosis factor; Discontinued	Discontinued		biotechnology:	Cancer
TNF			cytokine	Tooling.
tumor necrosis factor; Discontinued	Discontinued		biotechnology:	cancer
TNF			cytokine	
tumor necrosis factor Preclinical	Preclinical		biotechnology:	cancer
alpha; TNF-alpha			cytokine	
tumor necrosis factor	Discontinued		biotechnology:	cancer
alpha tip mutants;			cytokine	Tooling
TNF-alpha tip				
mutants	•			
gene therapy, IL-12;	Preclinical	0,0	biotechnology:	cancer
gene therapy, cancer		_ _	cytokine; gene	
			therapy;	
		<u>.a.</u>	biotechnology;	
		.11	mmunostimulant	
gene therapy,	Phase II	<u>.</u>	biotechnology;	cancer
interteron-alpha; gene			cytokine; gene	
therapy, cancer	7.17	=	therapy;	
		<u>. =</u>	immunostimulant;	
		i	interferon	

•	Discontinued	Discontinued 14-ala-18-ile-25-his- biotechnology;	biotechnology;	cancer
		29-arg-32-asn-37-pro-cytokine; growth	cytokine; growth	
synthokine; IL-3		42-ser-45-met-51-arg-factor	factor	
synthokine; SC 55494	4	55-thr-59-leu-62-val-	F	
		67-his-69-glu-73-gly-		
		76-ala-79-arg-82-gln-		
		87-ser-93-ser-98-ile-		
		101-ala-105-gln-109-		
	٠	glu-116-val-120-gln-	-	
		123-glu-14-125-	-	
		interleukin 3 (human	<u>.</u> .	
		clone D11)		
IL-6/IL-2 fusion	Preclinical		biotechnology;	cancer
protein	———		cytokine; growth	
	-		factor; hematopoietic	
			factor	
interleukin-6; IL-6;	Suspended		biotechnology;	cancer;
BEIAIROPIN			cytokine; growth	thrombocytopenia
			factor; hematopoietic	
			factor	
aldesleukin;	Marketed	125-L-serine-2-133-	biotechnology;	cancer; HIV
interleukin-2; IL-2;		interleukin 2 (human cytokine;	cytokine;	infection
PROLEUKIN		reduced)	immunostimulant	
cancer therapy,	Phase II		biotechnology;	cancer
monkey vero cell line			cytokine;	
secreting IL-2; vero-			immunostimulant	
11.2				

celmoleukin:	Marketed	A-P-T-S-S-T-K-K- hiotechnology:	hiotechnology.	wiral infection.
-2;	ā	T-Q-L-Q-L-E-H-L-L-cytokine;	cytokine;	cancer
TAKELEUKIN;		L-D-L-Q-M-I-L-N-G-immunostimulant	immunostimulant	
CELEUK		I-N-N-Y-K-N-P-K-L-		
		T-R-M-L-T-F-K-F-Y-		
		M-P-K-K-A-T-E-L-		
		K-H-L-Q-C-L-E-E-E-		
		L-K-P-L-E-E-V-L-N-	-	
		L-A-Q-S-K-N-F-H-L-		
		R-P-R-D-L-I-S-N-I-		
		N-V-I-V-L-E-L-K-G-		
		S-E-T-T-F-M-C-E-Y-	. . ~	
		A-D-E-T-A-T-I-V-E-	• -	
		F-L-N-R-W-I-T-F-C-		
		Q-S-I-I-S-T-L-T	·- 1.	
em,	Discontinued		biotechnology;	cancer; HIV
aldesleukin; drug			cytokine;	infection
delivery system,			immunostimulant	
interleukin-2;	0			
aldesleukin				
DepoFoam				
drug delivery system, Discontinued	Discontinued		biotechnology;	viral infection;
interleukin-2;			cytokine;	cancer
interleukin-2 delivery			immunostimulant	
system; drug delivery		-		
system, IL-2			•	
_	Phase II		biotechnology;	cancer
liposome interleukin-			cytokine;	
2; interleukin-2			immunostimulant	
liposome; OTx 287;				
OncoLipin-2;				
OncoLipin				

interferon alfa N11.	N Carlenda			
IFN alfa-N1;	Marketed		biotechnology;	cancer; viral
WELLFERON;			Egrokiiic, immiinostimiilant	Infection
SUMIFERON;	-			
TOMOFEROIN TO			·	
interieukin-1; IL-1	Discontinued		biotechnology;	cancer
			cytokine;	
			ımmunostımulant	
interleukin-1 alpha; II - 1 a	Discontinued	*	biotechnology;	cancer
81-71			cytokine;	
interlembin 1 olube	0.51		indianiostimulant	-
derimeteral alpha	Suspended		biotechnology;	cancer
dellyative; OC1 /000		7	cytokine;	
interlenkin-1 hets. II Dra	900		in in incommunity	
1 Posts: OCT 42			biotechnology;	cancer
1 pera; OC1 43;	registration		cytokine;	
			immunostimulant	
interleukin-2; IL-2	Suspended		biotechnology;	cancer
			cytokine;	
			immunostimulant	
Interleukin-2; IL-2;	Phase III		biotechnology;	cancer
NSC 600664;		<u> </u>	cytokine;	
LEUFERON 2			immunostimulant	
interleukin-2; IL-2	Discontinued		biotechnology;	cancer
		<u>.</u>	cytokine;	
T			mmunostimulant	
interieukin-5; IL-5	Discontinued	<u> </u>	biotechnology;	cancer
			cytokine;	
			immunostimulant	
interleukin-6; IL-6	Suspended		biotechnology;	cancer
		<u>.</u>	cytokine;	
			immunostimulant	

interleukin-7; IL-7	Preclinical	<u>q</u>	biotechnology;	cancer
		<u>0₽</u>	cytokine; immunostimulant	
mitoflaxone + interleukin-1;	Discontinued		biotechnology; cytokine:	cancer
interleukin-1 + mitoflaxone			immunostimulant	
oprelvekin;	Marketed	q	biotechnology;	cancer; HIV
interleukin-11; IL-11; VM 204: NFI IMEGA		<u></u> • • • • • • • • • • • • • • • • • • •	cytokine;	infection; mucositis;
polvethylene glycol	Phase II			CIOINI disease
interleukin 2; PEG				cancer
IL-2; interleukin 2		II	immunostimulant	
SC 71858: PMP	Phase I		hiotechnology.	Cancer
) (ordering.	TO THE
		·.=	immunostimulant	
interleukin-1 beta; IL-Preclinical	Preclinical	Ą		cancer; skin ulcer
1 beta	-	<u>v.</u>	cytokine;	
		<u>.11</u>	immunostimulant;	
		Ö	cicatrizant	
IL-3;	Suspended	. کړ	logy;	cancer
ALLEVORIN		<u>oʻ.</u>	cytokine;	
		11	immunostimulant;	•
		δò)	growth factor;	
		Ē	nematopoietic factor	
interleukin-3; IL-3	Discontinued	Q	biotechnology;	cancer
		· 6'	cytokine;	
		.T.	immunostimulant;	
		60	growth factor;	
		Ü	hematopoietic factor	
		4.		

tatonianian of Tr o	,			
mici leukin-5; 1L-5	Phase I		biotechnology;	cancer; leukopenia
•	-		cytokine;	
			immunostimulant;	
			growth factor;	
			hematopoietic factor	
lendistim; SC 70935; Phase III	Phase III		biotechnology;	cancer
D.J.W.			cytokine;	-
			immunostimulant;	
			growth factor;	
			hematopoietic factor	
muplestim;	Phase III	human interleukin 3	biotechnology;	cancer;
MINERIEUKIN-3; IL-3;			cytokine;	thrombocytopenia;
3D2 1LE904; 1LE			immunostimulant;	leukopenia
904; HEMOKINE			growth factor;	•
			hematopoietic factor	
drug delivery system,	Discontinued		biotechnology;	viral infection;
rrocease interreron			cytokine;	cancer
alia; interieron alta			immunostimulant;	
- 1			interferon	
1-1T-2	Preclinical		biotechnology;	cancer
rusion protein			cytokine;	
			immunostimulant;	
	:		monoclonal antibody	
Milenseukin-4; 1L-4;	Phase II		biotechnology;	cancer; viral
OI1400,			cytokine;	infection;
COADRAKINE			stimulant;	rheumatoid arthritis
			NSAID	
mierieukin-12; IL-12; Phase II	Phase II		biotechnology;	viral infection;
riatural Killer cell		:		cancer
NKSF. VM 010			immunostimulant;	
710 717 (170			vaccine adjuvant	

ř	~	
Ċ	`	
٠	0	
1	Ď)
	, ,	
۰	4	

interleukin-1 deletion Preclinical	Preclinical	biote	biotechnology;	cancer; infectious
mutants		cytok	ne	disease
		adjuvant;		
		radio	radioprotectant;	
		ımmı	mmunostimulant	
antisense	Preclinical	biote	biotechnology; DNA	cancer
oligonucleotide,		transc	transcription inhibitor;	
cancer; DNA binding		antisense;	ense;	
antisense		oligo	oligonucleotide	
oligonucleotide				
antisense	Discontinued	biotec	biotechnology; DNA	cancer
oligonucleotide,		transc	transcription inhibitor;	
epidermal growth	•	antisense;	ense;	-
factor receptor; triple		oligo	oligonucleotide	
helix oligonucleotide,		· .		
EGFR; T 03101	•	<u></u>		
antisense	Discontinued	biotec	biotechnology; DNA	cancer
oligonucleotide, her-		transc	ranscription inhibitor;	
2; triple helix		antisense;	ense;	
oligonucleotide, her-2		oligo	oligonucleotide	
sense oligonucleotide, Discontinued	Discontinued	biotec	ONA	cancer; viral
NF-kappaB decoy		transc	ranscription inhibitor; infection	infection
		oligo	oligonucleotide;	
		transc	transcription factor	•
•		regulator	ator	
methioninase; AC	Preclinical	biotec	biotechnology;	cancer
9301; ONCase		enzyme	me	

acidic fibroblast	Discontinued		biotechnology: fusion	cancer
growth factor-			toxin	
Pseudomonas				
exotoxin fusion			:	
protein; aFGF-				
Pseudomonas				
exotoxin fusion			••	
protein			e	
DWP 408	Preclinical		biotechnology; fusion toxin	cancer
epidermal growth	Phase II		biotechnology: fusion	cancer, restenosis.
factor diphtheria toxin		-	toxin	nsoriasis
chimeric protein;			-	
EGF diphtheria toxin		\$.		
chimeric protein;	٠		·	
EGF fusion protein;				-
DAB 389-EGF; DAB			. -	
389-EGF				
fusion toxin,	Preclinical		biotechnology; fusion cancer	cancer
interleukin-13 fusion	-		toxin	
protein; hIL13.E13K- PE4E	-		tuatu .	
GM-CSF diphtheria	Discontinued		biotechnology: fusion cancer	cancer
toxin chimeric			toxin	
protein; DT388 GM-				
	Preclinical		biotechnology; fusion	cancer
Pseudomonas		<u>.</u>	toxin	
exotoxin fusion		-		
protein				
-				

II -4 fileion toxin: II - bhase II	Dhosa II			
4(38-37)-PE38KDEL	11 20 11		blotechnology; fusion cancer	cancer
interleukin-4 fusion				
toxin; NBI 3001		-		
IL13-PE38QQR;	Preclinical		biotechnology: fision	cancer
interleukin-		-	toxin	
13/pseudomonas				
exotoxin derivative				
interleukin-4-	Preclinical		biotechnology: filsion	Concer
pseudomonas			foxin	
exotoxin A; IL-4-PE		<u> </u>		
interleukin-6	Preclinical		biotechnology: fision	HIV infaction.
diphtheria toxin		<u>. . .</u>	toxin	ALLY MILECHOM,
chimeric protein; IL-6		•		Calical
diphtheria toxin				
chimeric protein; IL-6				
fusion protein			*** . ****	
interleukin-6-	Preclinical	-	biotechnology: fiscion	Cancer
Pseudomonas		·_+=	toxin	Calloo
exotoxin 40 chimeric				
protein; IL-6-PE40				
interleukin-6-	Preclinical	2	biotechnology: filsion	Cancer
Pseudomonas		<u> </u>	toxin	Tooling
exotoxin 66(4Glu)				
chimeric protein; IL-			-	
6-PE66(4Glu)				
melanocyte	Preclinical	9	biotechnology: fireion	Cancer
stimulating hormone		<u> </u>		1001100
diphtheria toxin	•			
chimeric protein;	•		-	
MSH diphtheria toxin	:	-		
chimeric protein;				
MSH fusion protein		-		

mitotoxin fibroblast	Discontinued		biotechnology; fusion	cancer; restenosis;
Saporin: mitotoxin			Toxin	eye disease
FGF-saporin;			<u>.</u> .	
PANTARIN				
	Preclinical		biotechnology; fusion	cancer
I Graipha PE38 fusion toxin			toxin	
1	Phase II		biotechnology, fireion	Cancer
transferrin-toxin; HN		-	toxin	TOO! TOO!
00099		-		
transforming growth	Preclinical		biotechnology; fusion	cancer
factor alpha-			toxin	
Pseudomonas				
exotoxin 40 chimeric		•		
protein; TGF alpha-	•		- 4	-
.r.E40			-	
	Preclinical		biotechnology; fusion autoimmune disease;	autoimmune disease;
oipnineria toxin			toxin;	transplant rejection;
dinhtheric protein; 1L-4			immunosuppressant	cancer; HIV
dipnineria toxin				infection
fusion protein				
titox;	Marketed	1-388-toxin	biotechnology: fusion	diahetes: HTV
interleukin-2		(Corneybacterium		nfection;
diphtheria toxin		diphtheriae strain		rheumatoid arthritis:
chimeric protein;		C7), N-L-methionyl-		psoriasis: cancer
interleukin-2 fusion	. •	387-L-histidine-388-		
protein; DAB 389-IL-		L-alanine-,		
2; LY 335348;		(388.fwdarw.2')-		
DAB3891L2;		protein with 2-133-		
ONIAK		Interleukin 2 (human		
		cione p i iL2-21a)		

diphtheria toxin	Discontinued		biotechnology; fusion diabetes; HIV	diabetes; HIV
chimeric protein:			diagni, invoi	miecuon;
interleukin-2 fusion				medinatold arthrus;
toxin; IL-2 fusion				
toxin; DAB 486-IL-2;				-
D-11-7				
cancer therapy, into	Preclinical		biotechnology; gene	cancer
cancer therapy, tumor Preclinical	Preclinical		biotechnology; gene	cancer: diagnosis
suppressor,			3	
University				
Technologies				
International				
melastatin	Preclinical		biotechnology; gene	cancer
BRUSH-1 gene based Preclinical	Preclinical		biotechnology; gene	cancer
therapy; cancer			therapy	
therapy				
cancer therapy,	Preclinical	-	biotechnology: gene	cancer
modified adenovirus,			therapy	
Onyx; ONYX 838		-		
gene therapy,	Preclinical		biotechnology; gene	cancer
adenoviral herpes		- ;-	therapy	
simplex virus				
thymidine kinase;				
gene therapy, cancer				
gene therapy, anti-	Clinicals		biotechnology; gene	cancer
metastasis technology				
gene therapy,	Preclinical		ology; gene	cancer
anticancer stem cell;			therapy	
gene therapy, cancer				

gene therapy,	Phase II	<u>+</u>	biotechnology; gene	cancer
gene therapy, CC49; CC 49		.		
gene therapy,	Preclinical		biotechnology; gene	cancer
antisense c-myc; gene			therapy	
therapy, prostate				
cancer				
gene therapy, Bcl-xS, Preclinical cancer. IDI IN	Preclinical		biotechnology; gene	cancer
gene therapy. BCR-	Preclinical		notechnology, gene	***************************************
ABL transcription			therapy	Valicel
inhibitor protein			iotap)	
gene therapy, brca1,	Phase II	9	biotechnology; gene	cancer
Vanderbilt University	-		therapy	
gene therapy, breast	Preclinical	<u>.</u>	biotechnology; gene	cancer
cancer; gene therapy,			therapy	
gene therapy, breast	Preclinical		hiotechnology, gene	10000
cancer, Bavarian			therany	·
Nordic Research		•		
Institute; Procon				
CYP2B1				1
gene therapy, c-fos;	Phase I	-Q	biotechnology; gene	cancer
gene therapy, cancer		13	therapy	
gene therapy, cancer;	Preclinical	q	biotechnology; gene	cancer
GENECEUTICALS		Ţ,	therapy	
gene therapy, cancer;	Discontinued	q	biotechnology; gene	cancer
gene therapy, T-body		主.	therapy	
gene therapy, cancer	Preclinical	<u> </u>	biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical	q	nology; gene	cancer
		空	therapy	

gene therapy cancer	1			
sour areapy, cancer	riccillical		biotechnology; gene therany	cancer
gene therapy, cancer;	Preclinical		biotechnology; gene	cancer
gene therapy, cationic	v		therapy	
lipid vectors				
gene therapy, cancer;	Phase II		biotechnology; gene	cancer
gene therapy,			therapy	
immunostimulatory		÷ · ·	· · · · · · · · · · · · · · · · · · ·	-
Builds 2010 1	_			
gene merapy, cancer,	Precimical	•	biotechnology; gene	cancer
Copernicus Gene		•••	therapy	
Systems				
gene therapy, cancer, Preclinical	Preclinical		biotechnology; gene	cancer
gene therapy, chronic Phase I	Phase I		hiotechnolom: gene	
mvelopenous			H. Someonical Solution of the	calicel
leukemia		_	tnerapy	
gene therapy, CIITA;	Preclinical		biotechnology; gene	cancer
gene therapy, MHC			therapy	
class II deficiency				
gene therapy,	Phase I		biotechnology; gene	Cancer
cytosine deaminase			therapy	
gene therapy,	Suspended		biotechnology; gene	cancer
cytotoxic T cells;		- *	therapy	
gene therapy, cancer			•	
gene therapy, del-1;	Preclinical		biotechnology; gene	coronary artery
gene therapy, vascular				disease; peripheral
disease; del-1				vascular disease;
				cancer
gene therapy, delta- like protein	Preclinical		biotechnology; gene	cancer
gene therany day	Dreclinion			
activation	ricomincai		ology; gene	cancer
		3	ulerapy	

gene therapy. E1A	Phase II	ſ	
repressor; gene		the cancer the cancer	ıcer
therapy, cancer; RGG		Treat and	
0853; RGA 0853;	•		
tgDCC-E1A			
gene therapy, Egr-1 + Preclinical	Preclinical	biotechnology: gene	Cer
TNF-alpha; gene	0		
therapy, Ad5.Egr-			
TNF; gene therapy,		-	
radiation-controlled			
technology		-	
gene therapy, ErbB2- Preclinical	Preclinical	biotechnology; gene cancer	cer
K; gene therapy,			
gene thousant for			
gene merapy, ras	Preclinical	biotechnology; gene cancer	cer
ilgand; gene therapy,			
cono thousan			
fordelte TNV	Frechnical	biotechnology; gene cancer	cer
dasuella i IVI; gene		therapy	
merapy, cancer			
gene therapy, G156A	Preclinical	biotechnology, gene	je.
MGMT; gene			
therapy, cancer			-
gene therapy,	Preclinical	biotechnology; gene cancer	Ser
gene therapy, glioma	Discontinued	biotechnology; gene cancer	er
Т		therapy	
gene therapy, GM-	Preclinical	biotechnology; gene cancer	er
$\overline{}$		therapy	
gene therapy, H-Nuc	Preclinical	biotechnology; gene cancer	er
gene therany H10.	Drootining	therapy	
	riccinical	biotechnology; gene cancer therapy	er
r			

gene merapy, nerpes	Phase I	biotechnology; gene	cancer
simplex mymidine kinase		therapy	
gene therapy, herpes	Preclinical	biotechnology: gene	cancer
simplex tyrosine		therapy	
kinase; gene therapy HS-tk			
gene therapy, HLA-	Preclinical	This to the state of the state	
B7; gene therapy,		therany	cancer
melanoma		. Cd	
gene therapy, human	Preclinical	hiotechnology; gene	cancer
papillomavirus; gene		therapy	
Ary (Carry)			
gene therapy, IL-12	Preclinical	biotechnology; gene	cancer; viral
_		therapy	infection
	Phase I	biotechnology; gene	cancer
interleukin-2;		therapy	
AdCAIL-2			
gene therapy,	Discontinued	biotechnology; gene	cancer
interleukin-7		therapy	
gene therapy, LeIF	Discontinued	biotechnology; gene	cancer
		therapy	
	Phase I	biotechnology; gene	cancer
leukemia, Novartis; GVH 313		therapy	
	Preclinical	biotechnology: gene	cancer
- <u>}</u>	•	therapy	
stimulating factor			
gene therapy, mda-7; Preclinical	Preclinical	biotechnology; gene	cancer
gene therapy,		therapy	
filoranoma			

CON CHOMONIA	-			
gene merapy, MDK- Phase I	Phase I		biotechnology; gene	cancer
I; gene therapy,			therapy	
cancer				
gene therapy, men1;	Preclinical		biotechnology; gene	cancer
gene therapy, cancer			therapy	
gene therapy, multi-	Preclinical		biotechnology; gene	cancer
drug resistance			therapy	
gene therapy,	Discontinued		biotechnology; gene	cancer
multiple drug			therapy	
resistance-1; gene			٠.	
therapy, MDR-1				
gene therapy, p16,	Preclinical		biotechnology; gene	cancer
Introgen; gene		<u>, </u>	therapy	
therapy, cancer,				
Introgen; INGN 221				
gene therapy, p53;	Phase II	;	biotechnology; gene	cancer
gene therapy, cancer;			therapy	
SCH 58500				
gene therapy, p53;	Phase II		biotechnology; gene	cancer
gene therapy,			therapy	
retroviral p53; INGN			•	
101				
gene therapy, p53;	Phase II		biotechnology; gene	cancer
gene therapy,		<u></u>	therapy	
adenovirus p53; INGN 201			· ••• ·	
gene therapy, p53;	Preclinical		biotechnology; gene	cancer
gene therapy, cancer;			therapy	
p53 TCS				
gene therapy, p53;	Preclinical	.	biotechnology; gene	cancer
gene therapy, cancer		-	therapy	
gene therapy,	Preclinical	<u>.</u>	biotechnology; gene	cancer
D23/MINIMIZ		1	therapy	

gene therapy, p53/WAF1	Discontinued		biotechnology; gene	cancer
gene therapy,	Phase I		biotechnology, gene	Cancer
pancreatic cancer,			therapy	Carroot
Bavarian Nordic				
Research Institute;				
Procon CYP2B1				
gene therapy,	Preclinical		biotechnology: gene	Cancer
pRb2/p130; gene			therapy	
therapy, cancer				
gene therapy, pro-	Preclinical		biotechnology; gene	cancer
olug activation			therapy	
gene therapy, prostate Phase]	Phase I		biotechnology; gene	cancer
cancer, Calydon; CN			therapy	
00/	·			
gene therapy, PTEN; Preclinical	Preclinical .		biotechnology; gene	cancer
gene therapy, cancer			therapy	
gene therapy, RB 94;	Preclinical		biotechnology: gene	Cancer
SG 94; RB 94		-	therapy	Carico
	Preclinical		biotechnology; gene	cancer
recombinant			therapy	
oncolytic HSV				
expressing CYP2B1; rRp450				
\mathbf{T}	Preclinical		hiotechnology, gene	10000
la gene;				כמווכנו
gene therapy, Rb				-
C				

gene therapy.	Preclinical	2	otochnologic	
ribozyme, cancer.		7	therapy,	Calicel
City of Hope Medical			c data	
Center; ribozyme,		75.		
cancer, City of Hope		. <u></u>	٠.	
Medical Center		a few and a few	*** 	
gene therapy, scFv-	Preclinical	bid	biotechnology; gene	cancer
RAS; INGN 212		the	therapy	
gene therapy, solid	Preclinical	bic	biotechnology; gene	cancer
tumors, Oxford		the	therapy	
BioMedica; MetXia				
gene therapy, T cell	Discontinued	bio	biotechnology: gene	cancer
chimeric receptor;	7	the	therapy	
gene therapy, cancer		-	·	
gene therapy,	Phase III	oid	biotechnology; gene	cancer
thymidine kinase;		the	therapy	
gene therapy, cancer;				
gene therapy, HS-tk;				
SDZ GLI328; GLI				
328				
gene therapy,	Discontinued	bio	biotechnology; gene	cancer
thymidine kinase;		the	therapy	
gene therapy,				
leptomeningeal				
carcinomatosis; gene				
therapy, HS-tk gene				
gene therapy,	Phase I	oid	piotechnology; gene	cancer
thymidine kinase;		the	therapy	
gene therapy, HS-tk;				
gene therapy,	· .		77.24	
mesothelioma				

		. :		
gene therapy,	Phase I		hiotechnology, gene	
thymidine kinase;		 -	therapy	במווכר
gene therapy, HS-tk;			Character of the control of the cont	
gene therapy brain				
cancer			•••	
gene therapy,	Discontinued		hiotechnology, gene	***************************************
thymidine kinase;			therapy	calicel
gene therapy, HS-tk				
gene therapy,	Suspended		hiotechnology, gene	10000
thymidine kinase;			therapy	רמוויכו
gene therapy, HS-tk			d	
gene therapy,	Phase I		hiotechnology, gone	
thymidine kinase;			theran:	cancer
gene therapy, HS-tk			tilet apy	
gene therapy,	Preclinical		hiotechnology: gene	***************************************
thymidine kinase;			therany	called
gene therapy, HS-tk			uctapy	
gene therapy,	Preclinical		biotechnology: gene	Cancer
thymidine kinase;			therany	Calibo
gene therapy, HS-tk;			· Canon	
gene therapy, cancer				
gene therapy,	Preclinical		biotechnology, gene	10000
thymidine kinase;		•	therapy	
gene therapy, cancer; INXC-gTK				
	Phase I		biotechnology, gene	200000
			therapy	Called
National Institute of				
Neurological	•	:		
Disorders and Stroke;			-	
gene therapy, HS-tk, NINDS		-		

gene therapy, TNF	Preclinical		biotechnology; gene	cancer
gene therapy firmor	Dhare II		tnerapy	
necrosis factor alpha;	r ilase Li		biotechnology; gene	cancer
gene therapy, solid			(datom)	
tumor				
toxigenes	Preclinical		biotechnology; gene	cancer
gene therapy,	Preclinical		biotechnology, gene	Cancer
epithelial cell cancer,			therapy; alkylating	CallCol
CTL 302			agent	
gene therapy, liver	Preclinical		biotechnology: gene	cancer
cancer, Cobra			therapy; alkylating	
Therapeutics; CTL	-		agent	
gene therany prostoto	Droclinical			
cancer. Cobra	riccimical	-	biotechnology; gene	cancer
Therapeutics: CTI			rnerapy; aikylating	
401			agent	
gene therapy,	Preclinical	-	biotechnology: gene	cancer
angiogenesis			1, e	Carloci
	-		inerapy; angiogenesis	
gene therapy	Preclinical		יייייייייייייייייייייייייייייייייייייי	
.0.0	i comincai		ototechnology; gene	cancer
genes cancer			therapy; angiogenesis	
Builty, Califor			inhibitor	
cancer;	Preclinical	_	biotechnology; gene	cancer
gene therapy,			therapy; angiogenesis	
angiogenesis			inhibitor	
Inhibition				
		A		

and the same				
gene merapy,	Preclinical	biotechnology; gene		cancer
antisense K-ras;		therapy; antisense;	ntisense:	
antisense		oligonucleotide	otide	
oligonucleotide, K-		0		
ras; INGN 111			•	
gene therapy,	Preclinical	biotechnology; gene	ogy: gene	cancer
chemotherapy-		therapy;)	
resistance genes; gene		chemoprotectant;	ectant;	
therapy, MDR		hematoprotectant	tectant	
	Phase I	biotechnology; gene		cancer
gene therapy, cancer;		therapy;)	
gene therapy, MDR-		chemoprotectant;	ectant;	
I; MDRx1		hematoprotectant	tectant	
gene therapy, MDR-	Phase I	biotechnology; gene	ogy; gene	cancer
1; gene therapy,	•	therapy;	} }•• .	
cancer		chemoprotectant;	ectant;	
		hematoprotectant	tectant	
gene therapy,	Preclinical	biotechnology; gene		cancer
gp91phox; gene		therapy; coagulation		
therapy chronic	-	factor	0 -	
granulomatous				
disease			٠. ـ	
gene therapy, Sdi 1;	Discontinued	biotechnology; gene	Г	cancer
gene therapy, cancer		therapy; cyclin	clin	
		dependent kinase	kinase	
		inhibitor		
er;	Phase I	biotechnology; gene	Π	cancer
gene therapy, VV-		therapy; cytokine;	tokine;	
SM GM		immunostimulant	mulant	

gene therapy, cancer; Preclinical	Preclinical	biot	biotechnology: gene	cancer
gene therapy,		ther	therapy; cytokine;	
cytokine; gene		imi	immunostimulant	
therapy,				
immunostimulatory				
cell surface molecules				
gene therapy,	Preclinical	biot	piotechnology; gene	cancer
consensus interferon;		ther	herapy; cytokine;	
gene therapy, IFN-		umi	mmunostimulant	
con1; gene therapy,		-		
cancer			• • •	
gene therapy, IL-2;	Phase II	biot	biotechnology; gene	cancer
gene therapy, cancer;		ther	therapy; cytokine;	
BIWB 2		imn	mmunostimulant	
gene therapy, IL-3,	Preclinical ·	biot	biotechnology; gene	cancer
IntroGene; gene		ther	therapy; cytokine;	
therapy, cancer,		nmi	mmunostimulant	
IntroGene				
gene therapy,	Preclinical	biot	biotechnology; gene	cancer
interferon beta; gene		ther	therapy; cytokine;	
therapy, cancer		umi	immunostimulant	
gene therapy,	Phase II	biot	biotechnology; gene	cancer
interleukin-12; gene	٠.	ther	therapy; cytokine;	
therapy, cancer		imn	mmunostimulant	
gene therapy,	Preclinical	biot	biotechnology; gene	cancer
interleukin-12/B7-1;		ther	therapy; cytokine;	
gene therapy,		nmi	immunostimulant	
AdIL12.B7-1; gene				
therapy, cancer;			•	
Ad1L12.B7-1			•	
gene therapy,	Phase I	biot	biotechnology; gene	cancer
interleukin-2; gene		ther	therapy; cytokine;	
therapy, cancer		nmi	immunostimulant	

110000				
gene merapy,	Phase I		biotechnology; gene	cancer
merleukin-z; gene			therapy; cytokine;	
merapy, cancer			immunostimulant	
gene therapy,	Preclinical		biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine:	
therapy, melanoma			immunostimulant	
gene therapy,	Phase II		biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine:	
er			immunostimulant	
	Phase I		biotechnology: gene	Cancer
			therapy: cytokine:	Toolino.
therapy, cancer; AC			immunostimulant	
9401; MetaGene				
gene therapy,	Phase II		biotechnology, gene	Cancer
interleukin-2; gene			therany: cytokine:	סמווססו
therapy, cancer; VCL			imminostimiilant	
1102; LEUVECTIN				
gene therapy,	Discontinued		biotechnology, gene	200001
interleukin-2; gene		-	therapy cytokine.	CallCol
therapy, breast			imminostimiilant	
cancer; AVECTIN				
gene therapy,	Discontinued		biotechnology: gene	Cancer
interleukin-2; gene			therapy: cytokine:	
therapy, cancer;		· •	immunostimulant	
BIWB 1		***		
	Preclinical		biotechnology; gene	cancer
interleukin-2; gene			therapy: cytokine:	
therapy, cancer			mmunostimulant	
	Phase I	;	biotechnology; gene	cancer
interleukin-2; gene			herapy; cytokine;	
therapy, cancer			mmunostimulant	

gene therapy,	Phase I	hintechnolom: gang	
interleukin-2; gene		 therany cythkine.	calicer
therapy,		immunostimulant	-
neuroblastoma			
gene therapy,	Phase I	biotechnology: gene	Cancer
interleukin-2; gene		therapy, cytokine.	
therapy, colon cancer		immunostimulant	
gene therapy,	Phase I	hiotechnology, gene	20000
interleukin-2; gene		therany, cytoline.	calicel
therapy, IL-2; gene		imminostimulost	
therapy, melanoma		The interior of the interior	
gene therapy,	Preclinical	biotechnology: gene	Cancer
interleukin-2 +		therapy cytokine.	Califor
interferon gamma;		imminostimulant	
gene therapy, cancer			
gene therapy,	Phase I	hiotechnology, gone	
interleukin-2 +		 More and a serie	cancer
thymidine kinase.		 inerapy; cytokine;	
gene therapy concer		Immunostimulant	
Bond dietapy, cancel			
gene therapy,	Preclinical	biotechnology; gene	cancer
interleukin-2,	-	therapy; cytokine;	
interferon gamma,		immunostimulant	-
thymidine kinase;			
gene therapy, cancer		 	
gene therapy,	Preclinical	biotechnology: gene	cancer
interleukin-4; gene		therapy: cytokine:	
therapy, melanoma		imminostimulant	-
gene therapy,	Suspended	9	record
interleukin-7; gene			
therapy, IL-7; gene		imminostimulant	
therapy, malignant			
melanoma			

				i
gene therapy,	Phase I	oid	biotechnology; gene	cancer
interleukin-7; gene		the	therapy; cytokine;	
therapy, IL-7		imi	immunostimulant	
gene therapy, tumor	Preclinical	oid	biotechnology; gene	cancer
necrosis factor; gene		the	therapy; cytokine:	
therapy, TNF; gene		mi	mmunostimulant	
therapy, cancer				
	Phase I	bio	biotechnology; gene	cancer
		the	therapy: cytokine:	
therapy, cancer		ımi	immunostimulant	
NV 1030	Preclinical	bio	biotechnology; gene	cancer
		the	therapy; cytokine;	
		imi	immunostimulant;	
		ang	angiogenesis inhibitor	
ζ,	Phase I	bio	biotechnology; gene	cancer
granulocyte		the	rapy: cytokine:	
macrophage-colony		ımı	immunostimulant	
stimulating factor,		Vac	vaccine	
Geniva; gene therapy,				
cancer, Geniva				
MDR,	Phase II	biol	biotechnology: gene	Cancer
GenPak; gene		ther		
therapy, cancer	•	hen	hematoprotectant;	
		che	chemoprotectant	
	Preclinical	biot	ene	cancer
gene therapy, cancer		ther	therapy;	
		hen	hematoprotectant;	
		chei	chemoprotectant	

gene therany HI A	Dhogo III			
B7. gene thereas	I Hase III	pioteci	biotechnology; gene	cancer
D', gene merapy,		therapy;		
cancer; gene therapy,		immun	immunostimulant	
mry-b//cytorecum				
complex;				
ALLOVECTIN-7		:		
gene therapy, IL-2;	Phase I	biotech	biotechnology; gene	cancer
gene therapy, small		therapy:) }·	
cell lung cancer; gene			mmunostimulant	
therapy, BPV vector				
gene therapy, suicide Preclinical	Preclinical	biotech	biotechnology; gene	cancer
gene +		therapy	3	
immunotherapeutic;			imminostimulant	
gene therapy, cancer				
gene therapy, gamma	Phase I	biotech	biotechnology; gene	cancer
interferon; gene		therapy:		
therapy, cancer		grani	immunostimulant:	
		cytokine	e	
gene therapy, GM-	Phase II	biotech	biotechnology; gene	cancer
CSF; gene therapy,		therapy;) 	
cancer; vaccine,		immi	mmunostimulant:	
cancer; GVAX		cytokine		
gene therapy,	Preclinical	biotech	ology; gene	cancer
interleukin-10; gene		therapy;)	
therapy, cancer		immuni	immunostimulant;	
		cytokine		
	Phase I	biotech	ology; gene	cancer
interleukin-2; gene		therapy:		
therapy, melanoma;		immuri	immunostimulant;	
gene therapy,		cytokine		
tyrosinase promoter	7	•		

gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy;	
therapy, melanoma		:	immunostimulant;	
			cytokine	
gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy;	
tnerapy, melanoma			immunostimulant;	
gene therany	DL.		cytokine	
gene merapy,	rnase I		biotechnology; gene	cancer
interieukin-2; gene			therapy;	
merapy, melanoma		٠	immunostimulant;	
			cytokine	
gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy:	
therapy, AdCAIL-2;			immunostimulant.	
gene therapy, cancer;		∵	cytokine	
AdCAIL-2				
	Phase I		hiotechnology, gene	100000
gene			therapy:	כמווככו
therapy, cancer			immunostimulant;	
			cytokine	
gene therapy,	Preclinical	•	biotechnology; gene	cancer
interleukin-4; gene			therapy;	
therapy, melanoma			immunostimulant;	
			cytokine	-
gene therapy,	Preclinical		biotechnology; gene	cancer
leukemia; gene			therapy;	
therapy,	_		immunostimulant;	
immunostimulatory molecules			cytokine	

gene therapy,	Preclinical		biotechnology: gene	cancer
interferon alfa			therapy;	
			immunostimulant;	· ·
•			cytokine; interferon	
gene therapy,	Preclinical		biotechnology; gene	cancer
interferon gamma;			therapy;	
gene therapy, cancer			immunostimulant;	
			cytokine; interferon	
gene therapy, MRP;	Preclinical		biotechnology; gene	cancer
gene therapy, cancer	•		therapy; MDR	
		•	inhibitor	
gene therapy,	Discontinued		biotechnology: gene	cancer
multidrug resistance;			therany: MDR	
gene therapy, MDR			inhibitor	
SS	Phase I		biotechnology; gene	rheumatoid arthritis.
simplex thymidine	•		therapy: NSAID	restenosis: cancer
kinase gene; gene				יייייייייייייייייייייייייייייייייייייי
therapy, cancer				
	Phase I		biotechnology: gene	cancer
transforming growth			therapy:	
factor beta;			oligonicleotide	
oligonucleotide, TGF				_
beta				.
	Preclinical		biotechnology; gene	cancer
hammerhead	•		therapy:	
ribozyme, cancer,	•		oligoniicleotide:	
Berlex Biosciences;		•	rihozyme	
ribozyme, c-erb-B2,	-		•	
Berlex Biosciences				

-				
gene therapy,	Phase II	- 3	biotechnology; gene	cancer
Aa(GV)CD.10; gene			therapy;	
therapy, cytosine			radiosensitizer	
deaminase; gene				
therapy, colon cancer				
gene therapy, p53;	Preclinical		biotechnology: gene	cancer
vaccine, p53; gene			therapy: vaccine	
therapy, cancer				-
ed,	Phase I		biotechnology: gene	Cancer
			therapy; vaccine	
vaccine, gene-based,	Preclinical		biotechnology: gene	cancer
carcinoembryonic	• .	,	therapy: vaccine	
antigen; vaccine,				
gene-based, pGT37;	-			
vaccine, gene-based,				
cancer				
d,	Preclinical		biotechnology; gene	cancer
E7; vaccine, gene-			therapy: vaccine	
based cancer				
	Phase I		biotechnology: gene	cancer
gp100; vaccine, gene-	· .		therapy: vaccine	
based, melanoma				
ρ̈́	Phase II		biotechnology: gene	cancer
			therapy; vaccine	
vaccine, gene-based,				
melanoma				
T	Phase I		biotechnology: gene	cancer
			therapy; vaccine	***************************************
gene-based, cancer		;· ·		

vaccine, gene-based,	Preclinical		biotechnology; gene	cancer
melanoma, Bavarian			therapy; vaccine	
Nordic Research				
Institute; gene			-	
therapy, melanoma,			-	
Bavarian Nordic			-	
Research Institute;				
MVA TYR			:	
vaccine, gene-based,	Preclinical		biotechnology; gene	cancer
NY-ESO-1; vaccine,			therapy; vaccine	
gene-based, cancer			-	
vaccine, gene-based,	Preclinical		biotechnology; gene	cancer
T cell cancer			therapy; vaccine	
vaccine, human	Discontinued		biotechnology; gene	cancer
papillomavirus			therapy; vaccine	
antigens; vaccine			•	
HPV antigens;				
vaccine, cervical				
cancer				
anti-dorsalizing	Preclinical	-	biotechnology; growth cancer	cancer
morphogenetic			factor	
protein-1			-	
heregulin; Neu	Discontinued		biotechnology; growth cancer	cancer
differentiation factor;			factor	
Woodless of the state of the st				
megakai yocyte stimulating factor	Discontinued		biotechnology; growth cancer	cancer
Dod Llond and			racio,	
factor	Frecimical	-	biotechnology; growth cancer factor	cancer
	Preclinical		biotechnology; growth cancer; mucositis	cancer: mucositis
factor beta; TGF beta;			factor	
21012 TANE				

transforming growth	Preclinical		biotechnology: growth mucositis: cancer.	mucositis: cancer.
			factor	musculoskeletal
				disorder
keratinocyte growth factor 2: KGF 2: HG	Phase II		biotechnology; growth cancer; mucositis;	cancer; mucositis;
03400			chemoprotectant;	kidney disease
			cytoprotectant	
granulocyte	Preclinical		biotechnology; growth cancer	cancer
macrophage colony			factor; hematopoietic	
stimulating factor		_	factor	
muteins; GM-CSF				
muteins				
_	Phase I	-	biotechnology; growth cancer; anemia	cancer: anemia
; PEG-			factor; hematopoietic	
hemoglobin			factor	
polyethylene glycol	Discontinued		biotechnology; growth cancer;	cancer;
megakaryocyte			factor; hematopoietic	thrombocytopenia
growth and			factor	•
development factor;				
PEG-MGDF	•			
polyethylene	Preclinical		biotechnology; growth cancer	cancer
granulocyte			factor; hematopoietic	
macrophage colony			factor	
stimulating factor				
glycol; PEG-GM-				
CSF; PolyMASC-				
GM-CSF				
thrombopoietin; TPO; Phase III	Phase III		biotechnology; growth cancer;	cancer:
megakaryocyte			factor; hematopoietic	thrombocytopenia
growth and				
development factor;				
MGDF			-	

thrombopoietin; TPO Preclinical				
thrombopoietin; TPO Pre			factor; hematopoietic factor	thrombocytopenia
	eclinical		biotechnology; growth cancer; factor; hematopoietic thromb	cancer; thrombocytonenia
			factor	
	Discontinued		biotechnology; growth cancer	cancer
granulocyte		QPWEHVNAIQ	factor; hematopoietic	
macrophage colony		EALRLLDLSR	factor; cytokine;	
Stimulating		DTAAEMINEEV	immunostimulant	
factor/interleukin-3		EVISEMFDLQ		
chimeric; GM-		EPTCLQTRLE		
CSF/IL-3 chimeric		LYKQGLRGSL		
protein; PIXY 321;		TKLKGPLTMM		
BMS 185032;		ASHYKQHCPP		
PIXYKINE		TPETSCATQI		
		ITFESFKENL		
		KDFLLVIPFD	-	
		CWEPVQEGGG		
		GSGGGGSAD		
		MTQTTPLKTS		
		WVDCSNMIDE	٠.	
	- 1	ITHLKQPPL		
	·	PLLDFNNLNG		
·		EDQDILMENN		
		LRRPNLEAFN		
		RAVKSLQDAS		
œ	_3_	AIESILKNLL		
		PCLPLATAAP		
	<u> </u>	TRHPIHIKDG		
		OWNEFRRKLT		
	- -	FYLKTLENAQ	*	
	7	AQQTTLSLAI F		

SD-144110.1

cilmostim;	Discontinued		biotechnology; growth hyperlipidemia;	hyperlipidemia;
macrophage colony		•	factor; hematopoietic bacterial infection;	bacterial infection;
stimulating factor; M-			factor;	cancer
CSF; MACSTIM			immunostimulant	
filgrastim;	Marketed	N-L-methionyl-	biotechnology; growth cancer; HIV	cancer; HIV
granulocyte colony		ng	factor; hematopoietic	infection;
stimulating factor; G-		factor (human clone		pneumonia;
CSF; neutropoietin;			immunostimulant;	leukopenia; skin
KRN 8601;			cicatrizant	ulcer
NEUPOGEN;				
GRANULOKINE;				
GRAN; GRIMATIN				
filgrastim SD01;	Phase II		biotechnology; growth cancer; HIV	cancer; HIV
PEG-granulocyte-		-	factor; hematopoietic	infection;
colony stimulating				pneumonia:
factor; PEG-GCSF;			immunostimulant	leukonenia
SD-NEUPOGEN		٠		
granulocyte	Phase III		biotechnology; growth cancer; leukopenia	cancer; leukopenia
macrophage colony			factor; hematopoietic	•
stimulating factor;			factor;	
GM-CSF;			immunostimulant	
LEUCOTROPIN				
macrophage	Preclinical		biotechnology; growth cancer	cancer
inflammatory protein-			factor; hematopoietic	
lalpha; MIP-1alpha			factor;	
			immunostimulant	

molgramostim; Marketed colony stimulating biotechnology; growth cancer; leukopenia granulocyte pHG25 protein factor; hematopoietic factor; scriptulating factor; moiety reduced) immunostimulant factor; moiety reduced) immunostimulant factor; hematopoietic factor; h					
factor 2 (human clone pHG25 protein moiety reduced) 0; Marketed 1-(N-L-methionyl-L-alanine)-3-L-tyrosine-4-L-tyrosine-5-L-arginine-17-L-serine-colonystimulating factor (human clone 1034) Suspended Pegnartograstim 1 Discontinued Preclinical	molgramostim;	Marketed	colony stimulating	biotechnology; growth	cancer: leukopenia
Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-colony-stimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical Preclinical	granulocyte		factor 2 (human clone	factor; hematopoietic	
moiety reduced) Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-colonystimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	macrophage colony		pHG25 protein	factor;	
Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-colony-stimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	stimulating factor;			immunostimulant	
Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-colony-stimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	GM-CSF; GMC				
Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-throsine-5-L-arginine-17-L-serine-colonystimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	89107; SCH 39300;				
Marketed 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-colonystimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	CSF 39300;				
Marketed 1-(N-L-methionyl-L- alanine)-3-L- threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034) stimulating factor (human clone 1034) Suspended Pegnartograstim I Discontinued Preclinical	LEUCOMAX				
alanine)-3-L- threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical Breclinical	nartograstim;	Marketed		biotechnology: growth	cancer: leukonenia
threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034) Suspended Pegnartograstim Discontinued Preclinical	marograstim;			factor; hematopojetic	J
tyrosine-5-L-arginine-17-L-serine-colony-stimulating factor (human clone 1034) Suspended Pegnartograstim 15; Preclinical Preclinical	granulocyte colony			factor;	
Suspended Pegnartograstim O In Discontinued Preclinical In	stimulating factor		tyrosine-5-L-arginine-	immunostimulant	
Suspended Pegnartograstim O Is; Discontinued Preclinical Suspended Pegnartograstim Preclinical	mutein; G-CSF		17-L-serine-colony-		
Suspended Pegnartograstim o 15; Discontinued Preclinical Preclinical	mutein; KW 2228;		stimulating factor		
Suspended Pegnartograstim 15; 16. 17. Preclinical Preclinical	NEU-UP		(human clone 1034)		
15; In Discontinued Preclinical	pegnartograstim;	Suspended		biotechnology; growth	cancer
15; In Discontinued Preclinical	pegylated G-CSF			factor; hematopoietic	-
Discontinued Preclinical	mutein; PEG-G; Ro			factor;	
Discontinued Preclinical	258315; Ro 25-8315;			mmunostimulant	
Discontinued Preclinical	Ro 25-8315/000				
Preclinical	polyethylene glycol	Discontinued		piotechnology; growth	cancer
Preclinical	granulocyte colony			factor; hematopoietic	
Preclinical	stimulating factor;	-		factor:	
y Preclinical SD	PEG-G-CSF;			mmunostimulant	
Preclinical SD	granulocyte colony			-	
Preclinical SD	stimulating factor				
Preclinical	macrogol				
		Preclinical		piotechnology; growth	ancer
	progenipoietin G; SD			actor; hematopoietic	
	1001		.	actor;	
Immunostimulant				immunostimulant	

totipotent stem cell factor; T-SCF	Preclinical		biotechnology; growth cancer	cancer
			factor:	
			immunostimulant	
FLT3 ligand, DNAX Preclinical	Preclinical		biotechnology; growth cancer	cancer
Kesearch Institute;			factor;	
FL1 3			immunostimulant;	
			hematopoietic factor	
Fit3 ligand,	Phase II		biotechnology; growth cancer	cancer
mmunex; FLT 3;			factor;	
FLI 003; MOBIST			immunostimulant;	
			hematopoietic factor;	
			vaccine adjuvant	
stem cell proliferation Preclinical	Preclinical		biotechnology; growth cancer	cancer
ractor; SCPF			factor;	
	•	•	immunostimulant;	
			hematopoietic factor	
DWP 404	Preclinical		biotechnology;	cancer;
			hematopoietic factor;	thrombocytopenia
		-	growth factor	
(IPO-Rp	Preclinical	:	biotechnology;	thrombocytopenia;
			hematopoietic factor;	cancer
		·	growth factor; peptide	
thyroid stimulating	Marketed	thyrotropin (human	biotechnology;	cancer; diagnosis;
THYROGEN		.betasubunit)	hormone	hypothyroidism
		complex with chorionic	•	
	,	gonadotronin (human		
		alphasubunit)		
polyethylene glycol arginase; PEG-	Discontinued		biotechnology;	cancer
arginase; arginase			enzyme	
macrogor				

SD-144110.1

pegaspargase;	Marketed	pegaspargase	biotechnology:	cancer
polyethylene glycol			hydrolase;	
L-asparaginase;			asparaginase; enzyme	
asparaginase		— <u>*</u>		
macrogol; ONCASPAR				•
cervical cancer	Preclinical		biotechnology;	cancer
therapy, Transgene			immunostimulant	
immunotherapeutic,	Phase II		biotechnology;	cancer
cancer, Transgene			immunostimulant	
mistletoe lectin;	Preclinical		biotechnology;	cancer
mistellektin			immunostimulant	
totipotent stem cell	Discontinued		biotechnology;	cancer
receptor; FLK 2			immunostimulant	
gene therapy,	Phase II		biotechnology;	cancer
macrophage activated			immunostimulant;	
killer cells plus			gene therapy	
bispecific antibody;				
MAK therapy; MAK				
em cell	Pre-	N-L-methionyl-1-	biotechnology;	cancer
factor; SCF;	registration	165-hematopoietic	immunostimulant;	
STEMGEN		cell growth factor KL growth factor;	growth factor;	
		(human clone	hematopoietic factor	
		V 19.8:nSCF 162) dimer		
Į	Suspended		biotechnology;	cancer
stimulating factor;			immunostimulant;	
BM 800001			growth factor;	
			hematopoietic factor	

interleukin-9; IL-9	Discontinued		biotechnology;	cancer
			immunostimulant;	
			growth factor;	
			nematopoletic factor	
lenograstim;	Marketed	133-[O-[N-acetyl- biotechnology;	biotechnology;	anemia; HIV
granulocyte colony		alpha-neuraminosyl)- immunostimulant;	immunostimulant;	infection; cancer;
stimulating factor; G-		(2-3)-O-beta-D-	growth factor;	leukopenia
CSF; pluripoietin;			hematopoietic factor	•
NEOTROGIN;		3)-2-(acetylamino)-2-		
GRANOCYTE;		deoxy-beta-D-		
EUPROTIN;		galactopyranosyl]-L-		
MYELOSTIM		threonine]-colony		
•		stimulating factor	-	
		(human clone 1034)		
sargramostim;	Marketed	3	biotechnology;	cancer: infectious
granulocyte	٠	stimulating factor 2	immunostimulant;	disease; HIV
macrophage colony		(human clone pHG25 growth factor;	growth factor;	infection; leukopenia
stimulating factor;		protein moiety)	hematopoietic factor;	
GM-CSF; BI 61012;			vaccine adjuvant	
rhu GM-CSF;			· ·	
LEUKINE;	_			
PROKINE;			-	
INTERBERIN				
stem cell factor; SCF	Discontinued		biotechnology;	cancer
		· 	immunostimulant;	
		U.V.	growth factor;	
			hematopoietic factor	
ImmTher	Phase II	_ <u>.</u>		cancer
		· = 1	immunostimulant;	
			peptide	

D-144110

		**		
vaccine, prostate	Phase II		biotechnology;	cancer
Onco Vax-P;			immunostimulant;	
Onco Vax-Pr			, accinc	
cytokine cocktail;	Phase II		biotechnology;	cancer: infections
BC-IL; leukocyte			immunostimulant;	disease; HIV
interleukin injection;			vaccine adjuvant;	infection
TVNI I DEVED			cytokine	-
ZYN-LINKEK	Suspended		biotechnology;	rheumatoid arthritis;
conjugated			immunosuppressant;	cancer
superantigens		•	immunostimulant;	
			NSAID	
MAb, human	Phase I		biotechnology:	autoimmune disease.
interleukin-6		•	imminosinpressant	caccinition discase,
receptor; MAb,			monoclonal antihody	Califor
human IL-6 receptor;			Cocciona musicocciona	
hPM-1; MRA		٠		
E 21R	Preclinical		biotechnology;	cancer:
		-	immunosuppressant:	inflammation.
				allerov
G28-5 sFV-PE40	Preclinical		nology;	cancer
	·		immunotoxin	
immunotoxin,	Discontinued		biotechnology;	cancer
oma			immunotoxin	
MAb,	Phase I		biotechnology;	cancer
glioma/neuroblastoma			immunotoxin	
-gelonin; GLIOMAB- H				
immunotoxin cancer	Dreclinical			
			•	cancer
			monoclonal antibody	
-				The second secon

N A 12 : 4					
pyrao, epidermai	Preclinical	biotechnology	loov.	Concor	г
growth factor		mminotoxin	vin.	1001180	
receptor-DM1; MAb,			monoclonal antibody		
EGFR-DM1			at annough		
MAb, interleukin-13- Preclinical	Preclinical	hiotechnologic			_
PE38QQR;		imminotovin:	logy, vin:	cancer	
immunotoxin, IL-13-			Aitt,		_
PE38QQR		MONOCIONA	monocional antibody		
MAb, ricin A	Discontinued	hiotechnologic			
imminotoxin. MAb		TOTH TOTAL	, ég,	calicer	_
יייייייייייייייייייייייייייייייייייייי	•	hmmunotoxin;	xin;		
colorectal cancer; ZD		enologue de la conociona	monoclonal antibody		
0490; ICI D0490	-		ii alitioody		
MAh SS(dsFy) DF38 Draglining	Droolinias				
000 r-(v ten) 00 (01 r-1)	riccimical	biotechnology;		cancer	
		immunotoxin;	kin;		
		monoclonalantibody	l antibody		
ξ.	Preclinical	biotechnology;		cancer; diagnosis	
ciusici conjugate		immunotoxin;			
		monoclonal antibody	1 antibody		

nacolomab tatenatox; Phase I	Phase I	20-244-	biotechnology;	cancer
MAb, C242-		immunoglobulin G1,		
staphylococcal		anti-(human		
enterotoxin A; FAb,		colorectal tumor		
C242-staphylococcal		antigen C242) Fab		
enterotoxin A; PNU		fragment (mouse		
214565; LS 4565;		monoclonal r-	-	
TTMA LS 4585		C242Fab-SEA clone		
		pKP941 gamma1-	******	
		chain) fusion protein		
		with enterotoxin A	. *-	
		(Staphylococcus		
		aureus), disulfide		
		with mouse		
		monoclonal r-		
	•	C242Fab-SEA clone		
		pKP941 kappa-chain		
MAb, doxorubicin	Phase II		biotechnology;	cancer
conjugate; MAb, BR			immunotoxin:	
96-doxorubicin;			monoclonal antibody:	
MAb, BR 96-DOX;			anthracycline:	
BMS 182248; BMS			antibiotic; DNA	
18224801			intercalator	
3-genistein;	Phase I		gv:	cancer
B43-Gen				
immunoconjugate			monoclonal antibody;	
			tyrosine kinase	
			inhibitor	

drug delivery system, Pre- interferon alfa;	Pre- registration		biotechnology; interferon	viral infection;
interferon alfa drug delivery system:) 			
SUMIFERON				
MINIPELLEI				
drug delivery system,	Discontinued		biotechnology;	cancer; viral
interferon beta;		,	interferon	infection; cancer;
delivery system; drug				VII AIIICOLIOII
delivery system, IFN				
beta			s	
drug delivery system, Suspended	Suspended		biotechnology;	cancer; viral
oral interferon alfa-			interferon	infection
2a; IFN alfa-2a, oral				
interferon alfa,	Marketed		biotechnology;	cancer: viral
natural; IFN-alfa,			interferon	infection
natural; EGIFERON				
interferon alpha,	Preclinical		biotechnology;	viral infection;
hybrid; hybrid		-	interferon	cancer
interferon alpha				
interferon alpha,	Pre-		biotechnology;	viral infection:
$\neg \tau$	registration		interferon	cancer
IFI.	Marketed		biotechnology;	viral infection;
beta; DL 8234; FERON			interferon	cancer; retinopathy
interferon beta; IFN-	Discontinued		hiotechnology.	Cancer wirel
			interferon	infection
	Marketed	interferon beta-1a	biotechnology;	viral infection:
IFN beta; AVONEX			•-	multiple sclerosis;
				cancer

interferon beta-1a;	Marketed		biotechnology;	cancer; viral
beta; REBIF			interieron	infection; multiple
				SCICIOSIS,
,				inflammatory bowel
interferon beta-1h:	Marketed	7-166 interferon hote	1.0.40.1.2.0.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	יויין יייי
interferon hete comme				minipie scierosis;
out end are settlie;		I (numan nbroblast	ınterferon	cancer; viral
SH 5/9; ZK 15/046;		reduced)		infection
BETASERON;				
BENESERON;				
BETAFERON				
interferon omega;	Phase II		biotechnology:	viral infection.
IFN omega			interferon	cancer (2007)
polyethylene glycol	Phase III		biotechnology:	viral infection.
interferon alfa-2b;			interferon: cytokine	Concer Concer
PEG-interferon alfa-	•		merica cui, cy comine	Calibo
2b; interferon alfa-2b				
macrogol; PEG-			-	
INTRON A				
interferon alfa-2b;	Marketed		biotechnology:	cancer viral
IFN alfa-2b; SCH			interferon: cytokine:	infection
30500; YM 1490;			immunostimulant	
INTRON A;		_		
CIBIAN;				
VIRAFERON		-		
H	Discontinued		biotechnology:	cancer
+ interferon alfa-2a;			wth	
interferon alfa-2a +		<u> </u>	factor	
tumor necrosis factor;	•			
TNF + IFN alfa-2a				

0.144110

Ifficial alta-2a;	Marketed	(human leukocyte	biotechnology;	viral infection;
228181; ROFERON		protein moiety) interferon alpha A	Interteron;	cancer
A; CANFERON A;				
KOFEKON		-		
interferon gamma-1a; Marketed	Marketed		biotechnology;	cancer
BIOGAMMA			interferon;	
interferon gamma-1h: Marketed	Marketed		hinitaliosamuant	
interferon gamma:			ororecmorogy; interferon:	cancer; bacterial
IFN gamma:			intelletoll, i	intection; chronic
ACTIMMUNE:			TITUTI TO STITLE THE TELEVISION OF THE TELEVISIO	granulomatous
IMUKIN; IMUFOR GAMMA				disease; tuberculosis
interferon. consensus: Marketed	Marketed	interferon alaba 1	hi otoolaa 12 da	
consensus interferon:		100	oroccomonogy,	virai infection;
interferon alfacon-1;			imminostiminant	cancer
YM 643; INFERGEN		methionyl-22-L-arg-		
		76-L-ala-78-L-asp-		
		79-L-glu-86-L-tyr-90-	æ •	
		L-tyr-156-L-thr-157-	-	
· · · · · · · · · · · · · · · · · · ·		L-asn-158-L-leu-		
3622W94; BW	Phase II		biotechnology;	cancer
46 W 7700			monoclonal antibody	
antibodies, Sdi 1	Discontinued		biotechnology;	cancer
			monoclonal antibody	
detumomab; MAb,	Discontinued		biotechnology;	cancer
latotype B cell			monoclonal antibody	
lymphoma; MAb, B		:		
cell lymphoma; B cell				
lymphoma MAb;			-	

drig delivery exetem Bracisical	Drootiniool			
liposome MAb, 273-34A; MAb, 273-34A			protectinology; monoclonal antibody	cancer
lipsome; liposome, MAb 273-34A				
edrecolomab; MAb,	Marketed	immunoglobulin G 2a biotechnology;	biotechnology;	cancer
17-1A; MAb,		(mouse monoclonal	monoclonal antibody	
Colorectal cancer;		17-1A gamma-chain		
1A; C-1; PANOREX		and-fluinan colon		
		associated antigen),		
		disulfide withmouse		
		monoclonal 17-1A		
		light chain dimer		
lintuzumab; MAb,	Phase III	immunoglobulin G1	biotechnology;	cancer
MAb, humanized		(human-mouse : monoclonal	monoclonal antibody	
CD33; SMART		HuM195.gamma 1-		
M195; HuM195		chain anti-human		
		antigen CD 33),		
		disulfide with human		
		monoclonal		
•		HuM195.kappa chain, dimer		
o-bismuth-	Phase I		biotechnology;	cancer
213; MAb,			monoclonal antibody	
numanized M195- 213Bi				
LYM 2	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAB, 12G5	Preclinical	<u>, , , , , , , , , , , , , , , , , , , </u>	biotechnology;	cancer
		-	monocional antibody	

MAb, 2A11; MAb,	Phase II		biotechnology:	Cancer
gastrin releasing			monoclonal antibody	
peptide			inomocromai annibody	
MAb, 323A3; 323A3 Discontinued	Discontinued		biotechnology;	cancer
MAN STO T. CO.	,		monocional antibody	
MAb, 3r8; 1gG3 anti-Phase I	-Phase I		biotechnology;	cancer
ganglioside GD 2;			monoclonal antibody	
MAb, neuroblastoma				
MAb, 42/6; MAb,	Phase I		biotechnology;	cancer
transferrin receptor			monoclonal antibody	
MAb, 88BV59-	Discontinued	***	biotechnology:	cancer
rhenium 186			monoclonal antibody	
MAb, 977; MAb,	Preclinical	:.:	biotechnology;	cancer: diagnosis
bladder cancer		•	monoclonal antibody	
MAb, 9D9	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAb, adrenomedullin Preclinical	Preclinical		biotechnology;	cancer; diabetes;
			monoclonal antibody	Alzheimer disease;
			•	diagnosis
MAb, antiganglioside Preclinical	Preclinical		biotechnology;	cancer
GM2; KM 966			monoclonal antibody	
MAb, antinuclear	Preclinical		biotechnology;	cancer
auto-antibodies; MAb. cancer			monoclonal antibody	
MAb, B cell	Preclinical		hiotochnology	
lymphoma: 1D10			monopologal antibe 3.	calicer
١.	Dhose I		inionocional annociony	
	1 11430 1	_	biotechnology;	cancer
IL-6; B-E4		Ħ	monoclonal antibody	
MAb, B4-DC1	Discontinued		biotechnology;	cancer
			monoclonal antibody	

MAb, B6.2/212	Discontinued	bi	biotechnology;	cancer
single chain antibody;		<u>E</u>	monoclonal antibody	
MAb, B6.2/212 SCA			•	
MAb, BCD F9-	Phase I	id	iotechnology;	cancer: diagnosis
radionuclide; MAb,		<u> </u>	monoclonal antibody	
breast cancer; BCD		-		
F9				
MAb, bispecific	Discontinued	įq	biotechnology;	cancer
F(ab')2 OC/TR;		Ē	monoclonal antibody	
OCTR			•	
MAb, bispecific hu-	Discontinued	bio	biotechnology;	cancer
bsF(ab')2		Ŭ,	monoclonal antibody	
MAb, bladder	Discontinued	<u>id</u>	biotechnology:	cancer
carcinoma; RG 355		, m	monoclonal antibody	
MAb, BR 96; BR 96	Discontinued	bid	biotechnology;	cancer
		m	monoclonal antibody	
MAb, breast cancer	Discontinued	bid	biotechnology;	cancer
antigen; Pro 1.5.3		mc	monoclonal antibody	
MAb, BW 494	Discontinued	jid.	biotechnology;	cancer
		mc	monoclonal antibody	
MAb, c-Nd2; c-Nd2	Preclinical	bic	biotechnology;	cancer
		mc	monoclonal antibody	
MAb, C215-	Phase II	bic	biotechnology;	cancer
staphylococcal		mc	monoclonal antibody	
enterotoxin; FAb,				
C215-SEA			-	
MAb, C242; MAb,	Discontinued	bic		cancer; diagnosis
colonic	-	mc	monoclonal antibody	
adenocarcinoma	•			
MAb, C242-DM 1	Preclinical	bio	biotechnology;	cancer
conjugate; huC242-		om	ibody	
CIVIT				
	••			

SD-144110.1

MAb, C242-	Preclinical		biotechnology;	cancer
maytansine conjugate			monoclonal antibody	
MAb, cancer	Phase III		biotechnology;	cancer
MAb, cancer; MAb, EpCAM	Preclinical		biotechnology;	cancer
MAb, cancer; BW 1209W95	Preclinical		biotechnology;	cancer
MAb, cancer; hybrid	Preclinical		biotechnology;	cancer
antibody, anti-Her-2, anti-CD3			monoclonal antibody	
	Preclinical		biotechnology.	Contrar
			monoclonal antibody	Carroot
melanoma, glioma,				
neuroblastoma; MDX				
260	·			
Mab, cancer, BioInvent	Preclinical		biotechnology;	cancer
ser, PPL	Preclinical		hiotechnology.	Concer
			monoclonal antibody	Calical
	Preclinical		biotechnology;	cancer
Biopharmaceuticals;		-	monoclonal antibody	
cancer. Neoprobe			•	
	Preclinical		biotechnology.	onco.
embryonic			monoclonal antihody	Caricol
antigen; MAb, CEA		-		
MAb,	Preclinical		biotechnology:	cancer
carcinoembryonic	<u>· </u>	:	monoclonal antibody	
antigen; MAb, CEA				

A 4 1.				
MAb, SK-1; MAb,	Fnase 1	biotechnology; monoclonal ant	biotechnology; monoclonal antibody	cancer
cancer;	•			
MONOPHARM C				
MAb, CC49; MAb,	Phase II	biotechnology;	ology;	cancer
TAG B723; MAb,		monoclo	monoclonal antibody	
B723 second				
generation				
MAb, CC49-	Discontinued	biotechnology;	ology;	cancer
interleukin-2; fusion		monoclo	monoclonal antibody	
protein, CC49-IL-2				
MAb, CC49-lutetium	Discontinued	biotechnology;	ology;	cancer
177; MAb, anti-TAG-		monoclo	monoclonal antibody	
72-lutetium 177				
MAb, CC83; MAb,	Discontinued	biotechnology;	ology;	cancer
TAG B723; MAB,		monoclo	monoclonal antibody	
B723 second			•	
generation		•		
MAb, CD19/CD3;	Preclinical	biotechnology;	ology;	cancer
bispecific antibody,		monoclo	monoclonal antibody	
cancer		:		
MAb, CD28/CD30;	Preclinical	biotechnology;	ology;	cancer
Bi-MoAb		monoclo	nonoclonal antibody	
	Preclinical	biotechnology;	ology;	cancer
		monoclor	nonoclonal antibody	
antibody, CD3, CD30				
	Phase I	biotechnology;	ology;	cancer
CD34		monoclor	monoclonal antibody	
MAb,	Preclinical	biotechnology;	ology;	cancer
cancer, Wilex Biotechnology		monoclor	monoclonal antibody	
	Dhose II			
	rnase II	biotechnology; monoclonal and	tibody	cancer

MAR				
arthur,	Discontinuea		biotechnology;	cancer
conjugates, IDEC			monoclonal antibody	
MAh chimeric	Dhara I			
7740. 1441	1 Mase 1		piotechnology;	cancer
CC4%; IMAB,			monoclonal antibody	
chimeric TAG B723				
MAb, chimeric	Phase I		biotechnology	Cancer
CC83; MAb, TAG B723			monoclonal antibody	
AGAL ALITE				
MAO, chimeric IgGI	Preclinical		biotechnology;	cancer
anti CD20			monoclonal antibody	
MAb, colon-DM1	Preclinical		biotechnology;	cancer
MAR colomotal	,		monocional antibody	
raino, colorectar	ruase 1		biotechnology;	cancer; diagnosis
calicer			monoclonal antibody	
MAb, CYT 372	Preclinical		biotechnology;	cancer
humanized; MAb,			monoclonal antibody	
C46 humanized;)			
MAb, humanized				
panadenocarcinoma		-	-	
MAb, directed	Preclinical		biotechnology:	cancer
enzyme prodrug			monoclonal antihody	,
therapy; ADEPT,				
cancer therapy				
MAb, directed	Phase II		biotechnology:	Cancer
enzyme prodrug			monoclonal antibody	
therapy + CMDA;				
ADEPT + CMDA;				
ZD 2767				
MAb, EGF-R and Fc; Phase II	Phase II		biotechnology:	Cancer
bispecific antibody,		H	monoclonal antibody	
cancer; MDX 447; H				
447; EMD 82633				

.

MAb, epidermal	Discontinued		biotechnology:	Cancer
growth factor	-		monoclonal antibody	
receptor; MAb, EGF				
וביבקוטו, בואום איאטרי	_			
MAb, epidermal	Preclinical	-	biotechnology;	cancer
growth factor			monoclonal antibody	
receptor; MAb, EGF		-2-112-		
receptor; MAb, 528;				
MoAb528			- 1	
MAb, epidermal	Phase III		biotechnology:	cancer
growth factor		<u>. H</u>	monoclonal antibody	
receptor; MAb, EGFr;				
C 225				
nal	Phase I		biotechnology:	cancer
		- 13	monoclonal antibody	
receptor; MAb,				
EGFR; ICR 62				
al	Phase I	.0	biotechnology;	cancer
growth factor,		_ 🛱	body	
humanized; MAb,				
EGF, humanized;				
erbB-2; MAb,	Preclinical	<u>q</u>	biotechnology;	cancer
		E	monoclonal antibody	
MAb, erbB2	Preclinical	<u>.</u>	biotechnology;	cancer
		u	monoclonal antibody	
	Discontinued		biotechnology;	cancer
NRC002-rhenium		<u> </u>	monoclonal antibody	
186; MAb, antiCEA		٠		
MAb, F4	Preclinical	<u>o</u>	biotechnology;	cancer
		ш	monoclonal antibody	

D-144110

MAP FAH NRI 1110- Phase	- Phase I	777		
radionuclide; MAb.	1 20011	01016	biotechnology; monoclonal antibody	cancer; diagnosis
lung cancer; MAb,			octoniai antibody	
prostate cancer				
MAb, fas; MAb,	Preclinical	biote	biotechnology;	cancer
bladder cancer		monc	monoclonal antibody	
MAb, FC-2.15	Phase II	biote	biotechnology;	cancer
		ouom	monoclonaliantibody	
MAb, fibroblast	Discontinued	biote	biotechnology;	cancer
growth factor		ouom	monoclonal antibody	
receptor, MAD, L'OFF				
MAb, germ cell	Discontinued	biotec	biotechnology;	cancer
cancer; ImmuRAID-		ouom	monoclonal antibody	
יייכו				
MAb, gp75;	Preclinical	biotec	biotechnology;	cancer
MELVAXII		ouour	monoclonal antibody	
Mab, heparanase	Preclinical	biotec	biotechnology;	cancer; diagnosis
		ouour	monoclonal antibody	•
MAb, HER-2	Discontinued	biotec	biotechnology;	cancer
ummunoliposome		mono	monoclonal antibody	
MAb, HER2/neu20	Preclinical	biotec	biotechnology;	cancer
immunoliposomes,		ououi	monoclonal antibody	
breast cancer; C 6.5	-			
MAb, Hodgkin's	Preclinical	biotec	biotechnology;	cancer
lymphoma		ouour	ibody	
	Phase II	biotec	Г	cancer
antiganglioside		onom	ibodv	
MAb, human	Preclinical	biotec	1	cancer
chorionic		ouom	ibody	
gonadotropin; MAb,	·			
hCG; CTP 103				

MAK human	D			
obomionio	riecimical	010	biotechnology;	cancer
gonadotropin, human:		OIII	monoclonal antibody	
MAb, hCG, human				
MAb, human	Preclinical	oid	biotechnology	cancer
EpCAM; UBS 54		lom	monoclonal antibody	
MAb, humanized	Phase II	biol	biotechnology:	cancer
LL2; MAb, B cell		lom	monoclonal antibody	
lymphoma;				
LymphoCide				
MAb, humanized	Preclinical	biot	biotechnology;	cancer
N901-DCI		ош	monoclonal antibody	
MAb, humanized,	Discontinued	biot	biotechnology;	cancer
cancer; MAb, cancer		nou	monoclonal antibody	
numanized				
MAb, IgG1 fragment	Preclinical ·	biot	biotechnology;	cancer
		mor	monoclonal antibody	
MAb, IGX	Preclinical	biot	biotechnology;	cancer
		mor	monoclonal antibody	
MAb, ING-1; MAb,	Discontinued	biot	biotechnology;	cancer
- 1		mom	monoclonal antibody	
leukin-6;	Phase I	biot	biotechnology;	cancer
		mon	monoclonal antibody	
KAII; MAb,	Preclinical	biot	biotechnology;	cancer
- 1		пош	monoclonal antibody	
Ab, KM641; KM	Discontinued	biote	biotechnology;	cancer
		nom	monoclonal antibody	
MAb, L 6; L 6	Discontinued	biote	biotechnology;	cancer
		nom	monoclonal antibody	

MAR I Calleding			
phoenhatasa	Danumung	 biotechnology;	cancer
pilospilatase		 monoclonal antibody	
conjugate; L6 alkaline	40		
phosphatase MAb			
conjugate; MAb,			
carcinoma			
MAb, Lewis Y; ABL	Phase I	biotechnology:	cancer
364; SDZ ABL 364		monoclonal antibody	
MAb, Lewis Y,	Preclinical	biotechnology:	cancer
humanized; HuABL		monoclonal antihody	
364; SMART ABL			
364; BR 55-2		:	
MAb, LL2-rhenium	Preclinical	biotechnology;	cancer
188; Re-188-LL2		monoclonal antibody	
MAb, MAb fragment, Discontinued	Discontinued	 biotechnology;	cancer
REC A33-nuclide	٠	monoclonal antibody	
MAb, mB43-	Phase II	biotechnology:	cancer: diagnosis
technetium 99m; Tru-		monoclonal antibody	arangan (
Scint OV			
	Phase II	biotechnology;	cancer
MAb, myeloid	-	monoclonal antibody	
leukemia; MAb,			
CD15; MDX 11; PM		 	
ma;	Preclinical	 biotechnology;	cancer
		 monoclonal antibody	
MONOPHARM M		-	
MAb, melanoma,	Phase I	biotechnology:	cancer
62360		 monoclonal antibody	
	Phase II	biotechnology:	diagnosis: cancer
carcinoembryonic		monoclonal antibody	1000000 (0000000
antigen; MAb, MN-			
יז כבת, כבת-כותפ			

ACAL MEDICOS				
MAD, MIKK 20;	Preclinical		biotechnology;	cancer
MKK 20			monoclonal antibody	
MAb, multiple	Preclinical		biotechnology;	cancer
myeloma, U-BiSys			monoclonal antibody	
MAb, oncology,	Preclinical		biotechnology;	cancer
Glaxo Wellcome			monoclonal antibody	
MAb, ONS M21;	Preclinical	;	biotechnology;	cancer
MAN DET. NAN			monocional antibody	
MAO, F-0/; MAb,	Preclinical		biotechnology;	cancer
acute myelogenous			monoclonal antibody	
MAb, PAM4	Phase I		biotechnology;	cancer
MAP nolymombia	7		inolocioliai alittoody	
with the polymorphic	Discontinued		biotechnology;	cancer
epitnellal mucin;			monoclonal antibody	
MAb, PEM; AS 125			-	
MAb, prostate cancer Preclinical	Preclinical	=	biotechnology;	cancer
			monoclonal antibody	
MAb, prostate cancer Discontinued	Discontinued		biotechnology;	cancer
			monoclonal antibody	
MAb, prostate cancer Preclinical	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAb, SM3	Discontinued		biotechnology;	cancer
phosphorus 32			monoclonal antibody	
MAb, TAG-72	Preclinical		biotechnology;	cancer
T			monoclonal antibody	
2 and	Phase II		biotechnology;	cancer
FC; Dispecific			monoclonal antibody	
antibody, cancer; MDX 220			:	

MAb, TB94, human;	Preclinical	biotechnology	Cancer
MAb, TB94, IgA1k;		monoclonal antibody	
MAb, small cell lung			
MAb. TH69	Preclinical		
		monoclonal antibody	cancer
MAb, transcobalamin Preclinical	Preclinical	biotechnology;	cancer
II; MAb, vitamin B12		monoclonal antibody	
carrier protein,			
Keceptagen			
MAb, transferrin	Preclinical	biotechnology;	cancer
receptor targeted		monoclonal antibody	
immunotoxin; MAb,			
tfnR targeted			
immunotoxin; tfnR-			
CRM107	·		
MAb, tumor necrosis	Preclinical	biotechnology;	Crohn disease:
factor; MAb, TNF;		monoclonal antibody	
SMA TNF			
MAb, tumor necrosis	Discontinued	biotechnology;	cancer
factor alpha; MAb,		monoclonal antibody	
TNF-alpha; MAb32			
MAb, U36/E48	Discontinued	biotechnology;	cancer
		monoclonal antibody	Α
MAbs, cancer,	Preclinical	biotechnology;	cancer
numan, Medarex		monoclonal antibody	
MAbs, chimeric,	Preclinical	biotechnology;	cancer
cancer		monoclonal antibody	
MAbs, pancarcinoma, Preclinical	Preclinical	biotechnology;	cancer
B-cell tumor;	•	monoclonal antibody	
bispecific antibody,			
cancer			
•			

D-144110

prostate carcinoma	Discontinued		biotechnology.	cancer. diagnosis
tumor antigens		-	monoclonal antibody	cancon, and Briosis
rituximab; MAb,	Marketed	immunoglobulin G1	biotechnology;	cancer
CD20; MAb, pan-B;		(human-mouse	monoclonal antibody	
IDEC 2B8; Ro		monoclonal IDEC-		
425294; IDEC 102;		C2B8 gamma 1-chain		
RITUXAN,		anti-human antigen		
MabThera		CD 20), disulfide		
		with human-mouse		
		monoclonal IDEC-		
		C2B8 kappa-chain,		
		dimer		
SDZ MMA 383; MMA 383	Phase I		biotechnology;	cancer
trastuzumah.	Marketed	imminoglopiilin C1	Liotota 1	
HERCEPTIN			ototecimiotogy, monoclonal antibody,	cancer
	•		moniocional annocio	
-		receptor) (manian-		
		mouse monoclonal	-	
•		rhuMab HER2		
		gamma 1-chain),		
		disulfide with human-	<··	
		mouse monoclonal		
		rhuMab HER2 light		
		chain dimer		
MAb, KDR; MAb,	Preclinical		biotechnology;	cancer
vascular endothelial			monoclonal antibody;	
growth factor		10	angiogenesis inhibitor	
receptor; DC 101)	
MAb, KDR; MAb,	Preclinical		biotechnology;	cancer
vascular endothelial		H _	monoclonal antibody;	
growth factor		-	angiogenesis inhibitor	
ליכיבטוניו, כל וכוו				

IMAD, VINK Integrin;	Fhase II	biotechnology;	ology;	cancer
LM 609; VII AXIN		monoclo	monoclonal antibody;	
		angiogen	angiogenesis inhibitor	
MAb, CEA and	Preclinical	biotechnology;	ology;	cancer
doxorubicin; MAb,		monoclo	monoclonal antibody;	
26-61-10; bispecific		anthracy	anthracycline; DNA	
antibody, CEA and		intercalat	intercalator; antibiotic	
doxorubicin				
MAb, antilaminin	Preclinical	biotechnology;	ology;	cancer; diagnosis
gamma2 chain; BST		monoclo	monoclonal antibody;	•
1001		contrast medium	medium	
MAb, cancer; MAb,	Preclinical	biotechnology;	ology;	cancer
tumor necrosis		monoclo	monoclonal antibody;	
technology; MAb,		contrast medium;	medium:	
TNT		radiodiagnostic;	gnostic;	
	-	radiotherapeutic	apeutic	
	Phase I	biotechnology;	ology;	cancer; diagnosis
radiolabeled;		monoclo	monoclonal antibody;	•
NOVOMAb-G2		contrast medium;	medium;	
		radiodiagnostic;	gnostic;	
		radiotherapeutic	apeutic	
ıal	Phase I	biotechnology;		cancer; diagnosis
growth factor		monoclor	ibody;	
receptor; MAb, EGFr;		contrast medium;	medium;	
DiaCIM; TheraCIM;		radiotherapeutic;	apeutic;	
RadioTheraCIM		radiodiagnostic	mostic	
MAb, TC5-Au198	Preclinical	biotechnology;		cancer; diagnosis
		monoclor	monoclonal antibody;	
		contrast medium;	nedium;	
		radiotherapeutic;	apeutic;	
		radiodiagnostic	mostic	

MAb, B cell-cytokine Preclinical	Preclinical		biotechnology;	cancer
fusion protein			monoclonal antibody:	
			cytokine	
interleukin-2,	Preclinical		biotechnology;	cancer
antiganglioside			monoclonal antibody;	
chimeric protein; G2-			cytokine; growth	
IL2 fusion protein;			factor	
MAb-G2 IL-2 fusion			-	-
protein; ch14.18-IL2				
MAb, L49-sFv-beta-	Preclinical		biotechnology;	cancer
lactamase			monoclonal antibody;	
			enzyme	
MAb, 2C11.F(ab')2 + Discontinued	Discontinued		biotechnology:	bacterial infection:
microbeads; MAb,		•	monoclonal antibody:	cancer
anti-CD3 +			immunostimulant	
microbeads;	.*			
PLATAR construct			. T.	
MAb, c-erbB-2 and	Phase I		biotechnology:	cancer
CD16; bispecific	•	_ #	monoclonal antibody:	
antibody, c-erbB-2	٠	··-	immunostimulant	
and CD16; 2B1				
MAb, c-Mpl; MAb,	Preclinical		biotechnology;	thrombocytopenia;
thrombocytopenia;	•	_ .	ibody;	cancer
BAH 1				
MAb, CD3 F(ab')2 +	Discontinued		biotechnology;	bacterial infection:
microbeads; MAb,		H.	tibody;	cancer
CD3 + microbeads;	•	. <u>.</u>	immunostimulant	
PLATAR construct				
		<u> </u>		

MAb, HER-2 and Fc: Phase II	Phase II		hiotechnology	20000
bispecific antibody,			monoclonal antibody:	Calico
ovarian and breast		٠	immunostimulant	
cancer; bispecific			-	
antibody 520C9x22;			·.·	
MDX 210			rs (s	
daclizumab;	Marketed	immunoglobulin G1	biotechnology;	transplant rejection:
dacliximab; MAb,		(human-mouse	monoclonal antibody;	cancer; autoimmune
Tac; MAb,		monoclonal clone	immunosuppressant	disease; eye disease
humanized Tac;		1H4 gamma chain		
MAb, SMART Tac;		anti-human antigen	•	
Ro 247375;		Tac), disulfide with		
ZENAPAX		human-mouse		
		monoclonal clone	**	
		1H4 light chain,	-	
		dimer		
MAb, alpha-tubulin	Preclinical		biotechnology;	cancer; autoimmune
			monoclonal antibody;	disease; diagnosis
			immunosuppressant	•
gen	Preclinical		biotechnology;	cancer; Crohn
receptor; TM 29			monoclonal antibody;	disease
		-	immunosuppressant	
MAbs, B cells; migis	Discontinued		biotechnology;	autoimmune disease;
	-		monoclonal antibody;	cancer
			mmunosuppressant	
MAb, MHC class II	Preclinical,			autoimmune disease;
			. ^	transplant rejection;
			osuppressant;	graft versus host
			NSAID	disease; cancer
				, and a second s

MAb, 791T/36-ricin	Discontinued	٠	biotechnology;	cancer
A immunotoxin;			monoclonal antibody;	
immunotoxin-			immunotoxin	
colorectal cancer;				
XOMAZYME 791				
MAb, A7 mitomycin	Preclinical		biotechnology;	cancer
C-dextran conjugate;			monoclonal antibody:	
MAb, A7-MMCD;			immunotoxin	
MAb, colon cancer	-			
mitomycin C-dextran				
conjugate				
MAb, alpha CD80-	Preclinical		biotechnology;	cancer
gelonin			monoclonal antibody;	,
			immunotoxin	
MAb, alphaCD86-	Preclinical		biotechnology;	cancer
gelonin			monoclonal antibody;	
			immunotoxin	
MAb, Anti-Tac	Discontinued		biotechnology;	cancer
Pseudomonas			monoclonal antibody:	
exotoxin;			immunotoxin	
immunotoxin, T cell				
cancers			-	-
	Phase I		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin;			immunotoxin	
immunotoxin B3-PE				
38; LMB 1				
MAb, B4-blocked	Discontinued		biotechnology:	cancer
ricin; MAb, B4-bR;		-	monoclonal antibody;	
ONCOLYSIN B			immunotoxin	
MAb, B7-	Preclinical		biotechnology;	cancer
immunotoxin			monoclonal antibody;	
-			immunotoxin	

MAb, BACH 250-	Preclinical		biotechnology;	cancer
gelonin conjugate;			monoclonal antibody;	
immunotoxin, BACH	-		immunotoxin	
250-gelonin				
MAb, basic fibroblast Preclinical	Preclinical		biotechnology;	cancer
growth factor			monoclonal antibody;	
receptor-saporin;			immunotoxin	
MAb, bFGF receptor-				
SAP; 11A8			-	
MAb, CD33-	Phase III		biotechnology:	cancer
calicheamicin; CMA			monoclonal antibody:	
676; CDP 771			immunotoxin	
MAb, CMB 401-	Phase II		biotechnology:	cancer
calicheamicin; MAb,			monoclonal antibody:	
ovarian cancer; CMB		· =	immunotoxin	
401; CDP 671	•			
MAb, CYT 103-	Preclinical		biotechnology;	cancer
		· H	monoclonal antibody;	
B72.3-aminopterin;			mmunotoxin	
ONCOTHER 130				
MAb, epidermal	Discontinued	,	biotechnology;	cancer
growth factor receptor		<u>-:}=i</u>	monoclonal antibody;	
immunotoxin;			mmunotoxin	
immunotoxin, EGRF;		- 1-4		
OLX 103; TP 40; L	-			
691912		-		

MAb, erbB-2-	Preclinical		biotechnology.	Cancer
Pseudomonas			monoclonal antibody:	Toolino.
exotoxin;			immunotoxin	
immunotoxin, single				
chain erbB-2-				
Pseudomonas				
exotoxin; OLX 209;				
AR 209				
MAb, F(ab')2 HRS-3	Discontinued		biotechnology:	cancer
deglycosylated ricin			monoclonal antihody:	
A; MAb, HRS-3			immunotoxin	
deglycosylated ricin				
A; MAb, F(ab')2		-	-	
HRS-3 dgA; Mab,		-	-	
HRS-3				
deglycosylated ricin				
A; MAb, F(ab')2		•	-	
HRS-3 dgA; MAb,				
IRac dgA				
MAb, F(ab')2 IRac	Discontinued		biotechnology:	Cancer
deglycosylated ricin			monoclonal antibody:	
A; MAb, IRac			immunotoxin	
deglycosylated ricin				
A; MAb, F(ab')2 IRac				
dgA				
	Phase I		biotechnology;	cancer
Pseudomonas			ibody:	
exotoxin;		Ţ	immunotoxin	
immunotoxin Fv B3-				
PE 38; LMB 7; NSC 658931				

MAH FVB1	Drootinion		• • •	
Pseudomonas	, iccimical		biotechnology; monoclonal antibody;	cancer
exotoxin;			inclications and order,	
immunotoxin FvB1-				
PE33				
MAb, LL2-	Preclinical		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin			immunotoxin	
MAb, ME20-	Discontinued	-	biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin;			immunotoxin	
immunotoxin ME20- LysPE40				
01-blocked	Phase II		biotechnology:	cancer
unotoxin,			monoclonal antibody:	
N901-bR;	٠		immunotoxin	
ONCOLYSIN S			-	
MAb, N901-DM1;	Preclinical		biotechnology;	cancer
immunotoxin, N901-		- 	monoclonal antibody;	
<u>DM</u> I			immunotoxin	
	Phase I		.;	cancer
Pseudomonas	•	- 11	tibody;	
exotoxin conjugate;			immunotoxin	
immunotoxin OVB3-		-		
HE				
MAb, RFB4(dsFv)-	Phase I		biotechnology;	cancer
PE38; immunotoxin,		-	monoclonal antibody;	
RFB4(dsFv)-PE38;			immunotoxin	
BL 22; NSC 691237				
FT5-ricin A	Phase II		biotechnology;	cancer
(CD25)		- H	monoclonal antibody;	
immunotoxin; RFT5 do A		·H_	mmunotoxin	
the things.		-		

MAb, ricin A	Discontinued	<u>.</u>	biotechnology:	cancer
immunoconjugate;		<u>. . </u>	nonoclonal antibody;	
immunotoxin			immunotoxin	
melanoma;				
XOMAZYME-MEL				
MAb, SN7-ricin A;	Preclinical	-C	biotechnology;	cancer
immunotoxin SN7-			monoclonal antibody;	
ricin A; SN7-RA		ii	immunotoxin	
MAb, Tac(Fv)-PE38;	Phase I	q	biotechnology;	cancer
immunotoxin		<u> </u>	monoclonal antibody;	
Tac(Fv)-PE38; LMB		<u>.E.</u>	immunotoxin	
7				
MAb, Tac(Fv)-PE40 Preclinical	Preclinical	0	biotechnology;	cancer
ımmunotoxin		<u>H</u>	monoclonal antibody;	
ĺ		.11	immunotoxin	
	Phase I	٥٠	biotechnology;	cancer
receptor targeted		Ħ	monoclonal antibody;	
immunotoxin; MAb,		ii	mmunotoxin	
tfnR targeted				
immunotoxin;				
454A12-rRA				
MAb, tumor	Preclinical	Įq.	biotechnology;	cancer
immunotoxins,		<u>. E.</u>	monoclonal antibody;	
Menarini		in	immunotoxin	
MAb, UV72	Preclinical		biotechnology;	cancer
immunotoxin		<u>.</u>	monoclonal antibody;	
		i	mmunotoxin	
	Preclinical	iq	biotechnology;	cancer
receptor/ligand		<u></u>	monoclonal antibody;	
complex-dgA;		<u>.</u> <u>.</u> <u>.</u> <u>.</u> <u>.</u>	immunotoxin	
immunotoxin VEGF			-	
receptor/ligand				
complex-dgA				

	j.			
MADS, CD22-saporin; Phase II	i, Phase II		biotechnology;	cancer
ımmunotoxın,			monoclonal antibody;	
bispecific, cancer; ITF 1265 + ITF 1269			immunotoxin	
MAb, doxorubicin	Discontinued		hiotechnology.	20000
conjugates; MAb,			monoclonal antibody:	Carico
CC49-doxorubicin			immunotoxin;	
	÷.		anthracycline;	
	·		antibiotic; DNA	
			intercalator	
MAb, anthracycline	Preclinical		biotechnology;	cancer
amine derivative			monoclonal antibody;	
			immunotoxin;	-
			antibiotic	
MAb, CD5-	Phase II		biotechnology;	cancer; transplant
momordin;	٠		monoclonal antibody;	rejection
immunotoxin CD5-			immunotoxin;	
momordin; ITF 1532			immunosuppressant	٠
MAb, humanized,	Preclinical		biotechnology;	cancer
MRK 16; MRK 16			monoclonal antibody;	
			MDR inhibitor	-
MAb, MRK 17;	Discontinued		biotechnology;	cancer
MRK 17			monoclonal antibody;	-
	-		MDR inhibitor	
MAb, humanized,	Phase II		biotechnology;	rheumatoid arthritis;
leukemia; MAb,		. н	tibody;	cancer: multiple
IgG2B; LDP 03; BW		-		sclerosis: transplant
7U; CAMPATH;				rejection
CAMPATH-1H				
iodine 131	Phase III		biotechnology;	cancer
tositumomab; MAb,		<u>. H.</u>	monoclonal antibody;	
CD20-10dine [31]; BEXXAR		.	radiotherapeutic	

14 16 00 11				
MAD, 10.88-yttnum	rnase I		biotechnology;	cancer
06			monoclonal antibody;	
			radiotherapeutic	
MAb, 35-67Cu;	Phase I		biotechnology;	cancer
MAb, murine colon			monoclonal antibody;	
carcinoma; MAb,			radiotherapeutic	
cancer			•	
MAb, 88BV59-	Phase I		biotechnology:	cancer
yttrium 90			monoclonal antibody;	
			radiotherapeutic	
MAb, B3-yttrium 90	Phase I		biotechnology;	cancer
			monoclonal antibody;	
			radiotherapeutic	
MAb, CC49-yttrium	Phase I		biotechnology;	cancer
			monoclonal antibody;	
			radiotherapeutic	
MAb, CD20-iodine	Phase II		biotechnology;	cancer
131			monoclonal antibody;	
		Ĭ	radiotherapeutic	
	Phase I	1	biotechnology;	cancer
streptavidin + biotin-			monoclonal antibody;	
oftrium 90		1	radiotherapeutic	
MAb, CEA rhenium-	Phase II	٠	biotechnology;	cancer
188; MAb, colorectal		H	monoclonal antibody;	•
cancer; IMMURAIT-		_ H	radiotherapeutic	
Rhenium			•	
MAb, CG250-iodine	Phase II		biotechnology;	cancer
131		. H i.	monoclonal antibody;	
		ı	radiotherapeutic	
MAb, chimeric L6-	Discontinued	,10	biotechnology;	cancer
nodine 131; BMS		. 14	monoclonal antibody;	
180548		L	radiotherapeutic	

MAb, CYT 103-	Phase II	Ç	biotechnology:	cancer
yttrium 90; MAb,			monoclonal antibody:	
B72.3-yttrium 90;		21	radiotherapeutic	
ONCORAD OV103;				
UNCURAD CR103				
MAb, ERIC1 yttrium Discontinued	Discontinued	ِ ۾	biotechnology;	cancer
06			nonoclonal antibody;	
		ITA	radiotherapeutic	
MAb, F(ab)2	Discontinued	iq	biotechnology;	cancer
NRLU10-rhenium			nonoclonal antibody;	
186; MAb, F(ab)2			adiotherapeutic	
pancarcinoma;			4	
KHENEX				
MAb, G250-iodine	Phase II	iq.	oiotechnology;	cancer
131		<u>#</u>	nonoclonal antibody;	
		ra	radiotherapeutic	
şeq	Phase I	id	biotechnology;	cancer
MN-14; MAb,		<u>E</u>	monoclonal antibody;	
humanized		_ra	radiotherapeutic	
carcinoembryonic			•	
antigen; MN 14;		-	:	
CEA-Cide				
MAb, iodine-131,	Phase II	bi	biotechnology:	cancer
DNA-associated		<u> </u>	monoclonal antibody:	
antigens; 1311-		ra	radiotherapeutic	
chTNT-1/B;			, J	•
COTARA; Tumor		•	-	
Necrosis Therapy;				
TNT				
	Phase II	jq	biotechnology;	cancer
131; LymphoCide;		Ā	monoclonal antibody;	
ImmuRAIT-LL2		ra	radiotherapeutic	

MAb, LYM-1-iodine Phase III	Phase III	biotechnology;		cancer
131; LYM 1;		monoclon	monoclonal antibody;	
ONCOLYM		radiotherapeutic	peutic	
MAb, MAb fragment, Discontinued	Discontinued	biotechnology;		ancer
REC A33-TFM-		monoclon	ibody:	
nuclide; CDP 833		radiotherapeutic	peutic	
MAP, NRLU13-	Phase II	biotechnology;		cancer
streptavidin + biotin-		monoclon	monoclonal antibody;	
yttrium 90;		radiotherapeutic	peutic	
- 1				
7-iodine	Phase I	biotechnology;		ancer
131; OKB7		monoclon	monoclonal antibody;	
		radiotherapeutic	peutic	
MAb, pan-B-yttrium; Phase III	Phase III	biotechnology;	Ť	cancer
MAb, B-cell radiation		monoclon	ibody:	
therapy; IDEC Y2B8	•	radiotherapentic	peutic	
MAb, PEM-antisense Preclinical	Preclinical	biotechnology		cancer
oligonucleotide-		monoclon	tibody:	
radionuclide; AS 102		radiotherapeutic	peutic	
MAb,	Preclinical	biotechnology;		ancer
squamous cell		monoclon	monoclonal antibody;	
carcinoma; AS 114		radiotherapeutic	peutic	
MAb, UJ13A yttrium Discontinued	Discontinued	biotechnology;	logy; cancer	ıcer
06		monoclons	monoclonal antibody;	
		radiotherapeutic	peutic	
	Phase II	biotechnology;	ogy; cancer	cer
capromab; MAb,		monoclona	monoclonal antibody;	
CYT 356-yttrium 90;		radiotherapeutic	peutic	
MAb, 7E11C5-				
yttrium 90; MAb,		· 		
prostate cancer;		•	· .	
OncoRad PR			-	

D-144110.

MAb, 4B5; MAb,	Preclinical	id	biotechnology;	cancer
anti-GD2 anti-		Ē	monoclonal antibody;	
idiotypic; NOVOVAC-M1		8	vaccine	
MAb, BEC-2;	Phase III	bid	biotechnology;	cancer
vaccine, BEC-2;		Ē	monoclonal antibody;	
EMD 60205; BEC2		Na	vaccine	
MAb, CA 125;	Phase III	bi	biotechnology;	cancer
vaccine, cancer;		Ŭ.	monoclonal antibody;	
B43.13; OvaRex		va	vaccine	
MAb, CA19.9; AR	Preclinical	bid	biotechnology;	cancer
44.6; GivaRex		Ä	monoclonal antibody;	
		va	vaccine	
MAb, idiotypic CEA; Phase II	Phase II	bid	biotechnology;	cancer
vaccine, cancer;		<u>.</u>	monoclonal antibody;	
cancer vaccine;	٠	Va	vaccine	
CeaVac				
MAb, idiotypic GD2; Phase II	Phase II	bid	biotechnology;	cancer; psoriasis
vaccine, cancer;		m	monoclonal antibody;	•
cancer vaccine;		va	vaccine	
TriGem				
MAb, idiotypic,	Phase II	bid	biotechnology;	cancer
MUC1; vaccine,		<u>m</u>	monoclonal antibody;	
cancer; cancer		Va	vaccine	
	Phase I	bid	biotechnology;	cancer
vaccine, cancer; AR		m	monoclonal antibody;	
20.5; BrevaRex		Va	vaccine	
·,	Preclinical	bic	biotechnology;	cancer
ProstaRex		mic	monoclonal antibody;	
		Va	vaccine	

monoclonal antibody, Clinicals	Clinicals	biotechnology:	v: cancer	
anti-idiotypic, cancer		monoclonal antibody;		
		vaccine		_
antisense	Preclinical	biotechnolog	biotechnology; mRNA cancer	
oligonucleotide, B		translation inhibitor;	hibitor;	
cell lymphoma		antisense;		
		oligonucleotide	de	
antisense	Preclinical	biotechnolog	biotechnology; mRNA cancer	
oligonucleotide, c-		translation inhibitor;	hibitor;	
. qku		antisense;		
		oligonucleotide	de	
antisense	Discontinued	biotechnolog	biotechnology; mRNA cancer	
oligonucleotide,		translation inhibitor;	hibitor;	
cancer		antisense;		
		oligonucleotide	de	
antisense	Preclinical	biotechnology	biotechnology; mRNA cancer	
oligonucleotide,		translation inhibitor;	hibitor;	-
cancer; mRNA		antisense;		
translation inhibitor,		oligonucleotide	de	
cancer)		
	Phase II	biotechnology	biotechnology; mRNA cancer	
oligonucleotide, Ha-		translation inhibitor;	hibitor:	
ras; ISIS 2503		antisense;	_	
		oligonucleotide	de	
antisense	Discontinued	biotechnology	biotechnology; mRNA cancer	
oligonucleotide,		translation inhibitor;	hibitor;	
Kaposi's sarcoma		antisense;		
		oligonucleotide	de	-

antisense oligonucleotide,	Phase II	id	biotechnology; mRNA cancer translation inhibitor;	cancer
Philadelphia chromosome;		ar Ol	antisense; oligonucleotide	
antisense				
oligonucleotide,				
leukemia; G 1128				
antisense	Preclinical	bid	biotechnology; mRNA cancer	cancer
oligonucleotides, Ki-		tra	ranslation inhibitor;	
ras		an	antisense;	
		[O	oligonucleotide	
GPs 0193; NAVIN	Discontinued	bid	biotechnology; mRNA HIV infection;	HIV infection;
		tra	translation inhibitor;	cancer
		an	antisense;	
	-	oli	oligonucleotide	
LR 3523	Discontinued	piq	biotechnology; mRNA cancer	cancer
		tra	translation inhibitor;	
	:	an	antisense;	
		oli	oligonucleotide	
BCG A4	Preclinical	id :	biotechnology;	cancer
		011	oligonucleotide	
LR 5165	Discontinued	bic bic	biotechnology;	cancer
		oli	oligonucleotide	
oligonucleotide	Discontinued	pic		cancer; genetic
directed DINA therapy		ilo	oligonucleotide	disorder; viral
			_	infection; bacterial
				infection
oligonucleotide,	Preclinical	bio	biotechnology;	cancer
cancer, Kimeragen		ilo	oligonucleotide	
oligonucleotide;	Preclinical	bio		cancer
chronic myelogenous leukemia. Kimeragen		oli	oligonucleotide	
	T			

oligonucleotide; antisense biotechnology; oligonucleotide; antisense d(P-thio) (T-C-C-C-biotechnology; oligonucleotide; antisense d(C-C-T-G-T-G-A-oligonucleotide; antisense biotechnology; oligonucleotide;	antisense	Preclinical		hiotechnology.	rencer
Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense biotechnology; oligonucleotide; antisense antisense c.A.T.G.C.C.C. biotechnology; oligonucleotide; antisense c.A.T.G.C.A.T.T.) antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense antisense antisense antisense	oligonucleotide, bcl- 2; ODN 2009			oligonucleotide; antisense	
Preclinical biotechnology; Preclinical biotechnology; Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-oligonucleotide; Preclinical biotechnology; Preclinical biotechnology; Oligonucleotide; antisense	antisense oligonucleotide,	Preclinical		biotechnology;	cancer
Preclinical biotechnology; oligonucleotide; antisense Preclinical biotechnology; oligonucleotide; antisense Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A- oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense	cancer, GeneSense			antisense	
Preclinical biotechnology; oligonucleotide; antisense Phase II d(P-thio) (T-C-C-C- biotechnology; G-C-C-T-G-T-G-A- oligonucleotide; C-A-T-G-C-A-T-T-) antisense antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense antisense antisense	Technologies; GTI 2040				
Preclinical Phase II d(P-thio) (T-C-C-C-Piotechnology; G-C-C-T-G-T-G-A-Oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical Preclinical Preclinical Diotechnology; Coligonucleotide; C-A-T-G-C-A-T-T-) antisense preclinical Diotechnology; Coligonucleotide; antisense preclinical Diotechnology; Coligonucleotide; antisense preclinical Diotechnology; Coligonucleotide; antisense	antisense	Preclinical		biotechnolom	1
Preclinical Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-oligonucleotide; C-A-T-G-T-T-) antisense Preclinical Preclinical Diotechnology; oligonucleotide; antisense preclinical Diotechnology; oligonucleotide; antisense Diotechnology; oligonucleotide; antisense preclinical Diotechnology; oligonucleotide; antisense	oligonucleotide,			oligonucleotide:	cancer
Preclinical Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical Preclinical Diotechnology; oligonucleotide; antisense pricedinical Diotechnology; oligonucleotide; antisense pricedinical Diotechnology; oligonucleotide; antisense pricedinical Diotechnology; oligonucleotide; antisense	cancer, GeneSense			antisense	
Preclinical biotechnology; oligonucleotide; antisense Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense antisense	Technologies; GTI 2501				
Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-cligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense	antisense	Preclinical		biotechnology;	cancer
Phase II d(P-thio) (T-C-C-C- biotechnology; G-C-C-T-G-T-G-A- oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense	ongonucieotide,			oligonucleotide;	
Phase II d(P-thio) (T-C-C-C-biotechnology; G-C-C-T-G-T-G-A-oligonucleotide; C-A-T-G-C-A-T-T-) antisense Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense	cancer,	•		antisense	
Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Diotechnology; Oligonucleotide; antisense Diotechnology; Oligonucleotide; antisense Diotechnology; Oligonucleotide; antisense Antisense Antisense Antisense	isis/Asuazeneca	i			
Preclinical Preclinical Preclinical Preclinical Preclinical Diotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense	alitischise	rhase II		biotechnology;	cancer
Preclinical biotechnology; oligonucleotide; antisense antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense	ongonucieotide, rat			oligonucleotide;	
Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense	Killase; antisense			antisense	
Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense	oligonucieotide,				
Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense antisense	Cancer; 1515 5132;			-6	
Preclinical biotechnology; oligonucleotide; antisense biotechnology; oligonucleotide; antisense	69846A; ODN 698				
Preclinical biotechnology; oligonucleotide; antisense antisense	_	Preclinical			cancer
Preclinical biotechnology; oligonucleotide; antisense	oligonucleotide, TAG 6; TAG 6			eotide;	
oligonucleotide; antisense	antisense	Preclinical			ancer
,	oligonucleotides, non- Hodekins lymphoma				
Center	Fox Chase Cancer		_	annsense	
	Center				

D-144110

olimone and a state of				
Ougonucieoudes,	Frechnical	· · · · ·	biotechnology;	cancer; psoriasis
Y TITLE	_		oligonucleotide;	
ribozyme, bcl-2,	Preclinical		hiotechnology.	
Ribozyme			oligoniicleotide:	calicer
			ribozvme	
ribozyme, europium-	Preclinical		biotechnology:	cancer viral
texaphyrin, cancer;			oligonucleotide:	infection
ribozyme, europium			Thorame	TODACTION
texaphyrin, viral infection			-	
ribozyme, K-ras	Preclinical		biotechnology;	cancer
			oligonucleotide;	
		н	ribozyme	
sense	Discontinued	-	biotechnology;	cancer: viral
oligonucleotides,			oligonucleotide;	infection
GenSet; transcription		_ ;	ranscription factor	
factor decoys, GenSet		1 -1	regulator	
polyethylene glycol	Discontinued		biotechnology:	golift cancer
uricase; PEG-uricase;	_		oxidoreductase.	gour, cancor
uricase macrogol			uricase	
class II restricted	Preclinical	.0	biotechnology: peptide cancer	cancer
melanoma antigens,			- J. J. (70	
National Institutes of				
Health	·			
urokinase receptor	Preclinical	2	biotechnology: nentide cancer: inflammation	cancer inflammation
antagonists, Chiron			2011 F. C. C.	omicot, minamination
interferon-inducible	Preclinical	-0	biotechnology.	Cancer
protein-10; IP-10		<u></u>	peptide: chemokine	
interferon-inducible	Preclinical	0	Γ	Cancer. eve disease
protein-10; IP-10		Ċ	kine	carrent, cyc anscase

antibody-derived	Discontinued	hiotechnology.	ology.	Cancer. disanceis
anticancer peptides,			contrast	cuical, diagnosis
Antisoma		medium		
RecepTox-GnRH	Preclinical	biotechnology;	ology;	cancer
chimonic montida		hebrine, I	peptide, insion toxin	
Motional Profitation -	Preclinical	biotechnology;	ology;	cancer; viral
Health		peptide; vaccine	vaccine	infection
plasminogen activator Phase II	rPhase II	hiotopho	1000	
inhibitor: PAI-2		oloiceimology,	Jiogy,	cancer;
		plasminos	plasminogen activator inhibitor: cicatrizant	inflammation; skin
matrix	Discontinued	biotechnology:		arthritis: cancer.
metalloproteinase		proteinase	bitor;	arthritis,
inhibitor		matrix		
		metalloproteinase	oteinase	
		inhibitor; NSAID	NSAID	
maspin; mammary	Preclinical	biotechnology;	logy;	cancer
serine proteinase		proteinase	proteinase inhibitor;	
inhibitor; LXR 023;		serine proteinase	teinase	
MEIAKEX		inhibitor		
neutral	Discontinued	biotechnology;		cancer; migraine;
endopepudase; NEF		proteinase;		inflammatory bowel
		metalloproteinase		disease;
		<u></u>	·H.	inflammation;
				asthma; respiratory
				disease
	Preclinical	biotechnology;	logy;	cancer
acute promyelocytic		ribozyme;		
		oligonucleotide	otide	
les,	Preclinical	biotechnology;		cancer
marictone		ribozyme;		
resistance		oligonucleotide	otide	

D-144110.

ribozyme, BCR-ABL Preclinical	Preclinical	biotechnology;	cancer
		ribozyme; oligonucleotide	
ribozyme, ras, Ribozyme	Preclinical	biotechnology; ribozyme;	cancer
ribozyme, vascular	Phase I	biotechnology;	retinopathy; cancer
endothelial growth factor receptor:		ribozyme;	
ribozyme, VEGF		antioarantioatro	
receptor; RPI 4610; ANGIOZYME			
screening technology, Preclinical	Preclinical	biotechnology; target	get drug design
growth regulatory compounds		based screening	
drug delivery system,	Preclinical .	biotechnology; vaccine cancer	ccinecancer
verotoxin rusion protein cancer	-		
vaccine; vaccine,			
cancer			
epidermal growth factor; EGF	Phase I	biotechnology; vaccinecancer	ccinecancer
MEDI 501	Phase I	biotechnology; vaccinecancer; viral	cinecancer; viral
	Preclinical	biotechnology: vaccinecancer	cinecancer
MEDI 504	Preclinical	biotechnology: vaccinecancer	cinecancer
tumor associated antigen; PP4X	Preclinical	biotechnology; vaccinecancer	cinecancer
sociated CTAA 79	Preclinical	biotechnology; vaccinecancer	cinecancer
AV1017			

vaccine, B cell	Preclinical	biotechnology: vaccinecancer	ancer
lymphoma specific			
idiotype-granulocyte	•		-
macrophage colony			
stimulating factor;			
vaccine, Id/MoGM-CSF			
vaccine, breast	Preclinical	biotechnology: vaccinecancer	ancer
cancer;			
immunotherapy,			
breast cancer; MUVAC			
vaccine, breast cancer Preclinical	Preclinical	biotechnology: vaccinecancer	ancer
vaccine, breast	Preclinical	hiotechnology, vaccine cancar	phoer
cancer, CelSci			aioci
vaccine, canarypox	Phase I	biotechnology: vaccinecancer	ancer
CEA; vaccine, cancer;			
	Preclinical	biotechnology; vaccinecancer	ancer
	Preclinical	biotechnology; vaccinecancer	ancer
er,	Discontinued	biotechnology; vaccinecancer	ancer
_	Phase I	biotechnology; vaccinecancer	ancer
cancer; vaccine,			
fision protein:			
Length protein,			
ONCOCINE			
=	Phase II	biotechnology: vaccinecancer	ancer
and lung cancers;			
colorectal and lung			
cancers vaccine;			-
טווכס י מא-כבו		-	

SD-144110.1

vaccine colorected	Dradinia			
cancer	T LCCIIIICGI	<u>o</u> .	piotechnology; vaccinecancer	ecancer
vaccine. Enstein Rarr	Preclinical			
viral coat protein:	r recillitedi	<u>o.</u>	olotechnology; vaccineglandular fever;	eglandular fever;
vaccine, EBV				cancer
vaccine, Epstein-Barr	Clinicals	-	hiotechnology: vaccinecancer	Concor
virus gp 220-340;		<u>)</u>	recentled, racelling	
vaccine, EBV			-	
vaccine, gp75	Preclinical	Ç	biotechnology: vaccine cancer	cancer
antigen; vaccine,		<u> </u>		Too
cancer				
vaccine, hepatitis B	Preclinical	q	biotechnology: vaccinecancer	Cancer
core antigen fusion	·	<u> </u>	, , , , , , , , , , , , , , , , , , ,	
proteins, National				
Institutes of Health;			-	
vaccine, cancer				
vaccine, HER/neu-2	Preclinical		biotechnology: vaccinecancer	cancer
oncogene; vaccine,				
breast cancer				
vaccine, human	Phase I	id	biotechnology: vaccinecancer	Cancer
papilloma virus;		!	, , , , , , , , , , , , , , , , , , ,	
vaccine, cervical			•	
cancer; vaccine, HPV				
vaccine, human	Phase II	ig	biotechnology: vaccinecancer: viral	cancer viral
papillomavirus;		-		infection
therapeutic antigen,		-		10000
cervical cancer;		-		
vaccine, HPV; TA-				
HPV		:		

vaccine, human	Phase II	<u></u>	hiotechnology, woologistics	Trimol in Contract
papillomavirus;			cocamoog), vaccino	ruai miccuoni, cancer
therapeutic antigen,				
genital warts;				
vaccine, HPV; TA-GW				
vaccine, mage-1:	Discontinued		otocha ole out	
vaccine, melanoma:		3	orotecimorogy; vaccinecancer	cancer
TBC-Mage-1;		***		
MAGEVAC				
vaccine, MART-1;	Phase I	ŅĢ	biotechnology: vaccinecancer	Cancer
vaccine, melanoma			ownoon, (Carrier	
vaccine, mutant p53	Phase I	jid	biotechnology: vaccinecancer	Cancer
and ras peptide			(/9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	מתונכנו
activated monocytes				
vaccine, neu; vaccine, Preclinical	Preclinical .	biq	biotechnology: vaccinecancer	Cancer
breast and ovarian			(6)	
cancer; TBC-NEU				
vaccine, papilloma	Discontinued	bic	biotechnology: vaccinecancer	Sancer
virus HPV 16;			(6)	
vaccine, cervical		-		
cancer				
, prostate	Phase I	oid	biotechnology: vaccinecancer	ancer
immunotherapy,		. s		
prostate cancer;	· ,-			
PROSTVAC				
vaccine, prostate	Preclinical	oid	biotechnology: vaccine cancer	oncer
cancer				TOO!B
0)	Phase II	bio	biotechnology; vaccinecancer	ancer
cancer; prostate	_		3	
cancer vaccine;				

vaccine, prostate cancer, CelSci	Preclinical		biotechnology; vaccinecancer	ecancer
vaccine, ras; vaccine, Discontinued colorectal cancer;	Discontinued		biotechnology; vaccinecancer	cancer
יייייייייייייייייייייייייייייייייייייי				
vaccine, recombinant Phase I dendritic cells, Duke University	Phase I		biotechnology; vaccinecancer	cancer
ne, TBC-CEA; ne, cancer; TBC-	Phase II		biotechnology; vaccinecancer	cancer
CEA				
vaccine, tumor; tumor Discontinued vaccine	Discontinued		biotechnology; vaccinecancer	cancer
virus derived	Discontinued		hiotechnology, wooding	100
particles, human			orecommongy, vaccinicance	calleer
papillomavirus;			-	
VDPs, HPV				
thymalfasin; thymosin alpha-1; Ta-	Marketed	(N-acetyl)-ser-asp- ala-ala-val-asp-thr-	biotechnology; vaccinecancer; viral adjuvant;	cancer; viral
I; ZADAXIN		ser-ser-glu-ile-thr-thr-immunostimulant;	immunostimulant;	
		lys-asp -leu-lys-glu-	peptide	
		lys-lys-glu-val-val-		
		glu-glu-ala-glu-asn- OH		
	Preclinical	v v	biotechnology:	Canopr
antigen;			vaccine; biotechnology	Carico
vaccine, HPV;			6	
vaccine, cervical				
cancer				
e, gene-based,	Preclinical		biotechnology;	cancer
called			vaccine; gene therapy	

vaccine oene-based	Dhase II		1. 1. 4 1 1.	
non-Hodgkin's B cell	TI ACCULT		ototechnology;	cancer
lymphoma; VAXID			receive, gene merapy	
vaccine, gene-based,	Preclinical		biotechnology;	cancer
T cell lymphoma;			vaccine; gene therapy	
APL 400020;				
GENEVAX		-	•	
vaccine, ALVAC-	Phase I		biotechnology;	cancer
hB7.1; vaccine,			vaccine;	
ovarian carcinoma;			immunostimulant	
AUT-OV-ALVAC-				
hB7.1		₩2.		
vaccine, cervical	Preclinical		biotechnology:	cancer
intraepitheal	,	-:	vaccine;	
neoplasia; TA-CIN;			immunostimulant	
TA-CIN				
MAb, I-Mel-1; I-Mel-Discontinued	Discontinued		biotechnology;	cancer
1; MELIMMONE-1			vaccine; monoclonal	
			antibody	
MAb, I-Mel-1 +	Discontinued		biotechnology;	cancer
MAb, I-Mel-2; MAb,			vaccine; monoclonal	-
I-Mel-2 + MAb, I-			antibody	
Mel-1;				
MELIMMUNE				
	Phase III		biotechnology;	cancer
105AD7; MAb, anti-		•	vaccine; monoclonal	
idiotypic gp72; 105AD7			antibody	
	Dreclinical		1.1.41	
lastoma/glioma	i commodi		piotecnnology;	cancer
; MAb, NG 1; MAb,			antihody	
cancer; NG 1;				
MONOPHARM G				
	, dans, 1		1	

vaccine, MAb, anti- Preclinical	Preclinical		biotechnology;	cancer
idiotype, cancer;			vaccine; monoclonal	
vaccine, cancer;			antibody	
MAb, cancer			•	
vaccine, melanoma;	Phase II		biotechnology;	cancer
MAb, MK2-23			vaccine; monoclonal	
			antibody	
minodronic acid; YM Phase II	Phase II	(1-hydroxy-2-	bisphosphonate	osteoporosis:
529; YH 529		(imidazo[1.2-	•	hypercalcemia;
٠,		a]pyridin-3-		cancer
~		yl)ethylidene)bisphos		
		phonic acid		
neridronic acid;	Discontinued	(6-amino-1-	bisphosphonate	Paget disease:
aminohexane		hydroxyhexylidene)di		osteoporosis: cancer
diphosphonate;		phosphonic acid	•	
AHDP Na		•		
pamidronic acid;	Marketed	(3-amino-1-	bisphosphonate	osteonorosis: cancer
pamidronate		ylidene)b	•	Tooms (avanced from
disodium; APD; CGP		isphosphonic acid		
23339AE; AREDIA;		•		
OSTEOKIT				1
	Marketed	[1-hydroxy-3-	bisphosphonate:	osteoporosis: cancer.
ibandronate sodium;		(methylpentylamino)posteoanagenetic		hypercalcemia
BM 210955;		ropylidene]bisphosph		
BONDRONAT		onic acid		

D-144110

RC:3095	Phase I	ŀ	hombeein ontogonist	
		tetrahydro-1H-		Calicol
		pyrido[3,4-b]indole-		
		3-carbonyl-L-		
		glutaminyl-L-	•	
		tryptophyl-L-alanyl-		
		L-valylglycyl-N-	-	
		[(1S)-1-[[[(1S)-1-	-	
		(aminocarbonyl)-3-		
		methylbutyl]amino]m		
		ethyl]-3-		
		methylbutyl]-L-		
		histidinamide		
D 22213	Phase I	R*)]]-	bombesin antagonist;	cancer
	_	N2-[(2,3,4,9-	peptide	
	•	tetrahydro-1H-		
-		pyrido[3,4-b]indol-3-		
		yl)carbonyl]-L-		
		glutaminyl-L-		
		tryptophyl-L-alanyl-		
		L-valylglycyl-N-[1-		
		[[[1-(aminocarbonyl)-	-	
		3-		
		methylbutyl]amino]m		
		ethyl]-3-	_	
		methylbutyl]-L-		
		histidinamide		
		monoacetate	. 1	

SD-144110.1

PAK 200	Discontinued	Discontinued 15-75 5-dimethyl-	Coloinm antagoniat	
		1,3,2-		Calicol
		dioxaphosphorinan-2-		
· 		yl)-1,4-dihydro-2,6-		
		dimethyl-1-[2-(4-		
		morpholinyl)ethyl]-4-		
	<u></u>	(3-nitrophenyl)-3-		
		pyridinecarboxylic		
		acid 2-		
		[phenyl(phenylmethyl		
)amino]ethyl ester, P-		
		oxide		
dilazep; ANGOSIR	Marketed	tetrahydro-1H-1,4-	calcium channel	cancer; cardiac
ST		diazepine-1,4(5H)-	blocker;	therapy
			hematoprotectant;	
		xybenzoate	chemoprotectant	
		(diester)		
D 1465	Discontinued		calcium channel	cancer
			blocker; MDR	
	·	-	inhibitor	
CP 55940	Preclinical	(1alpha, 2beta, 5alpha) cannabinoid	cannabinoid	cancer
		-(-)-5-(1,1-	-1-	
		dimethylheptyl)-2-[5-		
		hydroxy-2-(3-		
		hydroxypropyl)cycloh		
		exyl]phenol		
casein kinase	Preclinical		casein kinase inhibitor; inflammation; cancer	inflammation; cancer
innibitors, ICOS		.e.	immunosuppressant;	
			NSAID	
aragusteroi A; YTA 0040	Preclinical		Cdk/cyclin inhibitor	cancer
ONCONEX	Preclinical		chelating agent	Cancer
				CHICA

glucarolactam; ND	Discontinued	5-amino-5-deoxy-D-	chemoprotectant	cancer
1003		glucosaccharic acid- delta-lactam		
myeloid progenitor inhibitory factor;	Phase II		chemoprotectant; biotechnology;	cancer
MPIF-1; HG 00300		,	hematoprotectant;	
			hematopoiesis	
			inhibitor; stem cell division inhibitor; chemokine	
dexrazoxane;	Marketed	(+)-(S)-4,4'-	chemoprotectant:	cancer: heart failure
razoxane (+), (S);		propylenedi-2,6-	cytoprotectant	
ICRF 187; NSC		piperazinedione	·	
169780; ADR529;	•			
ICI 59118;			· ·	
CARDIOXANE;	٠			
EUCAKDION;			٠. ٠	
KAZUXIN;				
ZINECORE;				
ZINECARU;				
ANTRAGARD				
gammalinolenic acid	Discontinued		chemoprotectant;	cancer
+ eicosapentaenoic		:	cytoprotectant	
acid; EF 27;				
AMELORAD;				
TARAGAM				
ICRF 197	Preclinical		chemoprotectant;	cancer; heart failure
			cytoprotectant	
MGI 136	Discontinued	Discontinued diethyldithiocarbamat chemoprotectant;		cancer .
		e	cytoprotectant	

WK 151327; NSC Preclinical 335662 amifostine; ethiofos; Marketed gammaphos; WR 2721; NSC 296961; YM 08310; WR 2721C; ETHYOL hematopoietic growth Preclinical factor inhibitors, Ligand hematopoietic progenitor cell inhibitor, University of Indiana stem-cell division inhibitors, Terry Fox Laboratory tactor, natural; SCIF	3-[[3- chemoprotecta (methylamino)propyl]cytoprotectant amino]-1-propanethiol dihydrogen phosphate ester chemoprotectan aminopropyl)amino]e cytoprotectant thanethiol dihydrogen radioprotectant phosphate	chemoprotectant; cytoprotectant chemoprotectant; cytoprotectant; radioprotectant	cancer; HIV infection
s; Marketed ; th Preclinical Preclinical Discontinued A Discontinued	nethiol rogen phosphate propyl)amino]e hiol dihydrogen hate	temoprotectant; roprotectant; dioprotectant	
s; Marketed ; th Preclinical Discontinued Discontinued F	nethiol rogen phosphate propyl)amino]e hiol dihydrogen hate	nemoprotectant; Aoprotectant; dioprotectant	
s; Marketed ; th Preclinical Discontinued Discontinued F	propyl)amino]e hiol dihydrogen hate	nemoprotectant; Aoprotectant; dioprotectant	
s; Marketed the Preclinical Preclinical Discontinued Discontinued	propyl)amino]e hiol dihydrogen hate	nemoprotectant; rtoprotectant; dioprotectant	
th Preclinical Preclinical Discontinued Discontinued	propyl)amino]e hiol dihydrogen hate	toprotectant; dioprotectant	cancer
th Preclinical Preclinical Discontinued Discontinued	thanethiol dihydrogen ra phosphate	dioprotectant	
Ath Preclinical Preclinical Discontinued A Discontinued F	phosphate		
the second secon			
# × K			
> × [L	C1	chemoprotectant;	cancer
> × 'tı	he	hematopoiesis	
> × (t,	ui.	inhibitor	
> × (L	ch	chemoprotectant;	cancer
> × (r.	De	hematoprotectant;	
× (r.	. The	hematopoiesis	
× (t.	<u>ii</u>	inhibitor; stem cell	
×	ip	division inhibitor	
× (L	ch	chemoprotectant; stem	cancer
(T.	90	cell division inhibitor;	
(T.	he	hematopoiesis	
(t.	lui	inhibitor	
ractor, natural; SCIF	년 당	chemoprotectant; stem	cancer
	9	cell division inhibitor;	
	he	hematoprotectant;	
	he	hematopoiesis	
	ini	nhibitor	
	ch	chemosensitizer	cancer
	ch		cancer
glutathione-S- Preclinical	ch		cancer
tranferase inhibitors,			
LOUN			

D-[44]10.1

manavin	Preclinical	3 FFFO FFA Paido 2	the contract of the contract o	
		nitrophenyl)aminolet	CITCHIOSCHSIUZE	cancer
		hyl]amino]carbonyl]-		
		O4-deacetyl-3-		
		de(methoxycarbonyl)		
		vincaleukoblastine		
TER 199	Preclinical	(2R)-L-gamma-	chemosensitizer	cancer
	·	glutamyl-S-		
		(phenylmethyl)-L-	-	
	-	cysteinyl-2-		
		phenylglycine		
declopramide; OXI	Phase II		chemosensitizer;	cancer
104		_	apoptosis inducer;	
			radiosensitizer	
CMDA; CJS 8	Preclinical	N-[4-[(2-	chlormethine	cancer
-			derivative; alkylating	
			agent	
		zoyl]		
		-L-glutamic acid		
galamustine;	Discontinued		chlormethine	cancer
galactose-6-mustard;		yl)amino]-6-	derivative; alkylating	-
C6 GLM; G 6 M		deoxy-D-	agent	
		ranose		
SN 23862	Preclinical	5-[bis(2-	chlormethine	cancer
		chloroethyl)amino]-	derivative; alkylating	
		2,4-dinitrobenzamide agent	agent	
	Phase II	3-[2-[bis(2-	chlormethine	cancer
spirohydantoin		amino]eth	lerivative; alkylating	
mustard; SHM;	·	yl]-1,3-	agent	
speratine; NSC		4.5]decane	er Long &	
7117/1		-2,4-dione	· ·	

cancer	cancer	eating disorder; cancer	viral infection; skin ulcer; cancer	cancer; skin ulcer	septic shock; cancer; vascular leakage
N-[5-[[(3-amino-3-chlormethine minopropyl)amino]c derivative; alkylating arbonyl]-1-methyl-agent lH-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]be zoyl]amino]-1-nethyl-1H-pyrrol-2-nethyl-1H-pyrrole-2-arboxamide	chlormethine derivative; alkylating agent	cholecystokinin A antagonist; cholecystokinin antagonist	cicatrizant	cicatrizant	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor
N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide	(3beta, 16beta, 17beta, 22S, 25S)-17-methyl-18-norspirosola-5, 12-dien-3-ol	2-[[[4-(2-chlorophenyl)-2-antagonist; thiazolyl]amino]carbocholecystokinin nyl]-1H-indole-1-antagonist	l-docosanol		
Discontinued	Preclinical	Phase II	Pre- registration	Discontinued	Discontinued
tallimustine; FCE 24517	veramine; RL 0017	lintitript; SR 27897; SR 27897B	docosanol, n-; docosanol, 1-; behenyl registration alcohol; LIDAKOL	Myc/Max inhibitors, Apoptosis Technology; Myc/Max inhibitors, ICRF	OLX 501

SD-1441101

OI X 514	Discontinued		2.11.1.1.1.2.	
	חחווווווסספור		conagenase innibitor; septic snock; cancer	septic shock; cancer
			matrix	
		•	metalloproteinase	
			inhibitor; proteinase	-
			inhibitor	
MAb,	Phase I		contrast medium;	cancer; diagnosis
carcinoembryonic			monoclonal antibody;	
antigen; PR1A3			biotechnology;	
			radiotherapeutic;	
			radiodiagnostic	
NLCQ 1	Preclinical	4-[3-(2-	contrast medium; MRI diagnosis; cancer	diagnosis; cancer
		nitroimidazolyl)propy agent; imidazole	agent; imidazole	
	-	lamino]-7-	•	
		trifluoromethyl-		
		quinoline bydrochloride		
Vasoactive intestinal	Phace II			
peptide-iodine 123;		-	connast meanum; peptide	diagnosis; cancer
VIP-I 123				
cancer therapy,	Preclinical		contrast medium;	cancer
Angstrom/Diatide			radiotherapeutic;	
			radiodiagnostic	
fludarabine +	Discontinued		corticosteroid	cancer
prednisone;				
prednisone +				
fludarabine				
ORG 6632	Discontinued	a.	corticosteroid;	cancer; rheumatoid
		beta-	immunosuppressant	arthritis
		hydroxy-		
		16alfa,17alfa-		
-		dimethylpregna-1,4-		
		diene-3,20-dione		

HX 0836	Preclinical	(E)-3-(3,4-	COX inhibitor: 5	cancer
		dihydroxyphenyl)-1- (2,5-	dihydroxyphenyl)-1- lipoxygenase inhibitor (2,5-	
		dimethoxyphenyl)-2-		
celecovity QC 58635. Marketed	Mortrotod	4 fe (4		
YM 177;	TATALVEICH	ienv1)-3-	COX inhibitor; COX 2 arthritis; pain; cancer inhibitor: analoesic:	arthritis; pain; cancer
CELEBREX;		IH-	NSAID (NSAID)	
CELEBRA				
		yl]benzenesulfo		
		namide		
cyclocreatine; AM	Discontinued	2-amino-4,5-dihydro- creatine kinase	creatine kinase	cancer; viral
. 287		1H-imidazole-1-	modulator	infection
1.1.1. C.10.				
cake innibitors,	Preclinical		cyclin dependent	cancer
Molecumetics			kinase inhibitor	
cyclin-dependent	Preclinical		cyclin dependent	cancer
kinase inhibitor,			kinase inhibitor	
Agouron; cancer				
therapy, Agouron		•	-	
cyclin-dependent	Preclinical	9	cyclin dependent	cancer
kinase/cyclin		_=		
inhibitors, Mitotix;				
Cdk/cyclin inhibitors,				
Mitotix				
cyclin-dependent	Preclinical		cvclin dependent	cancer
kinase4 modulators,				
Pharmacopeia; cdk4				
modulator,				
Pharmacopeia			-	
	A			

flavopiridol; NSC	Phase II	cis-2-(2-	cvclin dependent	cancer
649890; HMR 1275		•	kinase inhibitor	
-	···-	hydroxy-1-methyl-4-		
		pipendinyl)-4H-1-	<u>. </u>	
		benzopyran-4-one		
CYC 202	Preclinical		cyclin denendent	and and a
			kinase inhibitor; anortosis inducer	
tumor necrosis factor	Pre-		cytokine	10000
alpha, natural; TNF	registration			Calice
alpha, natural;				
tonermin; MHR 24				٠
granulocyte-colony stimulating factor	Preclinical		cytokine agonist	cancer
agonists,				
Pharmacopeia;				
granulocyte-colony		-		
stimulating factor				
agonists, Regeneron				
interferon agonists,	Preclinical	J	cytokine agonist;	cancer; viral
Ligand				infection; infectious
				disease; multiple
				sclerosis
ap,	Preclinical		cytokine antagonist	cancer; asthma;
Negeneron				rheumatoid arthritis;
		-		allergy
antagonist, Peptor	Preclinical	<u>o s</u>	cytokine antagonist;	cancer
		2	יייייייייייייייייייייייייייייייייייייי	

SD-144110.1

CNI 1493	Phase I	N N'-bief3 5 bief1	2010	
		(1)	cytokine syntnesis inhibitor	сапсет
		hydrazono]ethyl]phen		
		yl]-decanediamide tetrahydrochloride		
drug delivery system, Preclinical	Preclinical		cytokine:	Cancer
IL-2, Biovector			biotechnology	Too Imp
Therapeutics			(9)	
delivery system, gene Preclinical	Preclinical		cytokine;	cancer
therapy, IL-2,			biotechnology: gene	
Biovector			therapy:	
Therapeutics; gene			mmunostimulant	
therapy, IL-2,		-		
Biovector				
Therapeutics		- 1		
cytotoxic lymphocyte Discontinued	Discontinued		cytokine;	cancer
maturation factor;			immunostimulant	
CLMF				
5501; ILX	Phase I		diarylsulfonylurea	cancer
295501		henyl)amino		
		[carbonyl]-2,3-		
		dihydro-5-		
		benzofuransulfonami		
sulofenur; LY 186641 Discontinued	Discontinued	N-1774-		
		henvilaminolo	dial yishiloliyimea	cancer
		arbonyll-2,3-dihydro-		
		1H-indene-5-		
		sulfonamide		
AN 9; PIVANEX	Phase II	d (2,2-	differentiation inducer	cancer
			-	
		oxopropoxy)methyl	-	
		Calci		

SD-1441101

CBHA	Preclinical	N-hvdroxv-3-f3-	differentiation inducer Longer	Concor
		(hydroxyamino)-3-		
		oxo-1-propenyl]-		*
		benzamide		
EMBA	Preclinical	diethyl bis-	differentiation inducer	cancer
		(pentamethylene-		
		Z,Z		
		dimethylcarboxamide		
)malonate		
hexamethylene	Phase II	N,N'-1,6-	differentiation inducer cancer	cancer
bisacetamide;		hexanediylbisacetami		
HMBA; NSC 95580; HEXABID		qe		
NF 036	Preclinical	8-[(7-chloro-4-	differentiation inducer cancer	cancer
		nyl)amino]-		
		1,3,5-		٠
		naphthalenetrisulfonic		
		acid trisodium salt		
SAHA; SW 064652	Preclinical		differentiation inducer cancer	cancer
11 00	Preclinical		differentiation inducer cancer	cancer
			-	
		bis(phenylmethyl)-		
		2,4-		
		diazabicyclo[4.2.0]oct		
		ane-3,5-dione	_	
CDDO	Preclinical	2-cyano-3,12-	differentiation inducer; cancer	cancer
		(11)-	antiproliferative agent	
		dien-20-01c acid		

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	Marketed	9-cis-retinoic acid	differentiation inducer; cancer; psoriasis retinoid agonist; RAR agonist	cancer; psoriasis
AG 187	Discontinued	2,4-diamino-6-(N-(4- dihydrofolate (phenylsulfonyl)benz reductase inhibitor yl)methylamino)quina zoline	dihydrofolate reductase inhibitor	cancer
LY 298207	Preclinical	N-[4-[4-(2,4-diamino-dihydrofolate 5- pyrimidinyl)butyl]ben 20yl-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
LY 316373	Preclinical	N-[4-[3-(2,4-diamino-dihydrofolate 5- pyrimidinyl)propyl]be nzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[[(3,4,5- dihydrofolate trimethoxyphenyl)amireductase inhibitor; no]methyl]-2,4- antifolate; NSAID quinazolinediam ine		cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, Discontinued methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued		dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Dhace I	N 1 1 1 10 10 4 4:500	11:1-11:00 E-1-4.	
	r mase r	14-[4-[4-4-ulanino-dinydrololate	umydroioiate	cancer; transplant
		of the office of	leduciase innibitor;	rejection;
		VII-4-methylene-DI a imminosiinnressant	inginosimpressant	rneumatord artumus;
		glutamic acid	minatio suppressant	astimita
eniluracil; 5-	Phase III	5-ethynyl-	dihydropyrimidine	cancer
ethynyluracil; 5-EU;			dehydrogenase	
776C85; BW 776C85		pyrimidinedione	inhibitor;	
			antimetabolite	
spirogermanium;	Discontinued		DMARD; NSAID	malaria; multiple
INSC 192905; SPIKO-		dimethyl-2-aza-8-		sclerosis; rheumatoid
25		germaspiro[4.5]decan		arthritis; cancer
acridine-derived	Preclinical		DNA intercalator	100000
bisintercalators, NIH				CallCo
anticancer agents,	Discontinued		DNA intercalator	cancer
KKO				
BBR 2778	Phase I		DNA intercalator	cancer
		aminoethyl)amino]be		
-		nz[g]isoquinoline-		
		5,10-dione (Z)-2-		
- 1		butenedioate (1:2)		
bisnafide; DMP 840	Phase II		DNA intercalator	cancer
		s[imino(1		
		-methyl-2,1-		
		ethanediyl)]]bis[5-		
		nitro-1H-		
		benz[de]isoquinoline-		
		1,3-(2H)dione]	-	
		dimethanesulfonate		
	Discontinued	Ţ	DNA intercalator	cancer
BW A502U; BW 502U83	Discontinued	- 13°	DNA intercalator	cancer

i SD-144110.1

nyl)ami 1,3- DNA intercalator 1,3- DNA intercalator 1[2-(5- 0-1H- inolin- inolin- do[3,4- do[3,4 ino]-2- ino]-2- bethyl] NYano[4 1-8-ol DNA intercalator inoline- ionate DNA intercalator ionate DNA intercalator ionate inoline- ionate DNA intercalator ionate ionate DNA intercalator ionate ionate inoline- ionate DNA intercalator ionate	ı	1.	,,,		
chrysenylmethyl)ami no]-2-methyl-1,3- propanediol Discontinued Preclinical [R-(R*,R*)]-5-[1- methyl-2-[[2-[2-(5- nitro-1,3-dioxo-1H- benz[de]isoquinolin- 2(3H)- yl)propyl]amino]ethyl Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate 4,6(5H)dione dimethylamino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol -5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione	natoi	Discontinued	-6)]-7	DNA intercalator	cancer
propanediol Discontinued Preclinical [R-(R*,R*)]-5-[1- Discontinued [R-(R*,R*)]-1- Discontinued [R-(R*,R*)]-1 Discon	mesilate; BW		chrysenylmethyl)ami		
Preclinical [R-(R*,R*)]-5-[1-DNA intercalator methyl-2-[[2-[[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]amino]ethyl Hhbenzolde]pyrido[3,4-glisoquinoline-4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[2-diethylamino)ethyl] S-[2-diethylamino)ethyl]	770U82; BWA 770U		no]-2-methyl-1,3-		
Discontinued Preclinical [R-(R*,R*)]-5-[1-DNA intercalator methyl-2-[[2-[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]amino]ethyl Jamino]ethyl Ja			propanediol		
Preclinical [R-(R*,R*)]-5-[1- DNA intercalator methyl-2-[[2-[[2-(5- nitro-1,3-dioxo-1H- benz[de]isoquinolin-2(3H)- yl)propyl]amino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline-4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[(2- aminoethyl)amino]-2-[2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4-3,2-cd]indazol-8-ol dimethylamino)ethyl]- 2-[2- dimethylamino)ethyl]- 5-nitro-1H- benz[de]isoquinoline-13,2H-dione	D 1411	Discontinued		DNA intercalator	cancer
methyl-2-[[2-[2-(5- nitro-1,3-dioxo-1H- benz[de]isoquinolin- 2(3H)- yl)propyl]amino]ethyl Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate 4,6(5H)dione aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione	DMP 315	Preclinical	[R-(R*,R*)]-5-[1-	DNA intercalator	cancer
hitro-1,3-dioxo-1H- benz[de]isoquinolin- 2(3H)- yl)propyl]amino]ethyl Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione			methyl-2-[[2-[[2-(5-	_	
benz[de]isoquinolin- 2(3H)- yl)propyl]amino]ethyl Jamino]ethyl-4H- Benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [3-5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione			nitro-1,3-dioxo-1H-	-	
2(3H)- yl)propyl]amino]ethyl Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [3,2-cd]indazol-9-ol [3,2-cd]indazol-9-ol [3,2-cd]indazol-9-ol [3,2-cd]indazol-9-ol [3,2-cd]indazol-9-ol [3,2-cd]indazol-9-ol			benz[de]isoquinolin-		
yl)propyl]amino]ethyl Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- ZH- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol			2(3H)-		
Jamino]ethyl-4H- benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [1,3,2-cd]indazol-8-ol [3,2-cd]indazol-8-ol [4,3,2-cd]indazol-8-ol [5,2-cd]indazol-8-ol [6,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol [7,2-cd]indazol-8-ol			yl)propyl]amino]ethyl		
benzo[de]pyrido[3,4- g]isoquinoline- 4,6(5H)dione dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione]amino]ethyl-4H-		
glisoquinoline- 4,6(5H)dione dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1,3(2H)-dione			benzo[de]pyrido[3,4-		
4,6(5H)dione dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol 3,2-cd]indazol-8-ol [2-[2- dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-			g]isoquinoline-		
dimethanesulfonate 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-			4,6(5H)dione		
958 Phase II 5-[(2- aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-			dimethanesulfonate		
aminoethyl)amino]-2- [2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-	ledoxantrone; CI 958	Phase II	5-[(2-	DNA intercalator	cancer
[2- (diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-	isomer; PD 121373		aminoethyl)amino]-2-		
(diethylamino)ethyl]- 2H- [1]benzothiopyrano[4 ,3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1 3(2H)-dione			[2-		
2H- [1]benzothiopyrano[4 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-			(diethylamino)ethyl]-		
[1]benzothiopyrano[4] 3,2-cd]indazol-8-ol Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline- 1.3(2H)-dione			2H-		
Phase II 2-[2- DNA intercalator (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-13(2H)-dione			[1]benzothiopyrano[4		
Phase II 2-[2- (dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-			,3,2-cd]indazol-8-ol		
(dimethylamino)ethyl]-5-nitro-1H- benz[de]isoquinoline-				DNA intercalator	cancer
]-5-nitro-1H- benz[de]isoquinoline- 1.3(2H)-dione	3002888		no)ethyl		
benz[de]isoquinoline-]-5-nitro-1H-		
1.3(2H)-dione			benz[de]isoquinoline-		
			1,3(2H)-dione		

S 160202; S 16020-2; Phase II	Phase II	N-f2-	DNA intercalator	Cancer
S 16020; NSC 659687; NSC D659687		thylamino)ethyl droxy-5,6- 1yl-6H- [4,3- azole-1- amide		
cyclopentanthraquino Preclinical nes, Sloan Kettering Institute	Preclinical		DNA intercalator; anthraquinone	cancer
OC 4845	Preclinical		DNA intercalator; anthraquinone	cancer
		irino[2',3':3,4]cyclope nta[1,2-a]anthracene- 5,10-dione		
C 1311	Phase I	no)ethvI]a	DNA intercalator; DNA tonoisomerase	cancer
		mino]-8-hydroxy-6H-inhibitor imidazo[4,5,1- delacridin-6-one	nhibitor	
NLP 1	Preclinical		tor;	cancer
		ımıdazol-1- yl)propyl]phenanthrid inium bromide	adiosensitizer	

aphidicolin glycinate; Preclinical	Preclinical	glycine,	DNA polymerase	cancer
NSC 303812		(3alfa,4alfa,5alfa,17al inhibitor fa)-3,17-dihydroxy-4-	inhibitor	
		methyl-9,15-cyclo-		
		C,18-dinor-14,15-		
		secoandrostane-4,17-		
		dimethanol ester		
		hydrochlonde		
DNA polymerase betaDiscontinued	Discontinued		DNA polymerase	cancer
inhibitors, Agouron	·- <u>-</u>		inhibitor;	
		-	radiosensitizer;	
			chemosensitizer	
NU/ICRF 505	Discontinued		DNA topoisomerase	cancer
			inducer	
UCT 4B; UCTB 4	Discontinued		ooisomerase	bacterial infection;
	•	[1,2,3,4,4a,7,8,8a-		cancer
	٠.	octahydro-3-hydroxy-		
		5-(hydroxymethyl)-		
		1,2,4a-trimethyl-4-	-	
		oxo-1-		
		naphthalenyl]ethyl]-		
		alpha-oxo-		
		oxiraneacetaldehyde		
-6	Phase II	(S)-10-amino-4-ethyl-DNA topoisomerase		cancer
aminocamptothecin;		4-hydroxy-1H-		-
9-AC; NSC 603071		pyrano[3',4':6,7]indoli		-
(S); NSC 629971 (+,-		zino[1,2-b]quinoline-		
); FCE 28044		3,14(4H,12H)-dione		
AMP 53; azonafide	Discontinued		ooisomerase	cancer
7		<u> </u>	innibitor	

asulacrine; amsalog;	Phase I	9-[[2-methoxy-4-	DNA topoisomerase	cancer
SN 21407		l(incuty)suitonytjami no]phenyl]amino]-	ınınıoıtor	
		N,5-dimethyl-4- acridinecarboxamide		
azatoxin; NSC	Preclinical	(5R-cis)-5,6,11,11a-	DNA topoisomerase	cancer
640737		tetrahydro-5-(4-	inhibitor	
<u>.</u>		hydroxy-3,5-	. 1010	
-		dimethoxyphenyl)-		
		1H,3H-	-	
		oxazolo[3',4':1,6]pyri		
2000. 10		do 3,4-b indol-3-one		
88601 FR	Discontinued	2-(5-amino-4,7-	DNA topoisomerase	cancer
		dihydro-1-methyl-	inhibitor	
	-	4,7-dioxo-1H-indol-		
		3-yl)-4-		
		thiazolecarboxamide		
BE 13793C	Discontinued	12,13-dihydro-1,11-	DNA topoisomerase	cancer
		dihydroxy-5H-	inhibitor	
		indolo[2,3-	-	
		a]pyrrolo[3,4-		
		c]carbazole-5,7(6H)-	-	
BE 22179	Discontinued		DNA topoisomerase	cancer
			inhibitor	
BN 80915	Phase I		DNA topoisomerase	cancer
			nhibitor	
BNP 1350	Phase I		DNA topoisomerase	cancer
			inhibitor	
BNPI 1100	Preclinical		oisomerase	cancer
		1	inhibitor	

BO 2367	Discontinued	Discontinued (-)-7-[1R*,2R*,6R*)- DNA topoisomerase 2-amino-8-	DNA topoisomerase	cancer
		azabicyclo[4.3.0.]- non-3-en-8-vI]-1-		
		cyclopropyl-6,8- difluoro-1 4-dibydro-		
-		4-0x0-3-		
		quinolinecarboxylic acid		
camptothecin	Preclinical		DNA topoisomerase	cancer
analogues, Research Triangle Institute			inhibitor	
camptothecin derivatives, Daiichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-	DNA topoisomerase	cancer
			inhibitor	
		methylethyl)amino]et		
		11. 11. 11. 11. 11. 11. 11. 11. 11. 11.		
		pyrano[3',4':6,7]indoli zino[1,2-b]quinoline-		
DM II 33	Dreclinical	3,14(4H,12H)-dione	DNA tons	
	r recitiiicai		LIVA topoisomerase inhibitor	cancer
DNA topoisomerase	Preclinical		DNA topoisomerase	cancer
inhibitor, second			inhibitor	
XR 5942 series: XR				
5942				
DRF 1042	Preclinical		DNA topoisomerase	cancer
			inhibitor	

drug delivery system, Preclinical	reclinical		DNA tonoisomerase	Cancer
camptothecin;			inhibitor	
camptothecin delivery				
system; MPI 5019				
•	Phase I		DNA topoisomerase	cancer
liposome lurtotecan;			inhibitor	
lurtotecan liposome;				
drug delivery system. Preclinical	reclinical		DNA tonoisomersea	***************************************
microsphere 10-		1	inhibitor	Calloci
hydroxycamptothecin				
; 10-				
hydroxycamptothecin				
microsphere				
DX 8951; DX 8951f Phase II		(1S-trans)-1-amino-9-DNA topoisomerase	DNA topoisomerase	cancer
	•	ethyl-5-fluoro-	inhibitor	
		1,2,3,9,12,15-		
		hexahydro-9-		
		nydroxy-4-methyl-		
		10H,13H-		
		penzo[de]pyrano[3',4'		
		:6,7]indolizino[1,2-	-	
		olquinoline-10,13-		
		lione		
		monomethanesulfonat		
	7			

ER 37328 12,13-diby-dibydroxy-indolo[2,3-a]pyrrolo[3] c]carbazole dione 12,13-diby-dibydroxy-indolo[2,3-a]pyrrolo[3] c]carbazole 12,13-diby-dibydroxy-indolog 12,13-diby-dibydroxy-indolog 12,13-dibydroxy-indolog 12,	osyl- dro-1,11- 5H-	1.1.1.1.1.2.	CALICE
	dihydroxy-5H-		
	indolo[2,3-		
	a]pyrrolo[3,4-		
	c]carbazole-5,7(6H)-		
-	dione		
	12,13-dihydro-5-[2-	DNA topoisomerase	cancer
	(dimethylamino)ethyl inhibitor	nhibitor	
]-4H-		
	benzo[c]pyrimido[5,6		
	,1-jk]carbazole-		
	4,6,10(5H,11H)-		
	trione		
	[5R-	oisomerase	cancer
0084	1		
_	a,9beta(R*)]]-5-[3,5-	-	
	dimethoxy-4-	-	
	(phosphonooxy)phen	-	
-	yl]-9-[[4,6-0-		
	ethylidene-2,3-bis-O-		
	[(pentafluorophenoxy		
	(acetyl]-beta-D-		
	glucopyranosyl]oxy]-	-	
	5,8,829-	-	
-	tetrahydrofuro[3',4':6,		
	7]naphtho[2,3-d]-1,3-		
	dioxol-6(5aH)-one		

reclinical hase I	Phase 1 5,6-dihydro-6-	UNA topoisomerase	cancer
reclinical hase I	[3,6,13-trihydroxy-3-	inhibitor	
reclinical hase I	methyl-4-		
reclinical hase I farketed	(phosphonooxy)-		
reclinical hase I	1,7,9,11-		
reclinical hase I farketed	tridecatetraenyl]-2H-		
reclinical hase I farketed	pyran-2-one		
reclinical hase I farketed	monosodium salt		
hase I		DNA topoisomerase	cancer
hase I		inhibitor	
farketed	11-[[3-	DNA topoisomerase	cancer
farketed	(dimethylamino)prop	inhibitor	
farketed	yl]amino]-8-methyl-		
farketed	-HL		
farketed	benzo[e]pyrido[4,3-		
tecan Marketed t; 05; TO;	b]indol-3-ol		
	ted (1,4'-bipiperidine)-1'- DNA topoisomerase	Π	cancer
	carboxylic acid (S)-	inhibitor	
	4,11-diethyl-		
	3,4,12,14-tetrahydro-	-	
	4-hydroxy-3,14-		
	dioxo-1H-		
	pyrano(3',4':6,7)indoli		
	zino(1,2-b)quinolin-		
IRKAN 9-yl ester	9-yl ester,		
monohyd	monohydrochloride		

Discontinued Phase I Discontinued Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical	lurtotecan; lurtotecan dihydrochloride; GG 211; GI 147211; GI	Suspended	(S)-8-ethyl-2,3- dihydro-8-hydroxy- 15-[(4-methyl-1-	DNA topoisomerase inhibitor	cancer
Discontinued Di	147211A; GI 147211C		piperazinyl)methyl]- 11H-1,4-dioxino[2,3-		
b]quinoline- Discontinued Disc		 	Silvatio (2,4.0,7) mid olizino [1,2-	·.	
Discontinued Phase I N-(12-beta-D- BNA topoisomerase glucopyranosyl- 5,7,12,13-tetrahydro- 1,11-dihydroxy-5,7- dioxo-6H-indolo[2,3- a]pyrrolo[3,4- c]carbazol-6-yl)- formamide Discontinued 6-[[[2- Gumethylamino)ethyl inhibitor Jamino]carbonyl]-5- Inydroxy-10- methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical Bhase I 1-Hydroxy-2- DNA topoisomerase inhibitor Caclphenanthridinium, sulfate (1:1) (salt)			b]quinoline- 9,12(8H,14H)-dione		
Phase I N-(12-beta-D- DNA topoisomerase glucopyranosyl- inhibitor 5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl)-formamide (dimethylamino)ethyl inhibitor Jamino]carbonyl]-5-hydroxy-10-methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical cid monosodium salt phase I 1-Hydroxy-2- DNA topoisomerase methoxy-12-methyl-inhibitor [1,3]benzodioxolo[5,6-c]phenanthridinjum, sulfate (1:1) (salt)	MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
glucopyranosyl- 5,7,12,13-tetrahydro- 1,11-dihydroxy-5,7- dioxo-6H-indolo[2,3- a]pyrrolo[3,4- c]carbazol-6-yl)- formamide Discontinued 6-[[[2-	NB 506	Phase I		DNA topoisomerase	cancer
1,11-dihydroxy-5,7- dioxo-6H-indolo[2,3- a]pyrrolo[3,4- c]carbazol-6-yl)- formamide Discontinued 6-[[[2- dimethylamino)ethyl inhibitor Jamino]carbonyl]-5- hydroxy-10- methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical Preclinical Preclinical DNA topoisomerase inhibitor DNA topoisomerase inhibitor [1,3]benzodioxolo[5,6 -c]phenanthridinjum, sulfate (1:1) (salt)				inhibitor	
dioxo-6H-indolo[2,3- a]pyrrolo[3,4- c]carbazol-6-yl)- formamide Discontinued 6-[[[2-			1.11-dihydroxy-5.7-		
a]pyrrolo[3,4- c]carbazol-6-yl)- formamide Discontinued 6-[[[2-			dioxo-6H-indolo[2,3-		
c]carbazol-6-yl)- formamide Discontinued 6-[[[2-			a]pyrrolo[3,4-		
Discontinued 6-[[[2-			c]carbazol-6-yl)-		
O Discontinued 6-[[[2-			formamide		
(dimethylamino)ethyl inhibitor Jamino]carbonyl]-5- hydroxy-10- methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical DNA topoisomerase inhibitor Thase I 1-Hydroxy-2- methoxy-12-methyl- [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)	NC 190; NCU 190			DNA topoisomerase	cancer
Jamino]carbonyl]-5- hydroxy-10- methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical DNA topoisomerase inhibitor Phase I 1-Hydroxy-2- methoxy-12-methyl- [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)			(dimethylamino)ethyl	inhibitor	
hydroxy-10- methoxybenzo[a]phen azine-9-carboxylic acid monosodium salt Preclinical Phase I 1-Hydroxy-2- methoxy-12-methyl- [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)			[amino]carbonyl]-5-		
Preclinical acid monosodium salt Preclinical DNA topoisomerase inhibitor Phase I 1-Hydroxy-2- DNA topoisomerase methoxy-12-methyl- inhibitor [1,3]benzodioxolo[5,6] -c]phenanthridinium, sulfate (1:1) (salt)			hydroxy-10-		
Preclinical acid monosodium salt Preclinical DNA topoisomerase inhibitor Phase I 1-Hydroxy-2- DNA topoisomerase methoxy-12-methyl- inhibitor [1,3]benzodioxolo[5,6-c]phenanthridinium, sulfate (1:1) (salt)			methoxybenzo[a]phen		
Preclinical Phase I 1-Hydroxy-2- methoxy-12-methyl- [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)			azine-9-carboxylic		
Phase I 1-Hydroxy-2- DNA topoisomerase methoxy-12-methyl- inhibitor [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)	NCA 0465			oisomerase	cancer
Phase I 1-Hydroxy-2- DNA topoisomerase methoxy-12-methyl- [1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (salt)				nhibitor	
<u> </u>		Phase I			cancer
[1,3]benzodioxolo[5,6 -c]phenanthridinium, sulfate (1:1) (sait)				nhibitor	
-c]phenanthridinium, sulfate (1:1) (sait)			[1,3]benzodioxolo[5,6]	÷	
Sulfate (1:1) (sail)			-c]phenanthridinium,	:-	
			surface (1.1) (sait)		

NU/ICRF 500	Discontinued		DNA topoisomerase	cancer
NU/ICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer
polyethylene glycol-	Preclinical		DNA topoisomerase	cancer
camptothecin; PEG-			inhibitor	
camptothecin;		٠		
camptothecin		-		
macrogol;				
PROTHECAN				
	Phase III		DNA topoisomerase	cancer
tothecin;			inhibitor	
RFS 2000				
sobuzoxane; MST 16; Marketed	Marketed	1,2-	DNA topoisomerase	cancer
PERAZOLIN		ethanediylbis[(2,6-	inhibitor	
	-	dioxo-4,1-		
		piperazinediyl)methyl		
		ene]bis(2-		
		methylpropyl)		
		carbonic acid ester		
TAN 1496	Discontinued		oisomerase	cancer
			inhibitor	

TAN 1518A	Discontinued	Discontinued 2-hydroxybenzoic	DNA tonoisomerase	Concer
		acid 3-	inhibitor	
		(aminocarbonyl)-8-		
		[2,6-dideoxy-4-0-(2-		-
		methyl-1-oxo-2-		
		butenyl)hexopyranosy		
		<u></u>		
		1,4,4a,6,11,11a,12,12		
		a-octahydro-2,4a,5,7-		
	,	tetrahydroxy-11-		
		methoxy-11-methyl-		
		4,6-dioxo-1-		
		naphthacenyl ester		
TAS 103	Phase I	6-[[2-	DNA topoisomerase	cancer
		(dimethylamino)ethyl inhibitor	inhibitor	
	•	Jamino]-3-hydroxy-	-	
		7H-indeno[2,1-		
		c]quinolin-7-one		
teniposide; VM 26;	Marketed		DNA topoisomerase	cancer
NSC 122819;			inhibitor	
VUMON; BEKNOS;		8a,9-		
VEHEM SANDOZ		tetrahydro-5-(4-		
		hydroxy-3,5-		
		dimethoxyphenyl)-9-		
		[[4,6-0-(2-		
		thienylmethylene)-		
		beta-D-		
		glucopyranosyi]oxy]f		
		uro[3',4':6,7]naphtho[-	
		2,3-d]-1,3-dioxol-		
		6(5aH)-one		
			7	

TOP 53	Phase I	[5R-	DNA topoisomerase	cancer
		(5alpha,5abeta,8aalph inhibitor a,9beta)]-9-[2-[[2-	inhibitor	
		(dimethylamino)ethyl		
		[methylamino]ethyl]-		
-		5,8,8a,9-tetrahydro-5-		
		(4-hydroxy-3,5-	•	
		dimethoxyphenyl)fur		
		o[3',4':6,7]naphtho[2,		-
		3-d]-1,3-dioxol- 6(5aH)-one		··-
topoisomerase	Preclinical		DNIA to	
inhibitor, Biota			pita topousomerase inhihitor	cancer
topotecan;	Marketed	(S)-10-	DNA tonoisomeros	
hycamptamine; SKF		(dimethylamino)met		calicei
104864; SKF		hyl]-4-ethyl-4.9-		
104864A;		dihydroxy-1H-		
HYCAMTIN		pyrano[3',4':6,7]indoli		
		zino[1,2-b]quinoline-		
WIN 63320	Discontinued		DNA topoisomerase	cancer
			inhibitor	
WIN 64593	Discontinued		DNA topoisomerase	cancer
			inhibitor	
	Phase I	N-[2-	DNA topoisomerase	cancer
601316; DACA		(dimethylamino)ethyl inhibitor	inhibitor	
		J-4-		
		acridinecarboxamide		

AD 312	Dreclinical	1/00 0:00 00 000001110	114	
		[[3-[[](2- inhibitor;	inhibitor:	cancer
	***	chloroethyl)nitrosoam anthracycline;	anthracycline;	
		ino]carbonyl]amino]- alkylating agent; 2.3,6-trideoxy-alfa-L-antibiotic	alkylating agent; antibiotic	
		lyxo-		
		hexopyranosyl]oxy]-		
		7,8,9,10-tetrahydro-	·	
		0,6,11-mhydroxy-1- methoxy,5,12		
		naphthacenedione		
elsamitrucin;	Discontinued	10-[[2-0-(2-amino-	DNA topoisomerase	cancer
elsamicin A; BMY		2,6-dideoxy-3-0-	inhibitor; antibiotic	
28090; INSC 369327;		methyl-alfa-D-		
BMS 181171	-	galactopyranosyl)-6-	• • •	
		deoxy-3-C-methyl-		
		beta-D-		
		galactopyranosyl]oxy		
]-6-hydroxy-1-		
		methylbenzo[h][1]ben		
		zopyrano[5,4,3-		
	_	cde][1]benzopyran- 5.12-dione		
DNA topoisomerase	Preclinical		DNA tonoisomerase	Cancer, mycoeie.
inhibitors, AVAX			inhibitor; antifungal	parasitic infection
Technologies				
elinafide; LU 79553	Phase I	2,2'-[1,3-	DNA topoisomerase	cancer
		0	inhibitor; DNA	
		2,1-ethanediyl)]bis- i	intercalator	
		benz[de]isoquinolone		
		211010-(117-)-(1		

LU 55446	Discontinued		DNA topoisomerase	cancer
			inhibitor; DNA	
docomposito. AT 1		1000	intercalator	
dosergoside; A.F. 1	Discontinued	[8beta(1S,2R,3E)]-N- dopamine agonist	dopamine agonist	cancer; infertility
		(hydroxymethyl)-3-		
		heptadecenyl]-6-		
		methylergoline-8-		
drug delivery system, Pre-	Pre-		donamine aponist	disheter oberiter.
bromocriptine;	registration			cancer, oucoury,
bromocriptine				
delivery system;	··			
ERGOSET				
ST 557	Discontinued		dopamine agonist;	cancer
		Ī	immunostimulant	
0/018	Discontinued		dopamine agonist;	cancer
T			immunostimulant	
	Preclinical		EGF receptor inhibitor cancer	cancer
inhibitors, SUGEN				
LFM A12	Preclinical		Γ	cancer
		hydroxy-N-[4- ji	inhibitor; tyrosine	
)phe	inase inhibitor	
		ny]-2-butenamide		

ABT 627. A 122722	. M	003		
A 147677	, rnase II	-27]	endothelin antagonist;	
14/07/		(2alpha, 3beta, 4alpha) endothelin A	endothelin A	myocardial
	··-]-4-(1,3-benzodioxol- antagonist	antagonist	infarction
	-	[5-yl]-1-[2-		
		(dibutylamino)-2-		
		oxoethyl]-2-(4-		
_		methoxyphenyl)-3-		
		pyrrolidinecarboxylic		
		acid		
BE 14348B	Discontinued	2(S),3(S)-3-methyl-	estrogen agonist	cancer
		4',5,7-trihydroxy-		
		flavanone		
GW 5638	Preclinical	(E,Z)-3-[4-(1,2-	estrogen agonist;	osteoporosis; cancer;
		diphenyl-1-	antiestrogen	coronary artery
		butenyl)phenyl]-2-		disease
		propenoic acid		-
CP 336156	Phase II	(5R,6S)-5,6,7,8-	estrogen partial	osteoporosis; cancer
		henyl-	agonist	
		5-[4-[2-(1-		
		pyrrolidinyl)ethoxy]p		
		henyl]-2-naphthalenol		
		(28,38)-2,3-		
		dihydroxybutanedioat		
2-methoxyeetradio1	Dreolinion	c (1.1) (sait)		
2-ME	recuilical		estrogen; angiogenesis cancer inhibitor	cancer
estrogen receptor	Preclinical		hormone	hormone deficiency:
therapy,		<u> </u>	<u> </u>	contraception;
Ligand/Wyeth Ayerst	_			cancer; osteoporosis
EMATE	Discontinued	3-	ulfatase	cancer
		[(aminosulfonyl)oxy]-inhibitor	inhibitor	
-		estra-1,3,5(10)traen- 17-one		
		Suc 15		

cancer					cancer							cancer				cancer				cancer		
ether lipid					ether lipid	 4	<u>-</u>					ether lipid				ether lipid				ether lipid		
4-amino-1-[5-O-[1,3- ether lipid dihydroxy-6-[(1-	oxohexyadecyl)oxy]- 2,4-dioxa-8-thia-1,3-	diphosphahexacos-1-	arabinofuranosyl]-	2(1H)-pyrimidinone P,P'-dioxide	Ι.		trimethyl-3,5,9-	trioxa-4-	phosphaheptacosan-1-	aminium hydroxide	inner salt, 4-oxide		(octadecyloxy)ethoxy]ethoxy]butyl]pyridini	um methanesulfonate		tetradecyl-2-0-	palmitoyl-1-	thioglycerol	4		phosphonylcholine
Preclinical					Pre-	registration						Preclinical				Preclinical				Preclinical		
ara-CDP-DL-PTBA; Preclinical CYTOROS	·.				edelfosine; ET 18-	OCH3; ALP						EG 6	,		J	ether lipid, Roswell	Fark			ether lipid,	Vancouver University	

ilmofosine; BM	Discontinued	4-hvdroxv-7-	ether linid	Cancer
41440; BM 21440				
		N,N,N-trimethyl-3,5-		
		dioxa-9-thia-4-		
		phosphapentacosan-1-		
		aminium hydroxide,		
		inner salt, 4-oxide		
miltefosine;	Marketed	2	ether lipid	cancer: leishmaniasis
hexadecylphonylcholi		[[(hexadecyloxy)hydr	•	
ne; HPC; D 18506;		oxyphosphinyl]oxy]-		
MILTEX		-Z,Z,Z		
		trimethylethanaminiu		
		m, hydroxide, inner		
		salt		
ie; D 21266;	Phase I	4-	ether lipid	cancer
NKA 17		[[hydroxy(octadecylo		
		xy)phosphinyl]oxy]-		
	_	1,1-		
		dimethylpiperidinium	ě	
		inner salt	-	
	Discontinued		ether lipid	cancer
SRI 62834 I	Discontinued	(+,-)- 2-	ether lipid	cancer: multiple
	•	[[hydroxy[[tetrahydro	•	sclerosis
	•	-2-		
_		[(octadecyloxy)methy		
		1]-2-		
		furanyl]methoxy]phos		
		phinyl]oxy]-N,N,N-		
		trimethyl-		
		ethanamium, inner		
		salt.		
ILC ELL 12; ELL 12Phase I	Phase I	9	ether lipid	cancer

SDZ 62826	Discontinued		ether lipid;	cancer
			immunostimulant	
etoposide phosphate; Marketed	Marketed	(5R,5aR,8aR,9S)-5-	etoposide analogue	cancer
BMY 40481;		[3,5-dimethoxy-4-		
ET OPOPHOS		(phosphonooxy)phen		-
		yl]-9-[(4,6-0-(1R)-		
		ethylidene-beta-D-		
		glucopyranosyl)oxy]-		
		5,8,8a,9-		
		tetrahydrofuro[3',4':6,		
		7]naphtho[2,3-d]-1,3-		
		dioxol-6(5aH)-one		
IGT 13	Preclinical		etoposide analogue	cancer
NK 611; VP 19; 2'-	Phase II	[5R-[5alpha,5a-	etoposide analogue	cancer
tethylamino)etopo				
side		alpha,9beta(R*)]]-9-		-
		[[2-deoxy-2-		
		(dimethylamino)-4,6-		
		O-ethylidene-beta-D-		
		glucopyranosyl]oxy]-		
		5,8,8a,9-tetrahydro-5-		
		(4-hydroxy-3,5-		
		dimethoxyphenyl)fur		
•		o[3',4':6,7]naphtho[2,		
		3-d]-1,3-dioxol-		
		6(5aH)-one		
		hydrochloride		
!				

	Dhose II	feb		
×		(5alpha,5abeta,8aalph DNA topoisomerase a,9beta)]-5,8,8a,9- inhibitor tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)-9- [(4- nitrophenyl)amino]fur o[3',4':6,7]naphtho[2, 3-d]-1,3-dioxol- 6(5aH)-one	DNA topoisomerase inhibitor	
ARGLABIN	Registered		farnesyl protein transferase inhibitor	cancer
B 956	Preclinical	[2S-	farnesyl protein	
		,3Z,5R*,6E,8S*)	transferase inhibitor	calicel
	•]-N-[8-amino-9-		
		mercapto-5-(1-		
		methylethyl)-1-oxo-2-		
		(phenylmethyl)-3,6-		
		nonadienyl]-L- methionine		
farnesyl transferase	Discontinued	-	farnesyl protein	cancer
innibitors			transferase inhibitor	
L 639749	Preclinical			cancer
			transferase inhibitor	

cancer	cancer	cancer	cancer	cancer	cancer	cancer
farnesyl protein 1[R*(R*)],2R*(S),3 transferase inhibitor 1[R*(R*)],2R*(S),3 transferase inhibitor 2*]-2-[[2-[[2-amino- nercaptopropyl]amin	farnesyl protein	farnesyl protein	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor
[2S- [1[R*(R*)],2R*(S),3 R*]]-2-[[2-[[2-amino-3- mercaptopropyl)amin o]-3- methylpentyl]oxy]-1- oxo-3- phenylpropyl]amino]- 4-(methylsulfonyl)- butanoic acid, 1- methylethyl exter			4-(1-methylethenyl)- fractional fraction fractio	·	## ##	17. TT
Preclinical	Phase I	Preclinical	Phase II	Preclinical	Preclinical	Preclinical
L 744832	L 778123	PD 169451	perillyl alcohol; NSC Phase II 641066	ras farnesyl protein transferase inhibitors, Parke Davis	orotein chibitors,	35

SCH 50228	Dreclinical	1 /2 12000 0 2112		
027/2 1100	r recilliteat	1-(3-010110-6-cillolo- tarifesyl protein 6 11-dibydro-5H-	tantesyi protein transferase inhibitor	cancer
		benzo[5,6]cyclohepta[נו מוואוסונסו	
		1,2-b]pyridin-11-yi)-		
		4-[(1-oxido-4-		
		pyridinyl)acetyl]piper		
L 731734	Discontinued		famesvi protein	cancer
		[3R*[2R*[2R*(S*),3	transferase inhibitor;	
		S*],3R*]]]-2-[[2-[(2- p	peptide	
		amino-3-	.:	
		mercaptopropyl)amin		
		0]-3-	•	
		methylpentyl]amino]-		
		3-methyl-N-	-	
		(tetrahydro-2-oxo-3-		•
		furanyl)pentanamide		
L 731735	Discontinued		farnesyl protein transferase inhibitor;	cancer
		mercaptopropyl)amin peptide	peptide	
		o]-3-methylpentyl]-L-		
	-	isoleucyl]-L- homoserine		
R 115777	Phase II		farnesyl protein	cancer
			transferase inhibitor;	
			signal transduction	
			inhibitor	
SCH 66336	Phase II		farnesyl protein	cancer
			transferase inhibitor;	
			signal transduction	
			THIOTIOI	

(Salpha, Sabeta, Saalph inhibitor a, 9beta)]-9-[2-[[2- (dimethylamino)ethyl] 5,8,8a,9-tetrahydro-5- (4-hydroxy-3,5- dimethoxyphenyl],fur o[3',4':6,7]naphtho[2, 3-d]-1,3-dioxol- ((SaH)-one Marketed (S)-10- [(dimethylamino)met inhibitor hyl]-4-ethyl-4,9- dihydroxy-1H- pyrano[3',4':6,7]indoli zino[1,2-b]quinoline- 3,14(4H,12H)-dione Discontinued Discontinu	TOP 53	Phase I	[5R-	DNA topoisomerase	cancer
Preclinical Marketed (S)-10- SKF [(dimethylamino)met inhibitor hyl]-4-ethyl-4,9- dihydroxy-1H- pyrano[3',4':6,7]indoli zino[1,2-b]quinoline- 3,14(4H,12H)-dione Discontinued Discontinue			eta, 8aalph [2-[[2- nino)ethyl no]ethyl]- rahydro-5- rahydro-5- 3,5- hienyl)fur iaphtho[2, xxol-	inhibitor	
SKF [(dimethylamino)met inhibitor hyl]-4-ethyl-4,9- dihydroxy-1H- pyrano[3',4':6,7]indoli zino[1,2-b]quinoline- 3,14(4H,12H)-dione Discontinued J-4- acridinecarboxamide	topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
SKF [(dimethylamino)met inhibitor hyl]-4-ethyl-4,9- dihydroxy-1H- pyrano[3',4':6,7]indoli zino[1,2-b]quinoline- 3,14(4H,12H)-dione Discontinued Disc	topotecan;	Marketed	(S)-10-	DNA topoisomerase	cancer
pyrano[3',4':6,7]indoli zino[1,2-b]quinoline- 3,14(4H,12H)-dione Discontinued Discontinued Discontinued Discontinued Discontinued Discontinued Discontinued Discontinued Inhibitor Discontinued Inhibitor Discontinued Inhibitor J-4- acridinecarboxamide	hycamptamine; SKF 104864; SKF		[(dimethylamino)met hyl]-4-ethyl-4,9-	inhibitor	
Discontinued Disco	HYCAMTIN		pyrano[3',4':6,7]indoli zino[1.2-blquinoline-		
Discontinued DNA topoisomerase inhibitor Discontinued DNA topoisomerase inhibitor Phase I N-[2- DNA topoisomerase (dimethylamino)ethyl inhibitor 1-4- acridinecarboxamide			3,14(4H,12H)-dione		
Discontinued DNA topoisomerase inhibitor Phase I N-[2- DNA topoisomerase (dimethylamino)ethyl inhibitor 1-4- acridinecarboxamide	WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
Phase I N-[2- DNA topoisomerase (dimethylamino)ethyl inhibitor]-4- acridinecarboxamide	WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
(dimethylamino)ethyl i]-4- acridinecarboxamide				Γ	cancer
J-4- acridinecarboxamide	601316; DACA		(dimethylamino)ethyl	inhibitor	
acridinecarboxamide			J-4-		
			acridinecarboxamide		

BIM 26028	Discontinued	.	gastrin antagonist;	cancer; cachexia;
CDP 845	Discontinued		Coloting antagomst	respinatory disease
	Danimued		gelatinase innibitor; matrix	cancer
			metallonroteinase	
			inhibitor; proteinase	
			inhibitor; angiogenesis	
			inhibitor	
CT 1746	Discontinued		gelatinase inhibitor;	cancer
			matrix	
			metalloproteinase	
			inhibitor; proteinase	
			innibitor	
gelatinase inhibitors,	Preclinical		gelatinase inhibitor;	cancer
Celitech	٠		matrix	
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor	
basal cell carcinoma	Preclinical		gene	cancer: skin disease
therapy, Ontogeny;				
patched gene; ptc				
gene				
bcl-6-based non-	Preclinical		gene	cancer
Hodgkin's lymphoma)	
cancer therapy cancer Preclinical	Draclinical			
cell growth genes			. אביזוכ	cancer
ď,	Preclinical		gene	cancer
Axys; melanoma		-		
therapy, Axys	-			
HFE-based therapies, Preclinical	Preclinical		ene	iron overload; cancer
4 10 Semitor				

immune system	Preclinical		gene	autoimmune disease;
modulators, Chiroscience		·		rheumatoid arthritis; cancer; HIV
melanoma differentiation-	Discontinued		gene	cancer
associated genes MMAC1 based therapy, Myriad	Preclinical		gene	cancer
rapy,	Preclinical		gene	cancer
MTS3 based therapy, Preclinical Myriad; cancer therapy, Myriad	Preclinical		gene	cancer
mum-1-based cancer therapy	Preclinical		gene	cancer
based cancer Amplicon	Preclinical		gene	cancer
prostate tumor- inducing genes	Discontinued		gene	cancer; diagnosis
Tase	Preclinical		gene therapy; biotechnology	cancer
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen: INGN 231	Preclinical		gene therapy; biotechnology	cancer
1	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Preclinical	:	gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer

gene therany cancer	Draclinical			
Yourself)	I common		gene merapy; biotechnology	cancer
gene therapy, cancer,	Preclinical		gene therapy:	cancer
Cobra Therapeutics;			biotechnology	
CTL 102; TXS 0202			(9,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1	
gene therapy, cancer,	Preclinical		gene therapy:	cancer: respiratory
pulmonary disease			biotechnology	disease
gene therapy,	Preclinical		gene therapy:	cancer
hepatocellular			biotechnology	
carcinoma; HepXia			(9)	
gene therapy, ovarian Preclinical	Preclinical		gene therapy:	cancer
and pancreatic cancer			biotechnology	
gene therapy, ovarian Preclinical	Preclinical		gene therapy:	cancer
cancer; gene therapy,		•	biotechnology	10011110
brca1, MB 700			(9)	
gene therapy, p16,	Preclinical		gene therapy:	restenosis: cancer
p27; gene therapy,		•	biotechnology	Continues, cancer
restenosis; gene			6	
therapy, cancer				
	Phase I		gene therapy:	cancer
gene therapy, cancer			biotechnology	
gene therapy,	Preclinical		gene therapy;	cancer
scr V/gamma G250;			biotechnology	
gene therapy, renal			3	-
carcinoma				
gene therapy, stress	Preclinical		gene therapy;	cancer
			biotechnology	
	Phase I		gene therapy;	cancer
unymidine kinase;			biotechnology	
gene therapy, cancer;			} ·	
gone merapy, no-tk				

gene therapy,	Preclinical		gene therapy;	cancer
thymidine kinase;			biotechnology	
gene therapy, glioma			3	
gene therapy, tumor	Preclinical		gene therapy;	cancer
antigens; gene			biotechnology	
therapy, cancer			3 .	
gene therapy, ATF	Preclinical		gene therapy:	cancer
BTPI; gene			biotechnology;	
therapy, cancer			angiogenesis inhibitor	
gene therapy,	Preclinical		gene therapy;	cancer
colorectal cancer,			biotechnology:	
Oxford BioMedica;			angiogenesis inhihitor	
CoRectoGen				
ğ	Preclinical		gene therapy;	cancer
Oxford Biomedica;			biotechnology;	
GlioStat			angiogenesis inhibitor	
gene therapy, ovarian Preclinical	Preclinical		gene therapy;	cancer
cancer, Oxtord			biotechnology;	
BioMedica; BetOvaC			angiogenesis inhibitor	
gene therapy, prostate Preclinical	Preclinical	3	gene therapy:	cancer
cancer; ProCaStat		<u> کی</u>	biotechnology;	
		8	angiogenesis inhibitor	
	Phase I	OL.	gene therapy;	cancer
			biotechnology;	
Transgene; gene		_0	cytokine;	
therapy, cancer		. • •	immunostimulant	
gene therapy, wt p53; Preclinical	Preclinical	OU,		cancer
gene therapy, cancer		م د		
-			radiosensitizer;	
		3	chemosensitizer	

vaccine, gene-based, colorectal cancer;	Phase I		gene therapy; biotechnology: vaccine	cancer
vaccine, gene-based,		· ·		•
GA 7332		· ·	•	
vaccine, gene-based,	Preclinical		gene therapy;	cancer
human papilloma virus			biotechnology; vaccine	
progression elevated genes	Discontinued		gene; angiogenesis	cancer
glutathione inhibitors, Discontinued Telik	, Discontinued		glutathione inhibitor	cancer
AG 2026	Discontinued		glycinamide ribotide	cancer
			formyltransferase inhibitor	
AG 2032	Discontinued		glycinamide ribotide	cancer
			formyltransferase	
AG 2034	Phase I	(S)-N-[[5-[2-(2-	glycinamide rihotide	Cancer
		amino-4,6,7,8-		
		1H-	inhibitor	
		pyrimido[5,4-		
		0][1,4]thiazin-6-		
		thienyl]carbonyl]-L-	-	
AG 2037	Preclinical		glycinamide ribotide	cancer
			formyltransferase	
			inhibitor	
contortrostatin; CN	Preclinical		glycoprotein IIb/IIIa	cancer; thrombosis
			antigement, platelet	
		<u>, L</u>	dinaggregant; biotechnology	

mannostatin A	Preclinical	[1R-	glycosidase inhibitor	cancer
		(1alpha,2alpha,3alpha ,4alpha,5beta)]-4-	· · · · · · · · · · · · · · · · · · ·	
		amino-5-		
	-	(methylthio)-1,2,3-		
		cyclopentanetriol		
glycosidase inhibitor, Preclinical	Preclinical		glycosidase inhibitor:	cancer: rheumatoid
Oxford			NSAID	arthritis
GlycoSciences				מז וווו זווי
drug delivery system,	Preclinical		gonadorelin agonist	cancer
ATRIGEL sustained		•	10111292	Tooling.
release leuprorelin;	*			
leuprorelin ATRIGEL				
drug delivery system, Phase III	Phase III		gonadorelin agonist	cancer:
microparticle				endometriosis
buserelin; buserelin	•			
microparticle delivery				
system			-	
drug delivery system,	Clinicals		gonadorelin agonist	cancer
sustained release				
LHRH analogue;				
LHRH analogue				
delivery system;				
ProMaxx, LHRH				
analogue; ProMaxx				
100	•			

dimethylethyl)-D- serine]-1-9- luteinizing hormone- releasing factor (swine) 2- (aminocarbonyl)hydra zide Marketed 6-D-leucine-9-(N- i 0-deglycinamide- luteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Marketed 6-D-tryptophan- gonadorelin agonist factor (swine) Marketed 6-D-tryptophan- gonadorelin agonist factor (swine) Rawine)	goserelin; goserelin	Marketed	6-f0-(1,1-	gonadorelin agonist	cancer:
Warketed 6-[3-(2- Marketed 6-[3-(3-(3-(3-(3-(3-(3-(3-(3-(3-(3-(3-(3-(3	acetate; ICI 118630;		dimethylethyl)-D-)	endometriosis;
luteinizing hormone- releasing factor (swine) 2- (aminocarbonyl)hydra zide G-D-leucine-9-(N- ethyl-L-prolinamide)- 10-deglycinamide 10-deglyci	ZOLADEX		serine]-1-9-		infertility
releasing factor (swine) 2- (aminocarbonyl)hydra zide G-D-leucine-9-(N- i0-deglycinamide)- i0-deglycinamide inteinizing hormone- releasing factor (swine) Marketed G-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Phase II Rarketed G-D-tryptophan- gonadorelin agonist luteinizing hormone- releasing factor (swine) Sonadorelin agonist luteinizing hormone- releasing factor (swine)			luteinizing hormone-		•
(swine) 2- (aminocarbonyl)hydra zide G-D-leucine-9-(N- gonadorelin agonist ethyl-L-prolinamide- luteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- gonadorelin agonist naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist factor (swine) Phase II gonadorelin agonist luteinizing hormone- releasing factor (swine) Sonadorelin agonist luteinizing hormone- releasing factor (swine)		-	releasing factor		
(aminocarbonyl)hydra zide G-D-leucine-9-(N- gonadorelin agonist ethyl-L-prolinamide- luteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- gonadorelin agonist naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist factor (swine) gonadorelin agonist luteinizing hormone- releasing factor (swine) gonadorelin agonist luteinizing hormone- releasing factor (swine)			(swine) 2-		
Marketed 6-D-leucine-9-(N-gonadorelin agonist ethyl-L-prolinamide)- 10-deglycinamide luteinizing hormone-releasing factor (swine) Marketed 6-[3-(2-gonadorelin agonist naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone-releasing factor (swine) Rarketed 6-D-tryptophan-gonadorelin agonist luteinizing hormone-releasing factor (swine) Swine) Savine)			(aminocarbonyl)hydra		
Marketed 6-D-leucine-9-(N-gonadorelin agonist ethyl-L-prolinamide)- 10-deglycinamide 10	1,		zide		
ethyl-L-prolinamide)- 10-deglycinamide 10-deglycinamide Iuteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist Iuteinizing hormone- releasing factor (swine) gonadorelin agonist luteinizing hormone- releasing factor (swine)	leuprorelin;	Marketed	6-D-leucine-9-(N-	gonadorelin agonist	cancer;
4; 10-deglycinamide luteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone- releasing factor (swine) gonadorelin agonist luteinizing hormone- releasing factor (swine)	leuprorelin acetate;		ethyl-L-prolinamide)-		endometriosis
luteinizing hormone- releasing factor (swine) Marketed 6-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone- releasing factor (swine) Sonadorelin agonist luteinizing hormone- releasing factor (swine)	leuprolide; TAP 144;		10-deglycinamide		
releasing factor (swine) Marketed 6-[3-(2- gonadorelin agonist naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone-releasing factor (swine) Sonadorelin agonist luteinizing hormone-releasing factor (swine)	TAP 144SR;		luteinizing hormone-		
Marketed 6-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Marketed 6-D-tryptophan- luteinizing hormone- releasing factor (swine)	ABBOTT 43818;		releasing factor		
Marketed 6-[3-(2- alanine]-luteinizing hormone-releasing factor (swine) Marketed 6-D-tryptophan- luteinizing hormone- releasing factor (swine)	LUPRON; CARCIN;		(swine)		
Marketed 6-[3-(2- naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone- releasing factor (swine)	LEUPLIN; LUPRON				
Marketed 6-[3-(2- naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist Iuteinizing hormone- releasing factor (swine)	DEPOT; PROSTAP	•			
Marketed 6-[3-(2- gonadorelin agonist naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone-releasing factor (swine) Sonadorelin agonist luteinizing hormone-releasing factor (swine)	ST; PROSTAP SR;				
Marketed 6-[3-(2- gonadorelin agonist naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone-releasing factor (swine) Sonadorelin agonist luteinizing hormone-releasing factor (swine)	ENANTONE				
naphthalenyl)-D- alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist luteinizing hormone- releasing factor (swine)	nafarelin; nafarelin	Marketed	-	gonadorelin agonist	cancer:
alanine]-luteinizing hormone-releasing factor (swine) Phase II gonadorelin agonist Marketed 6-D-tryptophan- releasing factor (swine)	acetate; D-Nal(2)6				endometriosis:
hormone-releasing factor (swine) Phase II gonadorelin agonist Marketed 6-D-tryptophan-gonadorelin agonist releasing factor (swine)	LHRH; RS 94991;		alanine]-luteinizing		infertility
Phase II gonadorelin agonist Marketed 6-D-tryptophan-gonadorelin agonist releasing hormone-releasing factor (swine)	RS 94991 298;		hormone-releasing		
Phase II gonadorelin agonist Marketed 6-D-tryptophan-gonadorelin agonist luteinizing hormone- releasing factor (swine)	SAMYNAREL;		factor (swine)	-	
Phase II gonadorelin agonist Marketed 6-D-tryptophan-gonadorelin agonist luteinizing hormone-releasing factor (swine)	SYNAREL;				
Phase II gonadorelin agonist Marketed 6-D-tryptophan-gonadorelin agonist luteinizing hormone-releasing factor (swine)	NASANYL		- X		
Marketed 6-D-tryptophan- gonadorelin agonist luteinizing hormone-releasing factor (swine)	RL 0903	Phase II		gonadorelin agonist	cancer
luteinizing hormone- releasing factor (swine)	triptorelin; BN	Marketed		gonadorelin agonist	cancer; precocious
releasing factor (swine)	52014; BIM 21003;				puberty;
7 42462; (swine)	AY 25650; CL		releasing factor		endometriosis
ARVECAP; DECAPEPTYL	118532; WY 42462;		(swine)		
DECAPEPTYL	ARVECAP;				_
	DECAPEPTYL				

leuprolide + estrogen Phase I + progesterone	Phase I		gonadorelin agonist; estrogen; progestogen	contraception; cancer
gonadotropin releasing hormone	Preclinical		gonadorelin agonist; gonadorelin antagonist	cancer
analogue, conjugated;				
copolymer conjugate				
avorelin	Phase II	5-oxo-L-prolyl-L- gonador	elin agonist;	cancer; precocious
	· · ·	histidyl-L-tryptophyl-		puberty;
	•	L-seryl-L-tyrosyl-2- methyl-D-tryptophyl-		endometriosis
·		L-leucyl-L-arginyl-N-ethyl-L-prolinamide		
em,	Phase I	-	gonadorelin agonist;	precocious puberty;
histrelin hydrogel			peptide	cancer
hydrogel implant				
A 84861	Phase I		gonadorelin antagonist cancer	cancer
lix; PPI 149; R	Phase III		gonadorelin antagonist cancer; benign	cancer; benign
3827				prostate
		alanyl-4-chloro-D-		hypertrophy;
		phenylalanyl-3-(3-		endometriosis
		pyridinyl)-D-alanyl-		
		L-seryl-N-methyl-L-		
		asparaginyl-I -N6-(1-		
		methylethyl)-L-lysyl-		
		L-prolyl-D-		
		alanınamıde		

cetrorelix; SB 75; SB Registered	Registered	N-Acetyl-3-(2-	gonadorelin antagonist infertility; cancer:	infertility; cancer:
075; CETROTIDE		naphthalenyl)-D-		endometriosis;
		alanyl-4-chloro-D-		benign prostate
		phenylalanyl-3-(3-		hypertrophy:
		pyridinyl)-D-alanyl-		contraception
		L-seryl-L-tyrosyl-N5-	-	4
-		(aminocarbonyl)-D-		
-		omithyl-L-leucyl-L-		
		arginyl-L-prolyl-D-		
		alaninamide		
D 20453	Discontinued		gonadorelin antagonist cancer	cancer
D 21775; T 148	Discontinued	Discontinued N-acetyl-3-(2-	gonadorelin antagonist cancer	cancer
)	
		alanyl-4-chloro-D-		
		phenylalanyl-3-(3-		
		pyridinyl)-D-alanyl-	•	
		L-seryl-L-tyrosyl-N6-		
		[N-acetyl-3-		
		(acetylamino)-L-		
		alanyl]-D-lysyl-L-		
		leucyl-L-arginyl-L-		
		prolyl-D-alaninamide		
D 23487	Discontinued	Unspecified	gonadorelin antagonist cancer	cancer
D 26344	Preclinical		gonadorelin antagonist cancer: infertility	cancer infertility
		X	Service mine commence	current, miles milly

detirelix; RS 68439	Discontinued	Discontinued N-acetyl-3-(2-	gonadorelin antagonist contracention: cancer	Contracention: cancer
		naphthalenyl)-D-	0	
		alanyi-4-cnioro-D- Phenvialanvi-D-		
		tryptophyl-L-seryl-L-		
		tyrosyl-N6-		
		[bis(ethylamino)meth		
		ylene]-D-lysyl-L-		
		leucyl-L-arginyl-L-		
	_	prolyl-D-alaninamide		-
drug delivery system,	Discontinued		gonadorelin antagonist cancer;	cancer;
AIKIGEL sustained				endometriosis
release ganirelix;				
ganirelix ATRIGEL				
drug delivery system,	Discontinued		gonadorelin antagonist endometriosis:	endometriosis:
ATRIGEL sustained				cancer
release GnRH		-		
antagonists			:	
drug delivery system,	Preclinical		gonadorelin antagonist cancer: contraception	cancer: contracention
microcapsule SB 75;				
SB 75 microcapsule				
	Preclinical	3	gonadorelin antagonist contracention: cancer	contracention: cancer
releasing hormone				
antagonists, Alanex				
	Preclinical	3.0	gonadorelin antagonist cancer	Sancer
releasing hormone		<u>.</u>		
antagonist, Agouron;				
GnRH antagonist,				
Agouron				
HOE 2013	Suspended		gonadorelin antagonist cancer;	ancer;
				endometriosis

t cancer	cancer; endometriosis; precocious puberty
gonadorelin antagonist cancer	gonadorelin antagonist; peptide
N-acetyl-3-(2- naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-D-tr yptophyl-L-seryl-L- tyrosyl-O-(6-deoxy- alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide	N-[3-(4-fluorophenyl)-1-oxopropyl]-3-(1-naphthalenyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide
Phase II	Preclinical
ramorelix; HOE 013 Phase II	A 76154

teverelix;	Phase I	N-acetyl-3-(2-	gonadorelin	cancer;
ANTARELIX		naphthalenyl)-D-	antagonist; peptide	endometriosis;
-		alanyi-4-chloro-L-		infertility
		phenylalanyl-3-(3-		
		pyridinyl)-D-alanyl-		
		L-seryl-L-tyrosyl-N6-		
		(aminocarbonyl)-D-	•	
	_	lysyl-L-leucyl-N6-(1-		
		methylethyl)-L-lysyl-		
-		L-prolyl-D-		
deslorelin: BACHEM Marketed	Marketed	S ove I medial	11:10:00	-
9022; SOMAGARD		-lvi	gonadorenn superagonist	cancer; precocious
-		L-seryl-L-tyrosyl-D-	0	(troopal
		tryptophyl-L-leucyl-		
	•	L-arginyl-N-ethyl-L-		
drug delivery eyetem	Dreclinical	DIOIIIIAIIIIUC	11.	
declarelin implant:			gonadorenn	cancer;
destoreim impiant,			superagonist	gynecological;
desionellii iiiipiani				infertility
nematology	Discontinued		growth factor	cancer
cytokines, AMRAD;				
hematology				
cytokines, Chugai				
hematopoietic growth Preclinical	Preclinical		growth factor	cancer; bacterial
factor mimetics,				infection; anemia
Ligand				
GM 1306	Preclinical	3	growth factor	diabetes;
		ı	modulator	retinopathy; cancer
GM 1474	Preclinical	Unspecified	growth factor	cancer
		Jesi 	modulator	
Keratinocyte growth factor antagonist	Preclinical		growth factor	cancer
			nodulator, peptitie	

nepatocyte growth	Preclinical		growth factor;	cancer
factor related			biotechnology;	
proteins; HGF-related			chemoprotectant:	
proteins			cytoprotectant	
CMI SAF9	Preclinical		growth factor;	cancer
			hematopoietic factor	
thrombopoietin; TPO Phase II	Phase II		growth factor;	cancer;
-			hematopoietic factor;	thrombocytopenia
		٠	biotechnology	
Tie-2 ligands,	Preclinical		growth factor;	cancer; restenosis;
Regeneron;			hematopoietic factor;	retinopathy; skin
angiogenesis ligands,				ulcer;
Regeneron			angiogenesis inhibitor; atherosclerosis;	atherosclerosis;
			angiogenesis inducer	peripheral vascular
				disease
SB 251353	Preclinical		growth factor;	cancer
			hematopoietic factor;	
			immunostimulant	
	Phase II	1-[N2-[N-(N-acetyl-	hematoprotectant;	cancer
seraspenide; BN		L-seryl)-L-alpha-	chemoprotectant;	
52040; BIM 32001		aspartyl]-L-lysyl]-L-	peptide	
pentosan polysulfate	Marketed	sta-D-xvlan	henarinoid.	orthrition or or inch
			NGAID	armerlinidemia,
68; CARTROPHEN;		sulfate), sodium salt		riypempioenna;
LASONIL;				cancer exception
ELMIRON;				cancer, eysuus
LELONG MOUSSE				
MAXAMINE	Phase III		histamine agonist;	cancer; viral
			ist	infection: henatitis

MAP 30	Preclinical	N2-IN-IN-IN2-	HIV integrase	LITY infaction:
		(N-L-threonyl-L-	inhibitor	cancer
		isoleucyl)-L-lysyl]-L-		
		threonyl]-L-threonyl]- L-threonyl]-L-ivsine		
lovastatin; mevinolin; Marketed	Marketed	(S)-2-methylbutyric	HMG CoA reductase	hynerlinidemis
monakolin K; MK		acid, 8-ester with	inhibitor	rij portipiaciiila,
803; MSD 803; MB		(4R.6R)-6-[2-		Calicol
530B; L 154803;		[(1S.2S.6R.8S.8aR)-		
MEVACOR;		1.2.6.7.8.8a-	- ••	
MEVLOR;		hexahvdro-8-	•••	
LOVACOL;		hydroxy-2.6-		
HIPOVASTIN;		dimethyl-1-		
DISLIPIN;		naphthyllethylltetrahy	-	
LOVASTEROL;		dro-4-hvdroxv-2H-		
LINCIL	•	pyran-2-one		
cancer therapy, Oxis	Preclinical		hormone	cancer
drug delivery system,	Preclinical		hormone	Osteonorosis. Paget
PEPTITROL				dispace. cancer
calcitonin; calcitonin			•	aroare, carren
PEPTITROL			٠	
drug delivery system, Preclinical	Preclinical		hormone	precocione nuberty:
subcutaneous				processors publicy,
gonadotropin				Cancer contracention
releasing hormone;		•		omicos, comacopinon
gonadotropin				-
releasing hormone			•	
subcutaneous				
implant; GnRH				
subcutaneous implant				
glycoprotein hormone Preclinical	Preclinical		ormone	infertility: cancer
superagonists, NIH		•		mediuity, cancol

Preclinical				cancer
gonadotropin beta; beta hCG				cancer
	Preclinical		hormone; apoptosis inhibitor; antiproliferative agent;	cancer
1			differentiation inducer	
gallium nitrate; NSC 15200; CALSTAT;	Marketed	gallium nitrate nonahvdrate	hypocalcemic; nitric	hypercalcemia;
. 1			inhibitor	cancer
AS 101; IVXQ 101;	Phase II	(SP-5-22)-ammonium immunostimulant	immunostimulant	HIV infection.
		trichloro(1,2-		cancer
		ethanediolato(2-)-		
		0,0')-tellurate		
	Suspended	N2-[[[5-[6-	immunostimulant	cancer
		(dimethylamino)-9H-		
		purin-9-		
		yl]pentyl]oxy]carbon		
ľ	;	yı)-D-algımile		
	Phase II		immunostimulant	cancer
		niercaptoetnyt)- propanamide		
	Pre-	-9-om	immunostimulant	cancer: viral
J 54461; U 54461S;	registration			infection
		pyrimidinone		
	Phase II	3,6-bis(2-	immunostimulant	viral infection: HIV
		piperidinoethoxy)acri		nfection: cancer
7		dine trihydrochloride		
7	Discontinued		mmunostimulant	cancer
<u> </u>	Preclinical	<u> </u>	mmunostimulant	cancer
		-	-	
1		z-memyi-т-senne		

DNA repair	Preclinical		immin ortina	
enhancers, OXiGENE	(1)			cancer
drug delivery system, Phase III liposome muramyl	Phase III		immunostimulant	cancer
tripeptide-				
phosphatidylethanola				
mine; drug delivery				
system, liposome MTP-PE: MTP-PF		·		
liposome				
FCE 24578	Discontinued	-	immunostimulant	cancer; bacterial
		N,1-	٠.	Intection
		diphenyl[1]benzothio	•	
		pyrano[4,3- c]pyrazole-3-		
4		propanamide		
FCE 25276	Suspended		immunostimulant	cancer; bacterial
FCE 25648	Suchended			mechon
	naniradeno		ımmunostımulant	cancer; bacterial
FCE 25651	Suspended	,	immunostimulant	cancer; bacterial
FR 001235		\neg		infection
	Discontinued		immunostimulant	cancer
		2-(2-oxopropyl)-1H-	•••	
		phenalene-1,3(2H)-		
	$\neg \neg$	dione		
HAB 439	Discontinued	dro-3-	immunostimulant	cancer; bacterial
		isoxazolyl)phosphoni		infection
		c acid		

icadamines, Comell Research Foundation	Preclinical		immunostimulant	viral infection;
idramantone;	Phase I	5-	immunostimulant	cancer
Kemantane		hydroxytricyclo[3.3.1 [1(3,7)]decanone		
imiquimod; R 837; S	Marketed	1-(2-methylpropyl)-	immunostimulant	viral infection;
20308; DZ 2036; ALDARA; ZARTRA		lH-imadazo[4,5- clquinolin-4-amine		cancer
immunostimulant,	Preclinical		immunostimulant	cancer infections
Repligen;		er est		disease
immunostimulant, Pfizer		: : -	*	
immunostimulants,	Preclinical	٠	immunostimulant	cancer: autoimmune
Massachusetts General Hospital				disease
JT 3002; CGP 40774	Preclinical		imminostimilant	Cancer
KRN 7000	Phase I	[1S-(1R*,2R*,3S*)]-	immunostimulant	cancer
	<u> </u>	galactopyranosyloxy)		
		methyl]-2,3-		
		dihydroxyheptadecyl] hexacosanamide		
arge multivalent mmunogen: LMI	Preclinical		immunostimulant	cancer
×	Pre-			4 444 4
	registration		ımmunostımulanı	cancer; HIV
LIMONAL; EMONAL	· -			
ate.	Marketed			
LENTINAN	TATA VCICA		ımmunostımulant	HIV infection; cancer
LK 409	Preclinical	N-(1,7-dioxooctyl)-L-immunostimulant		cancer
		alanyl-D-alpha- glutamine		
Y				

loxonbine; KWJ 21757	Discontinued 7-allyl-8-	7-allyl-8-	immunostimulant	cancer
		oxoguanosine		
mirmostim; human	Marketed	1-214-colony-	immunostimulant	cancer
urne denved		stimulating factor 1		
stimulating factor		(human clone		
inducer; CSF-HU; P		p3ACSF-69 protein		
100; LEUKOPROL; COSTILATE		moiety reduced)		
MMS 2	Preclinical		immunostimulant	Cancer
Nocardia-CWS; N-	Discontinued		imminostimulant	Concor
CWS; rubratine;				Calloci
OM 163	Dreatinical			
201 100	riconnical	Unspecified	ımmunostimulant	cancer
OM 1/4	Phase I		immunostimulant	cancer
RG 003; RG 136	Discontinued		immunostimulant	HIV infection;
2000				cancer
KM 06	Discontinued		immunostimulant	cancer; transplant
		dihydro-6-oxo-9H-		rejection
		1)		
		yi)pentyi joxy jcarbon		
		yl]-L-leucyl]-L-		
		methionine		
romurtide;	Marketed		immunostimulant	cancer; bacterial
muroctasin; MDP-		[(R)-1-[[(S)-1-[[(R)-		infection
Lys (L18); MDP-Lys;		1-carbamoyl-3-[((S)-		
DJ 7041; NOPIA		1-carboxy-5-		
-		stearamidopentyl)carb		
		amoyl]propyl]carbam		
		oyl]ethyl]carbamoyl]e		
		thyl]-2-deoxy-D-		
		glucopyranose		-

RS 0481 S 0481	Discontinued	[P_(P*D*)] 2	1	
		benzovl-N-(1-	niminostiniajui	cancer
		phenylethyl)-4-	-	
		thiazolidinecarboxami		·.
S 27609	Discontinued	4-amino-	in min o of image of	
	TO THE PROPERTY OF THE PARTY OF		minimostimulant	cancer
		aipha,alpha,2-		
		trimethyl-1H-		
		imidazo[4,5-		
SRT 172	Dhasa III	-14miioiiiic-1-ciiiaii01		
2/1 7/2	Fnase III		immunostimulant	tuberculosis; cancer;
				asthma; bacterial
				infection; leprosy;
				rhinitis
S1 789; PCF 39	Phase I	N-[5-(hypoxanthin-9-immunostimulant	immunostimulant	cancer; bacterial
		yl)pentyloxycarbonyl]		infection
thromotrinon	7	Ť		
urymotiman,	oabeugeg	_	Immunostimulant	cancer
Inymopoletin 32-34; PGH 0205: TD2		lysyl)-L-aspartic acid		
111 0203, 113				
vaccine, malignant	Phase II		immunostimulant	cancer
melanoma; LP 2307				
vaccine, Maruyama;	Pre-	I	mmunostimulant	cancer
Maruyama vaccine;	registration			
SSM				
noma,	Phase I		mmunostimulant	cancer
University of				io
Pittsburgh; melanoma				
vaccine				
tiprotimod; HBW 538 Discontinued			imulant;	mycosis; cancer
		pyl)thio]-	antifungal	
		4-methyl-5-		
		thiazoleacetic acid		

MGN 3	Phase I	Unspecified	immunostimulant;	cancer
			biological response modifier	
NSC 631570; E	Pre-	5,5',5"-	immunostimulant;	cancer
B238865; UKSR 222;	registration	Lphosphinothioyhdyn biological response etris(imino-2.1-	biological response modifier	
W 122; UKRAIN				
		methylchelidoninium]		
CD40 ligand,	Phase I		immunostimulant;	cancer
minimics, CD40L1			biotechnology	
prolactin	Preclinical		ant;	cancer; infectious
				disease
	•		hormone; vaccine	
			adjuvant	
pentoxifylline:	Discontinued		immunostimulant;	cancer
ciprofloxacin;			chemoprotectant;	
ciprofloxacin:		-	cytoprotectant	
pentoxifylline; CT		-	•	
1500				
acemannan; CARN	Marketed	-ia-	immunostimulant;	inflammatory bowel
1000; CARN 750;		D-galacto-beta-D-	cicatrizant	disease; skin ulcer;
CARRASYN;		mannan acetate		inflammation; cancer
ALIMINASE;				
VORALEX;			-	
CARRAVEX				
tetrachlorodecaoxide; Marketed	Marketed		immunostimulant:	skin ulcer. HIV
TCDO; WF 10;				infection; cancer
OXOFERIN				

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preclinical		immunostimulant; cytokine agonist	cancer; viral infection; bacterial infection
thiethazole	Preclinical	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
tabilautide; RP 56142 Discontinued	Discontinued	yl-L- yl-L- ne	immunostimulant; lipopeptide	bacterial infection; cancer
hemoregulatory peptide, Nycomed	Preclinical		immunostimulant; peptide	bacterial infection;
immunostimulant peptides, BioChem Pharma	Discontinued	·	stimulant;	cancer; viral infection
interleukin-2 receptor Preclinical agonist; IL-2R agonist	Preclinical		immunostimulant; peptide	cancer; HIV infection
SUIS-gonadorelin; SUIS-LHRH	Phase I		immunostimulant; peptide	cancer
thymopoietin receptorPreclinical agonist	Preclinical		stimulant;	cancer; HIV
ubenimex; bestatin; NK 421; BESTATIN	Marketed	(-)-N-[(2S,3R)-3- amino-2-hydroxy-4- phenylbutyryl)]-L- leucine	stimulant;	cancer

THERAMIDE	Suspended		immunostimulant;	cancer; infectious
			peptide; oligosaccharide	disease
monophosphoryl lipidPhase III A + myobacterium	Phase III		immunostimulant; vaccine adjuvant	cancer
cell wall sk;				
wall skeleton +				
monophosphoryl I; MPL + CWS;			-	
DETOX				
D5; PM 92114	Discontinued		immunosuppressant	cancer
dehydrodidemnin B;	Preclinical		immunosuppressant	viral infection;
DDB		dioxopropyl)-L- prolyl]didemnin A		cancer
dinaline; GOE 1734;	Discontinued	4-amino-N-(2-	immunosuppressant	cancer
NSC 328786;		aminophenyl)benzami	:	
		de		
fluasterone	Phase I		immunosuppressant	cancer; diabetes;
				systemic lupus
pusnerimus.	Marketed	(+-)-7-	ta constanting out that the	transalant acceptant
gusperimus,	Polovinia	iminomethv1)	นแนนเบรนมุที่เรารสมเ	transplant rejection; multiple sclerosis:
hydrochloride;		amino]-N-[2-[[4-[(3-		cancer
deoxyspergualin, 15-;		aminopropyl)amino]b		
desoxyspergualin;		utyl]amino]-1-	-	
DSG; NKT 01; NSC		hydroxy-2-		
356894; BMS		oxoethyl]heptanamide		
181173; BMY 42215-				
I, SPANIDIN; SUPANIDIN			•	
promedulan; TERICIMUS	Discontinued		immunosuppressant	cancer

			1	
XENOJECT	Preclinical		immunosuppressant	cancer; autoimmune disease
protein A-based	Preclinical		immunosuppressant;	autoimmune disease;
signal transduction	Preclinical		imminostillinialit	calicel
modulators National	I recimical		immunosuppressant;	autoimmune disease;
Jewish Center for			NSAID	cancer; inflammation
Immunology and			,	***************************************
Respiratory Medicine				
CI 972	Discontinued	2,6-diamino-1,5-	immunosuppressant;	rheumatoid arthritis;
		dihydro-7-(3-	NSAID	cancer; psoriasis
		thienylmethyl)-4H-		
		pyrrolo[3,2-		
		d]pyrimidin-4-one		
olodaitian. O C. A.	A Contract of	mononydrochlonde		
NIGO 10001 17 WILL	ואזקועבובח	z-cmoro-z -	immunosuppressant;	cancer; multiple
NSC 105014F; KWJ		deoxyadenosine	nucleoside analogue;	sclerosis; rheumatoid
26251; LEUSTATIN;			NSAID	arthritis
LEUSTAT;				
MYLINAX				
T cell peptide,	Preclinical		immunosuppressant;	autoimmune disease:
University of Illinois				cancer; bacterial
MAb, BR96 sFv-	Phase I		immunotoxin:	cancer
PE40; SGN 10; BMS			biotechnology	
191352				
MAb, TES-23-	Discontinued		immunotoxin;	cancer
neocarzinostatin; TES-23-NCS		•	biotechnology	

MAb, TP3-pokeweed Preclinical	Preclinical		immunotoxin:	cancer
viral protein		-	biotechnology;	
conjugate;			monoclonal antibody	
immunotoxin, TP3-				
pokeweed viral			-	
protein conjugate;				
TP3-PAP				
MAb, doxorubicin-	Preclinical		immunotoxin;	cancer
CEA; DOX-CEA			biotechnology;	
			monoclonal antibody;	
			anthracycline;	
			antibiotic; DNA	
			intercalator	
drug delivery system, Preclinical	Preclinical	*	integrin antagonist;	cancer
ANCHOR angiostatic		•	angiogenesis inhibitor;	
agent	-		cell adhesion inhibitor	
S 836	Discontinued		integrin antagonist;	cancer
		- 13	angiogenesis inhibitor;	
			cell adhesion inhibitor;	
	-		alpha5 beta3 integrin	
			antagonist	
CDP 850	Preclinical		integrin antagonist;	cancer
			biotechnology; cell	•
			adhesion inhibitor;	
			immunosuppressant;	
			monoclonal antibody;	
			E selectin antagonist	

024IVF4				
		dimethyl-4-	cell adhesion inhibitor	
		(phosphonooxy)-		
		7,9,11-tridecatrienyl]-		
		5-methyl-2H-pyran-2-		
		one		
SB 223245 Pre	Preclinical	(S)-7-[[(1H-	ntegrin antagonist;	osteoporosis;
		benzimidazol-2-	cell adhesion inhibitor restenosis; cancer	restenosis; cancer
		ylmethyl)methylamin		
		o]carbonyl]-2,3,4,5-		
		tetrahydro-4-methyl-		
		3-oxo-1H-1,4-		
		benzodiazepine-2-		
		acetic acid		
	Preclinical		integrin antagonist;	osteoporosis; cancer;
antagonists, DuPont		· O	cell adhesion inhibitor; restenosis	restenosis
			alpha5 beta3 integrin	
		8	antagonist	

cancer; bacterial infection	inflammation; cancer	cancer; inflammation	cancer; inflammation	inflammation; cancer		cancer; rheumatoid
integrin antagonist; can cell adhesion inhibitor; infe immunostimulant; peptide; antibiotic	integrin antagonist; inflacell adhesion inhibitor;	integrin antagonist; canc cell adhesion inhibitor; NSAID	integrin antagonist; canc cell adhesion inhibitor; NSAID	antagonist; esion inhibitor;	}	antagonist;
(alphaS,2R,5S,6R)-6- integrin antagonist; cancer; b ethyltetrahydro-alpha-cell adhesion inhibitor; infection 2-dihydroxy-alpha-immunostimulant; methyl 1-5-(3-pyran-2-acetyl-(3S)-bex ahydroxy-L-leucyl-hex ahydroxy-L-alanylglycyl-(3S)-hexahyd ro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	inte cell NS	inte cell NS	inte cell NS.	integrin cell adh NSAID		inte
_	Preclinical	Preclinical	Preclinical	Discontinued		Preclinical
IC 101	anti-inflammatory agents, Chiroscience/Trega	cell adhesion inhibitor, GlycoTech/Novartis	very system, H cell inhibitors	GM 7050		RGD-based

SD-14411

10 min 10	-			
interpretation of the continued in the c	Discontinued		Interteron	cancer
interferon alfa; interferon alfa depot				
delivery; MPI 7057				
drug delivery system, Preclinical	Preclinical		interferon	cancer; viral
transdermal				infection
BIPHASIX interferon				
alfa; interferon alfa			-	-
transdermal			0	
interferon alfa;	Marketed		interferon	cancer; viral
BALL-1; MR 22;				infection; mucositis;
BALL 1; OIF; IFN		•	•	musculoskeletal
ALPHA MOCHIDA				disorder
interferon alfa;	Marketed		interferon	cancer; viral
Interferon Alfanative			-	infection
interferon alfa-n3;	Marketed		interferon	viral infection;
KEMRON;				cancer
ALFERON;				
ALFERON N;				
ALFERON LDO;				
ALTEMOL;				
REFERON				
interferon beta;	Marketed		interferon	multiple sclerosis;
FKONE		٠		cancer; eye disease
interferon gamma,	Marketed		interferon	cancer
natural; IFN gamma,				
natural; OH 6000;		.~		
OGAMMA 100				
interferon-alpha; IFN-Preclinical	Preclinical		interferon;	cancer; viral
alpha			biotechnology	infection
ron, modified,	Preclinical		interferon;	cancer
Tanox			biotechnology;	
			immunosuppressant	

leukocyte alpha interferon:	Marketed		interferon;	viral infection;
ALFAFERONE; CILIFERON			iminunostimulant	cancer
doretinel; BASF 47011; RWJ 20257;	Discontinued	(E)-1,2,3,4- tetrahydro-7-[2-[4-	keratolytic	cancer
ORF 20257		(hydroxymethyl)phen		
		1,1,4,4-	·	
		tetramethylnaphthalen ol		
U 74389	Preclinical	Unspecified	lazaroid	cancer
U 74500A	Preclinical	21-[4-[3,6-	lazaroid	cerebrovascular
		bis(diethylamino)-2-		disease; cancer
	٠	pyrindinyl]-1- piperazinyl]-16-		
		methylpregna-		
		1,4,9(11)-triene-3,20-	٠	
		dione hydrochloride		
lysofylline;	Phase III		lysophosphatidate	cancer;
isotyline; CT			acyltransferase	cardiovascular
1501R; ProTec		dimethylxanthine	inhibitor; xanthine	disease; respiratory
hreflate, NSC	Droclinical			disease; mucositis
656202: NAS 656202	riconnical	IN,IN-dimetnyl-	macrolide; antibiotic	cancer
		(1R*,2E,6S*,10E,11a		
-		S*,13S*,14aR*)]-		-
		1,6,7,8,11a,12,13,14,1		
		4a-decahydro-1-		
		hydroxy-6-methyl-4-		
		NOTOBERT FOR SERVICE		
		cyclopentrioxacyclor		

duocarmycin SA; DC Discontinued	1	(7bR)-1,2,4,5,8,8a-	macrolide; antibiotic	bacterial infection;
1113		hexahydro-4-oxo-2-		cancer
		[(5,6,7-trimethoxy-	٠	
		1H-indol-2-		
		y])carbonyl]cycloprop		
		a[c]pyrrolo[3,2-		
		e]indole-6-carboxylic		
		acid methyl ester		
rhizoxin; lizoxine	Phase II		macrolide; antibiotic	cancer
drug delivery system,	Discontinued		macrophage	cancer
liposome CGP 31362;			stimulator;	
CGP 31362 liposome;			immunostimulant	
MLV-CGP 31362				
GPX 325	Preclinical		MAO inhibitor;	cancer
			chemoprotectant;	•
			cytoprotectant;	
			radioprotectant	
matrilysin inhibitors, Preclinical	Preclinical		matrilysin inhibitor;	cancer
Attymax			matrix	
-			metalloproteinase	
		.tel	inhibitor; proteinase	-
			inhibitor	
matrix	Discontinued		matrix	arthritis; periodontal
metalloproteinase				disease; skin ulcer;
inhibitors,			inhibitor; cicatrizant;	cancer
Osteo Arthritis;			proteinase inhibitor:	
cartilage degrading			NSAID	
enzyme inhibitors,	-			
Osteo Arthritis;	. ,			
CHONDROPROTEC TORS	•			

metalloproteinase inhibitors CMT 3; COL 3; NSC Phase I (4aS,5aR,12aS)- 683551; METASTAT octahydro- 3,10,12,12a- tetrahydroxy-1,11- dioxo-2- naphthacenecarboxam ide D 1927 Preclinical D 2163 Phase II N4-hydroxy-N1-[1- CS 610; GALARDIN; GALARDIN; methylamino)-2- oxoethyl]-2-(2- methyloronyl)-	Preclinical matrix		cancer
ASTAT Preclinical Phase I Phase I Phase I Phase I Phase II Phase II OOU;	metallo	metalloproteinase	
ASTAT Preclinical Phase I Phase I MPI	inhibito	inhibitor; proteinase	•
Preclinical Phase I MPI MPI	(0-01 d-3 0-1)	Jr.	
Preclinical Phase I Fhase III MPI	(4a5,5aK,12a5)-		cancer
Preclinical Phase I 16001; Phase III C	1,12a-	metalloproteinase	
Preclinical Phase I 16001; Phase III MPI	7,-	inhibitor; proteinase	
Preclinical Phase I Fhase III MPI O		or	
Preclinical Phase I Fhase II MPI O	tetrahydroxy-1,11-	• ••	
Preclinical Phase I Fhase II MPI O	dioxo-2-		
Preclinical Phase I f 6001; Phase III	naphthacenecarboxam		
Preclinical Phase I f 6001; Phase III	ide		
Phase I f 6001; Phase III	nical		cancer
Phase I f 6001; Phase III	metallo	metalloproteinase	
Phase I f 6001; Phase III	. inhibito	inhibitor; proteinase	
Phase I f 6001; Phase III MPI			
1 6001; Phase III MPI	I matrix		cancer
1 6001; Phase III MPI	metallor	metalloproteinase	
1 6001; Phase III MPI	inhibitor	inhibitor; proteinase	
f 6001; Phase III	inhibitor		
MPI	N4-hydroxy-N1-[1-		retinopathy;
MPI	-		diabetes; cancer
		inhibitor; proteinase	
oxoethyl]-2-(2- methylpronyl)-	-5	, 10	
methylpronyl)-	oxoethy1]-2-(2-		
(-C-4	methylpropyl)-		
butanediamide	butanediamide		

marimastat; BB 2516; Phase III TA 2516	; Phase III	(2S,3R)-N4-[(1R)-	matrix	cancer
		ရှ	inhibitor; proteinase	
		nyl]propyl]-N1,,2- dihydroxy-3-(2-	inhibitor	
		methylpropyl)butaned iamide		
matrix	Preclinical		matrix	cancer
metalloproteinase			metalloproteinase	
inhibitors, Agouron			inhibitor; proteinase inhibitor	
S 3304	Phase I			cancer; inflammation
			inhibitor; proteinase	
nrinomastat: AG 3340Phase III	Dhace III	Thenevitied	-	1,
	200		poroteinase	cancer, reunopainy
			inhibitor; proteinase	
			inhibitor; angiogenesis	
			inhibitor	
CH 104	Discontinued	П		cancer; inflammation
		A	metalloproteinase	
			inhibitor; proteinase	
			inhibitor; NSAID	
CH 715	Discontinued			cancer; inflammation
			metalloproteinase	
		· -	inhibitor; proteinase	
		-	inhibitor; NSAID	
matrix	Preclinical			periodontal disease;
metalloproteinase		· · · · · · · · · · · · · · · · · · ·	<u>\</u>	kidney disease;
inhibitor, State		- prod	ase	cancer; arthritis;
University of New				osteoporosis
Total				

matrix	Preclinical		matrix	cancer; arthritis
metalloproteinase			metalloproteinase	
inhibitors, ProScript			inhibitor; proteinase inhibitor; NSAID	
PI 88	Phase I		matrix	inflammation; cancer
		-	metalloproteinase	
			inhibitor; proteinase	
colimatet. DD 2644	DLess 1	000000000000000000000000000000000000000	CINCIO, INSTITUTION	
sonniasial, DD 5044	rnase I	-7,7-(0	matrix :	multiple sclerosis;
		pyridylcarbamoyl)pro inhibitor: TNF	inhibitor: TNF	inflammatory bowel
		pyl]carbamoyl]-2-	inhibitor; proteinase	disease; cancer
		methoxy-5-	inhibitor	
		methylhexanohydroxa		
		mic acid		
BIBW 22; BIBW 22BS	Discontinued		MDR inhibitor	cancer
biricodar; biricodar	Phase II		MDR inhibitor	cancer
dicitrate; VX 710;		trimethoxyphenyl)ace		
INCEL		tyl]-2-		-
		piperidinecarboxylic	-	
		acid 4-(3-pyridinyl)-		
		1-[3-(3-		
		pyridinyl)propyl]buty	:	
		l ester	 2	
	Phase I		MDR inhibitor	cancer
sulfoximine; BSO;		butylsulfonimidoyl)b		
NSC 326231		utanoic acid		

dexniguldipine: (+)-	Discontinued	(R)-1 4-dihydro-2 6- MDD inhihitor	MDD inhibitor	
niguldipine; (R)-			ייינים אומונטונטון	Calical
niguldipine;		nitrophenyl)-3,5-		
niguldipine, (R)-; B		pyridinecarboxylic		
8509035; BY 935		acid 3-(4,4-diphenyl-		
		1-piperidinyl)propyl methyl ester		
drug delivery system,	Discontinued		MDR inhibitor	cancer
liposome ciclosporin;		-		
ciclosporin liposome; CYCLOXOME	·			
flezelastine; D 18024 Preclinical	Preclinical	4-((4-	MDR inhibitor	cancer
		fluorophenyl)methyl)		
		2-(hexahydro-1-		
		(phenylethyl)-1H-	-	
		azepin-4-yl)-1(2H)-		
		phthalazinone		
		monohydrochloride		
H 85	Preclinical	N-[2-[[3-(4-	MDR inhibitor	cancer
		chlorophenyl)-2-	<u></u>	
		propenyl]formylamin	•	
		o]ethyl]-5-	-	
		isoquinolinesulfonam		
LU 49667	Discontinued		MDR inhibitor	cancer
LU 51903	Discontinued		MDR inhibitor	cancer
MDR inhibitor,	Preclinical			cancer
BioNumerik				
MDR inhibitor, Xenova	Preclinical		MDR inhibitor	cancer
MDR inhibitors, Fox	Preclinical		MDR inhibitor	cancer
Chase Cancer Center			~	
	•			

MS 209	Phase II	4-(diphenylacetyl)- MDR inhibitor		cancer
		alpha-[(5-		
	-	quinolinyloxy)methyl		-
		J-1-piperazineethanol,		
		(E)-2-butenedioate		
		(2:3)		
NA 382	Preclinical	Γ,	MDR inhibitor	cancer
		7-oxostaurosporine		
PAK 104P	Preclinical	trans-5-(4,6-dimethyl-MDR inhibitor	MDR inhibitor	cancer
		2-oxido-1,3,2-		
		dioxaphosphorinan-2-	-	
	•	yl)-2,6-dimethyl-4-(3-		
		nitrophenyl)-3-		
		pyridinecarboxylic		
		acid 2-[4-		
		(diphenylmethyl)-1-	-	
		piperazinyl]ethyl	-	
		ester trihydrochloride		
propyl bis-acridone	Preclinical	1,3-bis(9-oxoacridin- MDR inhibitor		cancer
		10-yl)propane		
	Phase I		MDR inhibitor	cancer
Ro 112933	Discontinued N-[2-(3,4-			cancer
		dimethoxyphenyl)eth		
		yl]-N-methyl-2-(2-		
•		naphthalenyl)-1,3-		
		dithiane-2-		•
		propanamine		
		hydrochloride		

S 16209	Preclinical	(+)-4-(2 3-	MDD inhihitor	-00000
		dichlorophenyll-1.4	IONG ITHIN NAME OF THE	calical
		dihvdro-2-methyl-6-	-	
		[[7-[7-[7-[7-		
		nitropnenyi)metnyi ja		
		mino_ethoxy]ethoxy]		
:		methyl]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		
		ester		
S 16317	Preclinical		MDR inhibitor	cancer
-		dihydro-2-methyl-6-		
		[[2-[2-[(4-		
		pyridinylmethyl)amin		
		o]ethoxy]ethoxy]meth		
		yl]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		
		ester		
S 16324	Preclinical	(+)-4-(2,3-	MDR inhibitor	cancer
		dichlorophenyl)-1,4-		
		dihydro-2-methyl-6-		
		[[2-[2-[(3-		
		thienylmethyl)amino]		
		ethoxy]ethoxy]methyl		
]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		
		ester		

0000		ı		
28/88	Discontinued	Discontinued 6-[4-[[2,2-bis(4-	MDR inhibitor	cancer
		7		-
		mino]-1-piperidinyl]-		
		N,N'-di-2-propenyl-		
		1,3,5-triazine-2,4-		
		diamine	-	
SB RA 31012	Preclinical		MDR inhibitor	cancer
SDZ 214103	Discontinued		MDR inhibitor	Cancer
		acid)-4-L-leucine-7-	.	
		L-threonine-10-L-		
		leucinecyclosporin A		
XR 1500	Suspended	Τ-	MDR inhibitor	roccor
CRL 1336	Discontinued		MDR inhibitor:	cancer
·			chemosensitizer	
valspodar; SDZ	Phase III		MDR inhibitor;	cancer
PSC833; PSC 833;			chemosensitizer; P	
SDZ PSC 833;			glycoprotein inhibitor	
AMUKAY		aminooctanoic acid]-		
		7-L-valine-	-	
		cyclosporn A		
elacridar; GF 120918; Suspended		N-[4-[2-(3,4-dihydro-MDR inhibitor; P	MDR inhibitor; P	cancer
016.00		6,7-dimethoxy-2(1H)-glycoprotein inhibitor	glycoprotein inhibitor	
		isoquinolinyl)ethyl]p		
		henyl]-9,10-dihydro-		
		5-methoxy-9-oxo-4-		
		acridinecarboxamide		

umcodar; umcodar	Phase II	(alphaS)-4-chloro-	MDR inhibitor: P	cancer: neuropathy
dimesylate; VX 853			glycoprotein inhibitor	
х-		[methyl[oxo(3,4,5-		
		trimethoxyphenyl)ace		
		tyl]amino]-N-		
		(phenylmethyl)-N-[3-		
		(4-pyridinyl)-1-[2-(4-	-	
		pyridinyl)eth		
		yl]propyl]benzenepro panamide		
XR 9051	Suspended	2-(3,4-	MDR inhibitor; P	cancer
			glycoprotein inhibitor	
			•	
		isoquinolinyl)ethyl]p		
		henyl]-4-[[4-methyl-		
	•	3,6-dioxo-5-		
		(phenylmethylene)pip		
		erazinylidene]methyl]		
		benzamide		
SDZ 280446	Discontinued	cyclo[N-methyl-L-	hibitor;	cancer
		alpha-Asp-N-methyl- peptide	peptide	
		L-Ile-N-methyl-L-Ile-		
		Gly-N-methyl-L-Val-	-	
		O-methyl-L-Tyr-(2S)-		
		2-hydroxypropanoyl-		
-		(2S)-2-		
		piperidinecarbonyl-N-		
		methyl-L-Val-L-Val],		
		1,1-dimethylethyl	-	
		ester		

With the properties of the protein	melanostatin; BMY 28566; BU 3619E	Discontinued	(S)-3-[[1-carboxy-2- (1H-imidazol-4-	melanin synthesis inhibitor	cancer
linolenate; EF AMOLEC AMOLEC AMOLEC AMOLEC (Inydroxyamino)carb inhibitor; proteinase inhibitor; proteinase onyl]-4-[(4- inhibitor; proteinase onyl]-4-[(4- inhibitor; proteinase onyl]-1- piperazinecarboxylic acid phenylmethyl ester proteinase Preclinical rs, Syntem Syntem Syntem Syntem Syntem Syntem (2S)-3-chloro-N- inhibitor; NSAID inhibitor; proteinase inhibitor; NSAID (2S)-3-chloro-N- inhibitor inhibitor (2S)-3-chloro-N- inhibitor inhibitor heptenyl]-2- heptenyl]-2- heptenyl]-2- heptenyl]-2- heptenyl]-2- hydroxy-4-methyl-pentanoic acid (3fwdaryl)-lactone			yl)ethyl]amino]-N- (N-methyl-L- phenylalanyl)-L- alanine		
AMOLEC AMOLEC AMOLEC Preclinical 3- [(hydroxyamino)carb inhibitor; proteinase onyl]-4-[(4- methoxyphenyl)sulfo nyl]-1- piperazinecarboxylic acid phenylmethyl ester proteinase Preclinical ester proteinase Preclinical inhibitor; proteinase inhibitor inhibitor inhibitor inhibitor hydroxy-1-oxo-6- [(2E,5S,6S)-5- heptenyl]-2- heptenyl]-2- hydroxy-4-methyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	lithium	Discontinued		metalloproteinase	cancer; HIV
Preclinical 3- (hydroxyamino)carb inhibitor; proteinase onyl]-4-[(4- methoxyphenyl)sulfo myl]-1- piperazinecarboxylic acid phenylmethyl ester nase Preclinical inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor. Suspended inhibitor microtubule assembly inhibitor (2S)-3-chloro-N- hydroxy-1-oxo-6- [(2E,5S,6S)-5- hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	gammalinolenate; EF 13; GLAMOLEC		-	inhibitor; proteinase inhibitor	infection
[(hydroxyamino)carb inhibitor; proteinase onyl]-4-[(4-methoxybhenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester metalloproteinase inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor; proteinase inhibitor; NSAID microtubule assembly inhibitor inhibitor hycin 52; LY Phase I (2S)-3-chloro-N-microtubule assembly inhibitor hydroxy-1-oxo-6-[(2R,5S,6S)-5-minhibitor hydroxy-1-oxo-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenyl]-0-methyl-pentanoic acid (3fwdarw1)-lactone	PGE 2946979	Preclinical	3-	metalloproteinase	inflammation; cancer
methoxyphenyl)sulfo myl]-1- piperazinecarboxylic acid phenylmethyl ester rs, Syntem syc85 Suspended hycin 52; LY Phase I (2S)-3-chloro-N- hydroxy-1-oxo-6- [(2E,5S,6S)-5- hydroxy-1-oxo-6- [(2R,3R)-3- heptenyl]-2- hydroxy-4-methyl- beta-alanyl-2- hydroxy-4-methyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone		 	[(hydroxyamino)carb	inhibitor; proteinase	
proteinase Preclinical acid phenylmethyl ester proteinase Preclinical inhibitor; proteinase inhibitor; proteinase inhibitor; NSAID microtubule assembly inhibitor inh			methoxyphenyl)sulfo	Inminoitor	
piperazinecarboxylic acid phenylmethyl ester proteinase Preclinical metalloproteinase inhibitor; proteinase inhibitor; NSAID S9C85 Suspended microtubule assembly inhibitor microtubule assembly inhibitor microtubule assembly (2S)-3-chloro-N-microtubule assembly (2E,5S,6S)-5-mydroxy-1-oxo-6-[(2R,3R)-3-phenyloxiranyl]-2-phenyloxiranyl]-2-phenyloxiranyl]-2-phenyloxy-4-methyl-pentanoic acid (3fwdarw1)-lactone			ny1]-1-		
proteinase Preclinical metalloproteinase inhibitor; proteinase inhibitor; proteinase inhibitor; NSAID microtubule assembly inhibitor microtubule assembly inhibitor microtubule assembly (I(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			piperazinecarboxylic	• •	
proteinase Preclinical metalloproteinase inhibitor; proteinase inhibitor; noteinase inhibitor; noteinase inhibitor; noteinase inhibitor; noteinase inhibitor. S9C85 Suspended microtubule assembly inhibitor microtubule assembly (2S)-3-chloro-N- microtubule assembly (2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	:		acid phenylmethyl		
rs, Syntem inhibitor; proteinase inhibitor; NSAID microtubule assembly microtubule assembly inhibitor microtubule assembly (2S)-3-chloro-N- microtubule assembly (1(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	metalloproteinase	Preclinical		metalloproteinase	cancer. arthritis
hycin 52; LY Phase I (2S)-3-chloro-N- microtubule assembly inhibitor microtubule assembly [(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2- hydroxy-4-methyl-bentanoic acid (3fwdarw1)-lactone	inhibitors. Syntem				cuitati munita
hycin 52; LY Phase I (2S)-3-chloro-N- microtubule assembly [(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	:			inhibitor; proteinase	
hycin 52; LY Phase I (2S)-3-chloro-N- microtubule assembly [(2E,5S,6S)-5- inhibitor hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone		Suspended	-	ale assembly	cancer
nycin 52; LY Phase I (2S)-3-chloro N- microtubule assembly [(2E,5S,6S)-5- inhibitor hydroxy-1-0xo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-0-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2- hydroxy-4-methyl-pentanoic acid (3fwdarw1)-lactone				inhibitor	
l(2E,5S,6S)-5- hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	cryptophycin 52; LY	Phase I			cancer
hydroxy-1-oxo-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone	50/555		[(2E,5S,6S)-5-	inhibitor	
[(2K,3K)-3- phenyloxiranyl]-2- heptenyl]-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			hydroxy-1-oxo-6-		-
phenyloxiranyl]-2- heptenyl]-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			[(2K,3K)-3-		
heptenyl-O-methyl- tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			phenyloxiranyl]-2-	٠	-
tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			heptenyl]-O-methyl-		
beta-alanyl-2- hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			tyrosyl-2,2-dimethyl-	-	
hydroxy-4-methyl- pentanoic acid (3fwdarw1)-lactone			beta-alanyi-2-		
pentanoic acid (3fwdarw1)-lactone			hydroxy-4-methyl-		
(3fwdarw1)-lactone			pentanoic acid	-	
			(3fwdarw1)-lactone		

cryptophycin 8	Preclinical	(2S)-3-chloro-N-	microtubule assembly cancer	cancer
		[(2E,5S,6R,7R,8S)-8- inhibitor	inhibitor	
		chloro-5,7-dihydroxy-		
		6-methyl-1-oxo-8-		-
		phenyl-2-octenyl]-O-		
		methyl-D-tyrosyl-		
		(2R)-2-methyl-beta-		
		alanyl-2-hydroxy-4-		
		methylpentanoic acid		
		(3->15)-lactone		
cryptophycin A	Preclinical		microtubule assembly cancer	cancer
derivatives, Wayne			inhibitor	
State University				
D 24851	Preclinical	1-[(4-	microtubule assembly cancer	cancer
		chlorophenyl)methyl] inhibitor	inhibitor	
		-alpha-oxo-N-4-	-	
		pyridinyl-1H-indole-		
		3-acetamide	-	
spothilone	Preclinical		microtubule assembly cancer	cancer
			inhibitor	

SD-14411

 $\pm i_{ij}$)

		1				
cancer	cancer	cancer	cancer	cancer	cancer	
N-acetyl-N-methyl-L-microtubule assembly cancer alamine [1S-inhibitor [1R*,2S*,3R*,5R*,6 [R*,16E,18E;20S*,21 [R*)]-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-fetramethyl-8,23-dioxo-4,24-dioxa-9,22-fiazatetracyclo[19.3.1] 110,14.03.5]hexacos a-10,12,14(26),16,18-bentaen-6-vlester	2-fluoro-1-methyl-4- microtubule assembly pentafluorophenylsulfinhibitor onamidobenzene	microtubule assembly cancer inhibitor	microtubule assembly inhibitor; angiogenesis inhibitor	microtubule assembly inhibitor; antibiotic	microtubule assembly inhibitor; peptide	
N-acetyl-N-methyl-L- alanine [1S- (1R*,2S*,3R*,5R*,6 R*,16E,18E,20S*,21 R*)]-11-chloro-21- hydroxy-12,20- dimethoxy-2,5,9,16- tetramethyl-8,23- dioxo-4,24-dioxa- 9,22- diazatetracyclo [19.3.1 110,14.03.5]hexacos a-10,12,14(26),16,18- pentaen-6-yl ester	2-fluoro-1-methyl-4- microtub pentafluorophenylsulfinhibitor onamidobenzene				yl-L- -N- yl-L- yl)-L-	prolinamide
Preclinical	Phase I	Preclinical	Preclinical	Preclinical	Phase II	
maytansine; maytansine; NSC 153858	Т 138067	T 900607	AC 7700	epothilones, Society for Biotechnology Research	cemadotin; LU 103793	

À

€B

Precinical N,N-dimethyl-L- walyl-L-valyl-N- methyl-L-valyl-N- methyl-L-valyl-L- prolyl-L-prolin-Tert. putylamide 11R*,3R*(E),7R*,10Smicrotubule assembly 11R*,12R*,12R*,16S*]- Promoter 11R*,12R*,12R*,16S*]- Promoter 11R*,12R*,12R*,16S*]- Promoter 11R*,12R*,12R*,16S*]- Promoter 11R*,12R*,12R*,10Smicrotubule assembly 11-dihydroxy- 8,8,10,12- methyl-2-(2-methyl) 4,17- dioxabicyclo[14.1.0]h Preclinical Preclinical B is [1S-, 16-methyl] A+17- dioxabicyclo[14.1.0]h Preclinical Preclinical B is [1S-, 16-methyl] A+17- dioxabicyclo[14.1.0]h C2-N,N-dimethyl-L- mitosis inhibitor A-2-[1-methoxy-2- methyl-3-oxo-3-{(2-bhentyl)amino]prop N]-1-pyrrolidinyl]-1- C1-methylpropyl]-4- cxobutyl]-N-methyl-3- cxobutyl]-N-methyl-3- cxobutyl]-N-methyl-3- cxobutyl-3-oxo-3-{(2-bhentyl)amino-lycop cxop cxobutyl-3-oxo-3-{(2-bhentyl)amino-lycop cxobutyl-3-o	111 22261	D			
Preclinical IR*,3R*(E),7R*,10Smicrotubule assembly IR*,3R*(E),7R*,10Smicrotubule assembly IR*,3R*(E),7R*,10Smicrotubule assembly IR*,3R*(E),7R*,10Smicrotubule assembly IR*,11R*,12R*,16S*] promoter 7,11-dihydroxy- 8,8,10,12- tetramethyl-2-(2-methyl-4,17- dioxabicyclo[14,1.0]h eptadecane-5,9-dione B is [1S-,16-methyl] mitosis inhibitor valyl-N-[2-methoxy-4-[2-1-methoxy-2- methyl-3-oxo-3-[(2-bhase II (S)-(5-amino-1,2- mitosis inhibitor (I-methylpropyl)-4- oxobutyl]-N-imethyl-1- (I-methylpropyl)-4- oxobutyl]-N-imethyl-1- (I-methylpropyl)-4- oxobutyl]-N-imethyl-2- mitosis inhibitor (B)-(5-amino-1,2- mitosis inhibitor I-valinamide Dipyrazin-7- phipyrazin-7-	100077.07	Frecimical		microtubule assembly	cancer
prolyl-L-valyl-L- prolyl-L-prolin-Tert. putylamide Preclinical [IR*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4,17- dioxabicyclo[14,1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Preclinical [2S-N,N-dimethyl-L- valyl-N-[2-methoxy- 4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- cyobutyl]-N-methyl- dihydro-2-methyl-3- phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			valyl-L-valyl-N-	inhibitor; peptide	
proly1-L-prolin-Tert. butylamide Preclinical [1R*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethy1-3-[1- methy1-2-(2-methy1- 4,17- dioxabicyclo[14,1.0]h eptadecane-5,9-dione (B is [1S-, 16-methy1]) Preclinical Ris [1S-, 16-methy1] Preclinical (B is [1S-, 16-methy1]) #12-[1-methoxy-2- methy1-3-oxo-3-[(2- phenethy1)amino]prop yl]-1-pyrrolidiny1]-1- (1-methylpropy1)-4- oxobuty1]-N-methy1- cyobuty1]-N-methy1- L-valinamide [S)-(5-amino-1,2- dihydro-2-methy1-3- phenylpyrido(3,4- inhibitor yl)carbamic acid ethy1 ester			methyl-L-valyl-L-	' - <u>-</u>	
Preclinical [IR*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- promoter 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl-4-17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-,16-methyl] mitosis inhibitor valyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl-3- mitosis inhibitor; dihydro-2-methyl-3- mitosis inhibitor; dihydro-2-methyl-3- thbulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			prolyl-L-prolin-Tert.		
Preclinical [1R*,3R*(E),7R*,10S microtubule assembly *,11R*,12R*,16S*]- promoter 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl-4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] mitosis inhibitor valyl-N-[2-methoxy- 4-[2-[1-methoxy- methyl-3-oxo-3-[(2- methyl)]amino]prop yl]-1-pyrrolidinyl]-1- (1-methyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl-3- mitosis inhibitor; dihydro-2-methyl-3- inhibitor dihydro-2-methyl-3- inhibitor blpyrazin-7- yl)carbamic acid ethyl ester			butylamide		
,11R,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy- 4-[2-[1-methoxy- methyl-3-oxo-3-[(2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- coxobutyl]-N-methyl- dihydro-2-methyl-3- dihydro-2-methyl-3- phenylpyrido(3,4- pheny	epothilones	Preclinical	[1R*,3R*(E),7R*,10S	microtubule assembly	cancer
8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl] Preclinical Ris [1S-, 16-methyl- A-[2-I-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- dihydro-2-methyl-3- dihydro-2-methyl-3- yl)carbamic acid ethyl ester			*,11R*,12R*,16S*]-	promoter	
8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L- valyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- intiosis inhibitor; dihydro-2-methyl-3- phenylpyrido(3,4- inhibitor yl)carbamic acid ethyl ester			7,11-dihydroxy-		
tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy- 4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- cycbutyl]-N-methyl- L-valinamide D-valinamide (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			8,8,10,12-		
methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-thiazolyl)ethenyl]-4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S., 16-methyl)] Preclinical Preclinical Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) (S)-(5-amino-1,2-mitosis inhibitor) phanylpyrido(3,4-inhibitor) yl)carbamic acid ethyl		···	tetramethyl-3-[1-		
4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S., 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor yl)carbamic acid ethyl ester			methyl-2-(2-methyl-		
dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor byprazin-7-yl)carbamic acid ethyl			4-thiazolyl)ethenyl]-		-
dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor b)pyrazin-7-yl)carbamic acid ethyl	-		4,17-		
eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4-oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor yl)carbamic acid ethyl			dioxabicyclo[14.1.0]h		-
Preclinical mitosis inhibitor (B is [1S., 16-methyl) mitosis inhibitor (2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl- L-valinamide (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor yl)carbamic acid ethyl ester			eptadecane-5,9-dione		
Preclinical mitosis inhibitor walyl-N-[2-methoxy-4-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor yl)carbamic acid ethylester		•	(B is [1S-, 16-methyl)		
Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-dihyl-L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor b)pyrazin-7-yl)carbamic acid ethyl	ntimitotics,	Preclinical		mitosis inhibitor	cancer
Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-L-valinamide Phase II (S)-(5-amino-1,2-dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) b)pyrazin-7-yl)carbamic acid ethylester	Vanodesign				
valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-D-methyl-L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor)lylograzin-7-yl)carbamic acid ethyl	CZT 1027	Phase I	·		cancer
4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			valyl-N-[2-methoxy-		
methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) b)pyrazin-7- yl)carbamic acid ethyl			4-[2-[1-methoxy-2-		
phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			methyl-3-oxo-3-[(2-		
yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			phenethyl)amino]prop		
(1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			yl]-1-pyrrolidinyl]-1-		
oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			(1-methylpropyl)-4-		
L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			oxobutyl]-N-methyl-		
Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			L-valinamide		
dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl	nivobulin; CI 980;	Phase II			cancer
o(3,4- acid ethyl	4SC 613862(-)			tubulin polymerase	
acid ethyl				inhibitor	
yl)carbamic acid ethyl					
ester			yl)carbamic acid ethyl		
			ester		